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1CHAPTER I
INTRODUCTION
There were nearly 148,000 new cases of colorectal cancer in the U.S. in 2006 and
over 55,000 deaths due to this disease.  The five-year survival rate for localized colorectal
cancer (stage 1) is around 90%, but more than 60% of cases present with stage III or IV
disease.  For patients with tumors that have spread to regional lymph nodes, the five-year
survival rate drops to around 68%; the 5-year survival rate plummets to a dismal 10% for
those patients with distant metastatic disease (American Cancer Society, Cancer Facts
and Figures, 2006). The genetic alterations occurring in the conversion of normal
intestinal epithelium to malignant carcinoma are well characterized (Vogelstein et al.,
1988). Tumor cell interaction with its microenvironment and mutations in oncogenes or
tumor suppressor genes play important roles in regulating cancer cell growth and
behavior. The interactions of these events and conditions, especially their cooperation,
are of particular importance during tumor development and progression. Several cellular
processes are altered when a normal cell converts to a cancer cell. Among these are
increased growth and proliferation, which can be affected by activating mutations in
oncogenes and disruption of growth inhibitory pathways. These events lead to the
increased expression of tumor promoting factors, such as cyclooxygenase 2 (COX-2) and
vascular endothelial growth factor (VEGF), which aid the development and progression
of tumors. A better understanding of the molecular mechanisms regulating gene
expression in carcinogenesis will aid us in developing successful therapeutic strategies.
2Transformation and EMT
In order for cancer cells to metastasize, they must invade adjacent tissues, gain
access to vascular or lymphatic channels, survive transit, extravasate, and finally colonize
a distant organ or tissue. Cancer cells acquire the capacity to invade and metastasize
through activation of oncogenes and the loss of tumor suppressors; however the
underlying molecular mechanisms involved in cellular invasiveness and metastasis are
incompletely understood. The majority of cancers are carcinomas, which arise from
epithelial cells. Normal epithelial cells are well organized, immobile, polarized cells with
complex cell-cell and cell-matrix junctions. Enhanced growth, disruption of cell
adhesion, and induction of neovascularization are crucial steps toward metastasis.
Epithelial to mesenchymal transition (EMT) is a process whereby epithelial cells
lose polarity, acquire a mesenchymal phenotype, and exhibit invasive behaviors.
Although EMT is a normal, tightly controlled and reversible event during embryonic
development and in response to injury, it can contribute to the progression of carcinomas.
EMT is characterized by a loss of cell-cell junctions, in part through loss of the adherens
junction protein E-cadherin, disruption of cell-matrix interactions mediated by altered
integrin expression and increased expression of matrix dissolving proteolytic enzymes,
and rearrangement of the cytoskeleton. These events result in the acquisition of a
fibroblastoid phenotype, accompanied by an increase in mesenchymal markers such as
vimentin and "-smooth muscle actin, and increased cell motility and invasiveness
(Zavadil and Bottinger, 2005).
3Transforming growth factor-!
TGF-! signaling and growth inhibition
A balance of autocrine and paracrine growth promoting signals and growth
inhibitory signals tightly regulate cell growth and epithelial architecture. Transforming
growth factor ! (TGF-!) is normally a potent inhibitor of epithelial cell growth (Filmus et
al., 1992; Kurokowa et al., 1987) and functions through activation of the Smad signaling
pathway, initiating transcription of target genes and potently inhibiting cell growth (Shi
and Massague, 2003). The three human isoforms of TGF-!, TGF-!1, TGF-!2 and TGF-
!3, are highly conserved and bind the same heteromeric receptor complex composed of
the type I and type II receptors (T!RI and T!RII) both of which have serine/threonine
kinase activity (Kurokowa et al., 1987). The T!RII binds TGF-! ligand, associates with
and phosphorylates the T!RI, which then phosphorylates and activates downstream
effectors known as Smad proteins, the mammalian homologues of the C. elegans Sma
and Drosophila Mad proteins (Figure 1). Phosphorylated Smad2 and Smad3 in turn bind
Smad4, and the complex translocates to the nucleus, where it interacts with several
different transcription factors to initiate transcription of target genes (Massague, 1998).
TGF-! can activate other signaling pathways independently of Smad signaling, including
the mitogen-activated protein kinases extracellular-regulated kinase (Erkinheimo et al.)
and c-jun N-terminal kinase (JNK), phosphatidylinositol-3 kinase (PI3K), and Rho
GTPases (Massague, 1998).
Growth inhibition appears central to TGF-!’s role as a tumor suppressor. Reduced
4expression of TGF-! or T!RI increases the malignancy of colon carcinoma cells (Wang
et al., 1996; Wu et al., 1993). T!RII is mutated and inactivated in colon cancers with or
Figure 1: The TGF-! signaling pathway. TGF-! ligand binds T!RI and T!RII,
recruiting the receptor-Smads (Smad2 and Smad3), which then bind Smad4 and the
complex translocates to the nucleus and activate gene transcription. TGF-! also
activates Smad-independent pathways such as Ras, TAKI, RhoA, and PI3 kinase.
Illustration from Wakefield and Roberts, (2002) Curr. Opin. Gen. & Dev. 12:22.
5without microsatellite instability (Grady et al., 1999; Markowitz et al., 1995). In addition,
mutations in Smad4, occurring in 30% of colorectal cancers and 50% of pancreatic
cancers, are associated with more aggressive tumors (Hahn et al., 1996; Takagi et al.,
1996). The tumor suppressor activity of TGF-! occurs partially though its regulation of
key genes involved in the regulation of the cell cycle. The TGF-! activated Smad
complex interacts with the transcription factor SP-1 to increase expression of p21Cip1,
p15Ink4b, and p27Kip1, potent negative regulators of the cyclins and cyclin-dependent
kinases involved in cell cycle progression (Feng et al., 2000; Massague et al., 2000;
Pardali et al., 2000). In intestinal epithelial cells, TGF-! causes cell cycle arrest at the
G1/S transition (Ko et al., 1994; Ko et al., 1995) and down regulates cyclin D1
expression (Ko et al., 1998). Furthermore, intestinal epithelial cells overexpressing cyclin
D1 become refractory to the growth inhibitory actions of TGF-! (Ko et al., 1998).
TGF-! signaling alterations in cancer
During tumorigenesis and neoplastic transformation, the growth inhibitory
response to TGF-! is often lost. In this case, TGF-! promotes growth, increases cell
motility, and promotes transformation.  TGF-! can induce an epithelial to mesenchymal
transition in keratinocytes, melanoma cells, and mammary epithelial cells (Cui et al.,
1996; Janji et al., 1999; Miettinen et al., 1994). In vivo data support the view of TGF-!
switching from a tumor suppressor to a tumor promoter. TGF-! expression is up-
regulated in more than 90% of colorectal cancers (Derynck et al., 1987). While TGF-!
acts as a tumor suppressor in early stage tumors (Engle et al., 1999), increased expression
of TGF-! in colorectal tumors correlates with depth of tumor invasion and advanced
6tumor stage (Xiong et al., 2002). Furthermore, TGF-! has been shown to promote
progression of late stage tumors by enhancing invasion and metastasis (Takenoshita et al.,
2002). Increased levels of TGF-! in plasma or the primary tumor also correlate with
advanced tumor stage (Robson et al., 1996; Shim et al., 1999) and predict liver
metastases in patients who have undergone surgical resection of a primary tumor
(Tsushima et al., 2001). A high level of TGF-! expression in primary tumors is an
independent risk factor for recurrence (Friedman et al., 1995) and is also associated with
shorter survival (Robson et al., 1996).
Activation of Ras signaling switches TGF-! to a growth promoter
Ras oncogene
The Ras proto-oncogene is a central component of many signal transduction
pathways regulating cellular growth and differentiation. The Ras family of GTPases is
composed of three highly conserved members, K-, H-, and N-Ras, with considerable
functional overlap. Ras proteins are activated by diverse extracellular signals, the best
characterized is via tyrosine kinase receptors such as the epidermal growth factor receptor
and G protein-coupled receptors. Ras activates multiple downstream effectors including
the classical mitogen activated protein kinase (MAPK) cascade, Raf-MEK (MAPK/ERK
kinase)-ERK1/2, and the PI3K-Akt pathway (Giehl, 2005) (Figure 2). Conserved
oncogenic mutations of Ras genes at codons 12, 13, or 61 locks Ras in an active, GTP-
bound state, triggering constitutive activation of its downstream effectors. This activation
7of Ras results in changes in expression of many autocrine growth factors and their
receptors, such as members of the TGF-! and epidermal growth factor (EGF) protein
families, and increases the expression of several factors with known tumor-promoting
activity including COX-2 (Sheng et al., 2000) and VEGF (Rak et al., 2000). Expression
of activated H-Ras in intestinal epithelial cells also leads to profound changes in cell
behavior including an increase in invasiveness, a resistance to growth inhibition by TGF-
Figure 2: The Ras signaling pathway. Growth factor binding to tyrosine kinase
receptors activates Ras through adaptors such as growth-factor-receptor bound protein
2 (GRB2), SH2-containing protein (SHC), and son-of-sevenless 1 (SOS1), which
increase Ras-guanosine diphosphate (GDP) exchange for guanosine triphosphate
(GTP). This activation of Ras effects multiple signaling pathways as depicted here,
such as Raf-MEK-ERK and PI3K-PKD1 (3-phosphoinositide-dependent protein
kinase 1)-Akt signaling, which control proliferation and survival, respectively.
Illustration from Schubbert et al., (2007) Nat. Rev. Cancer 7:295.
8!, and altered expression and localization of cell junction proteins like E-cadherin and !-
catenin leading to transformation to a malignant phenotype (Fujimoto et al., 2001; Sheng
et al., 2000). Constitutive expression of oncogenic Ras, through these changes in gene
expression and cell behavior, drives cells to form tumors in nude mice (Sheng et al.,
1997).
Mutations in oncogenes or tumor suppressor genes, in combination with tumor
cell interaction with its microenvironment, play important roles in regulating cancer cell
growth and behavior. Ras is mis-regulated in at least one third of all human cancers (Bos,
1989) and K-Ras is mutated in 50% of colorectal malignancies and 90% of pancreatic
cancers (Kinzler and Vogelstein, 1996), while H-Ras is commonly mutated in bladder
cancer (Visvanathan et al., 1988) and mutations in N-Ras are observed in 25% of acute
leukemias (Bos et al., 1987). Furthermore, activation of the downstream MAP kinase,
MEK, occurs in more than 70% of colorectal tumors (Lee et al., 2004b), implicating Ras
activation as a central regulator of carcinogenesis.
Cooperation between oncogenic Ras and TGF-!
In normal epithelial cells, homeostasis is achieved by a balance of growth
promoting signals, like epidermal growth factor, and growth inhibitory signals, such as
TGF-!. We and others have found that transforming events, such as Ras activation,
contribute to both the resistance of epithelial cells to growth inhibition by TGF-! as well
as to the tumor promoting effects of TGF-! signaling (Cui et al., 1996; Filmus et al.,
1992; Fujimoto et al., 2001; Saha et al., 2001). The interactions between the Ras and
TGF-! signaling cascades are well described in keratinocytes and mammary epithelial
9cells. Oncogenic H-RasV12 transformed keratinocytes are refractory to TGF-!-mediated
growth inhibition and have reduced TGF-!-Smad signaling, due to decreased ligand and
T!RII expression and nuclear accumulation of Smad2/3 (Game et al., 1992; Kretzschmar
et al., 1999). TGF-! cooperates with Ras in EpRas mammary epithelial cells to induce a
spindly phenotype, loss of cell-cell junction integrity associated with cytoplasmic
localization of E-cadherin and !-catenin, decreased expression of epithelial markers,
increased expression of mesenchymal markers, and increased invasion (Oft et al., 1996).
Blocking TGF-! signaling with dominant negative T!RII expression in EpRas cells
blocks EMT, invasion, tumor growth, and metastasis (Oft et al., 1998). TGF-! stimulates
Ras-dependent ERK activity and increases motility and invasion in transformed
keratinocytes (Santibáñez et al., 2000). Furthermore, restoration of low levels of T!RII
expression in colon cancer cell lines increases cell invasiveness but high T!RII
expression restores the growth inhibitory effects of TGF-! (Oft et al., 1998). Expression
of Smad7, which inhibits TGF-!-Smad signaling, induces oncogenic Ras expressing
keratinocytes to form carcinomas instead of papillomas (Liu et al., 2003). TGF-! and Ras
cooperate to increase invasion and migration in breast cancer cells and TGF-!-induced
EMT requires active MEK/ERK signaling (Kim et al., 2005a; Xie et al., 2004). These
studies indicate that activation of oncogenes, such as Ras, induces a switch in the TGF-!
response in epithelial cells from tumor suppression to tumor promotion.
The mechanisms by which oncogenic Ras and TGF-! cooperate to induce EMT
and invasion are not completely understood. We have shown that oncogenic Ras induces
degradation of Smad4 in the rat intestinal epithelial cells, expression of which is
necessary for TGF-!-induced growth suppression (Saha et al., 2001). Oncogenic Ras also
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inhibits the TGF-!-induced nuclear accumulation of Smad2 and Smad3 by inducing
phosphorylation of Smad2/3 at several ERK consensus sites in the region linking the
DNA binding domain and the transcriptional activation domain (Kretzschmar et al.,
1999). In colon cancer cells that both lack Smad4 expression and harbor an activating K-
Ras mutation, expression of Smad4 together with a Ras-resistant mutant form of Smad3
lacking inhibitory MAPK phosphorylation sites restores the TGF-! anti-proliferative
response (Calonge and Massague, 1999). These studies indicate that oncogenic Ras
inhibits the growth inhibitory Smad-mediated responses of TGF-!.
We previously reported that conditional oncogenic Ha-RasV12 expression causes
morphological changes consistent with EMT, actin reorganization, increased vimentin
expression, decreased E-cadherin expression, and increased invasiveness of rat intestinal
epithelial cells (RIE:iRas cells) (Fujimoto et al., 2001). TGF-! enhances EMT in
RIE:iRas cells transformed by oncogenic Ras, further decreasing E-cadherin expression,
increasing nuclear localization of !-catenin, and increasing cell invasiveness (Fujimoto et
al., 2001; Sheng et al., 2000) (Figure 3). Interestingly, while blocking TGF-! signaling
with dominant negative T!RII expression decreases the growth inhibitory effect of TGF-
! regardless of RasV12 expression, dnT!RII also decreases TGF-! induced invasion in
Ras transformed cells, demonstrating that both growth suppressing and tumor promoting
activities of TGF-! act through T!RII (Fujimoto et al., 2001).
Additionally, TGF-! treatment of oncogenic Ras expressing cells was shown to
synergistically induce COX-2 mRNA and protein expression through a mechanism of
increased COX-2 mRNA stability involving the AU-rich element (ARE) region of the
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COX-2 3’untranslated region (UTR) (Roman et al., 2002; Sheng et al., 2000).
Interestingly, increased COX-2 expression and mRNA stability in colon cancer cell lines
is associated with increased tumor growth in vivo (Dixon et al., 2001). Taken together
these results suggest that post-transcriptional gene regulation is an important mechanism
for regulating gene expression that contributes to cancer progression and that Ras and
TGF-! collaboratively regulate mRNA stability of selected target genes.
Figure 3: Oncogenic Ras expression and TGF-! treatment induce epithelial-
mesenchymal transition in RIE:iRas cells. Cells were treated for 72 hours with or
without 5 mM IPTG to induce RasV12 expression or treated with 3 ng/ml TGF-!.
Phase contrast micrographs show phenotypic transformation (100x).
untreated IPTG
TGF-! IPTG+TGF-!
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Summary
In addition to unrestrained growth, Ras and TGF-! collaborate to induce epithelial
to mesenchymal transition (EMT), increase cell motility and invasiveness, and influence
the expression of genes involved in cell-cell and cell-matrix interactions, like E-cadherin,
integrins, and intermediate filaments, as well as genes involved in tumorigenesis, such as
COX-2 (Fujimoto et al., 2001; Sheng et al., 2000). In this study, the collaborative effects
of Ras and TGF-! were examined by gene expression profiling. Global gene expression
patterns induced by Ras transformation alone, TGF-! treatment alone, and the
combination of Ras transformation and TGF-! treatment were examined by
oligonucleotide microarray in order to characterize changes in gene expression related to
the cooperative effect on malignant behavior that occurs with TGF-! treatment of Ras
transformed cells. A pivotal role for EGFR signaling during EMT was examined, as well
as a global mechanism of post-transcriptional regulation of gene expression. Furthermore,
access to microarray data from 65 human colorectal cancer (CRC) patients, through the
GI SPORE, afforded a unique opportunity to examine data from human CRC samples.
Analysis of the gene expression changes associated with EMT in the well-controlled
intestinal epithelial cell line were used to inform the human CRC data, demonstrating the
utility of RIE:iRas cells to model colorectal cancer and implicating post-transcriptional
gene regulation as a novel mechanism involved in carcinoma progression.
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CHAPTER II
MATERIALS AND METHODS
Reagents
TGF-! and TGF-" were purchased from R&D Systems (Minneapolis, MN). EGF
was purchased from Sigma-Aldrich (St. Louis, MO). TNF-" and amphiregulin were gifts
from Robert Coffey, Vanderbilt University. U0126, LY294002, EKI-785-785, and
SB203580 were purchased from Calbiochem (San Diego, CA). A pharmacological
inhibitor of TGF-! type I receptor (LY364947 or TRKi) was provided by Eli Lilly
(Indianapolis, IN). NS398 was from Cayman Chemical Co. (Ann Arbor, MI) and
celecoxib from Pharmacia and Upjohn (New York, NY).
Cell culture
Rat intestinal epithelial cells (RIE-1) cells were maintained in DMEM containing
10% FBS as described previously (Saha et al., 1999). RIE cells stably expressing
inducible Ha-RasG12V cDNA under the control of the Lac operon (RIE:iRas) were
derived and maintained as previously described (Sheng et al., 2000) in DMEM
(Invitrogen, Carlsbad, CA) containing 10% FBS, 400 µg/ml G418, and 150 µg/ml
hygromycin B. Transcriptional expression of Ha-RasG12V was induced by treatment
with 5 mM isopropyl-1-thio-!-D-galactopyranoside (IPTG; Sigma-Aldrich, St. Louis,
MO). RIE-H-RasV12 were kindly provided by Dr. Robert Coffey (Vanderbilt
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University). Cells stably transfected with human H-RasV12 are maintained in DMEM
containing 10% FBS and 400 µg/ml G418 (Gangarosa et al., 1997).
Young adult mouse colonocytes (YAMC), YAMC cells expressing Ha-RasG12V
(YAMC-Ras), and YAMC cells derived from a COX-2 -/- mouse (YAMC-COX-2-null)
were kindly provided by Dr. Robert Whitehead (Vanderbilt University). Cells were
maintained as previously described (D'Abaco et al., 1996) in permissive conditions at
33ºC in RPMI medium containing 5% FBS and 5 U/ml murine interferon-# (Roche,
Indianapolis, IN). For all experiments, cells were cultured under non-permissive
conditions at 37ºC without interferon-#.
LIM1863 cells were a gift from Dr. Robert Whitehead (Vanderbilt University).
Cells were grown as organoids and maintained in RPMI 1640 (Invitrogen, Carlsbad, CA)
supplemented with 5%FBS and 1% Insulin-Transferrin-Selenium (Invitrogen, Carlsbad,
CA) as described (Whitehead et al., 1987).
Human Colorectal tissue collection and processing
65 patients were recruited at the Vanderbilt Ingram Cancer Center at Vanderbilt
University Medical Center (VUMC) and the Tennessee Valley Healthcare System
Veterans Affairs Medical Center (VAMC) in Nashville, TN between 2003 and 2005.  All
patients were diagnosed with adenoma or colorectal adenocarcinoma (stages I-IV)
according to current AJCC guidelines Patients utilized for this study were further selected
based on the diagnosis of adenoma (n=5 for Affymetrix analysis and n=5 for ABI
analysis), stage 1 (n=10), stage 2 (14), stage 3 (n=17), or stage 4 colorectal
adenocarcinoma (n=19 for Affymetrix analysis and n=6 for ABI analysis).  Informed
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consent was obtained from each patient and all protocols and procedures were approved
by the Institutional Review Board at VUMC and the Nashville VAMC.
Tissue specimens from all colon and rectal tumors were obtained in the operating
suite or at the time of endoscopic biopsy, respectively, and a representative specimen was
sent to pathology to confirm the diagnosis of adenoma or adenocarcinoma.  The
remaining specimen was immediately flash frozen in liquid nitrogen, transported to the
laboratory, and stored at -80°C.  Representative quality assessment slides were obtained
to verify the diagnosis and quality of all tissue sent to the laboratory.
RNA was purified from adjacent biopsy and surgical specimens with a confirmed
diagnosis of adenoma or adenocarcinoma using the RNeasy® kit from Qiagen (Valenica,
CA) according to manufacturer’s protocol, except !-mercaptoethanol was not added to
lysis buffer. RNA was eluted with 10mM Tris/DEPC H2O at pH 8.0 samples were
submitted to the VMSR. RNA quality was assessed with an Agilent 2100 bioanalyzer
(Foster City, CA).
Western blots
Cells were treated, washed 2x in PBS, then lysed in RIPA buffer (150 mM NaCl,
1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl (pH 8.0), 2 mM
EDTA, 1 mM PMSF, 3 µg/ml aprotinin, 10 µg/ml leupeptin, 250 µM vanadate, and 10
mM NaF) and stored at -80°C until use. Protein samples were separated by SDS-PAGE
(20 to 40 µg/lane) and transferred to PVDF. The blots were blocked in PBS containing
0.1% Tween-20 and 5% BSA or milk and incubated overnight in primary antibody at
4°C, rinsed, then incubated for 1 hour in horseradish-peroxidase conjugated secondary
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antibody (Santa Cruz Biotechnology, Santa Cruz, CA), and developed with ECL
(Amersham, Piscataway, NJ). Mouse anti-phospho-ERK, rabbit anti-ERK, and mouse
anti-!-actin antibodies were purchased from Sigma (St. Louis, MO). Rabbit anti-
phospho-Smad 2, rabbit anti-Akt, mouse anti-phospho-Akt(ser473), rabbit anti-p38
MAPK, mouse anti-p38 MAPK, and mouse anti-phospho-EGFR(tyr1068) antibodies
were purchased from Cell Signaling Technology (Danvers, MA). Mouse anti-Smad2
antibody was purchased from Invitrogen (Carlsbad, CA). Goat anti-COX-2 and mouse
anti-HuR (3A2) were purchased from Santa Cruz Biotechnology (Santa Cruz
Biotechnology, Santa Cruz, CA). Rabbit anti-EGFR was purchased from Upstate
Biotechnology (Lake Placid, NY). Mouse anti-phospho-tyrosine (clone 4G10) were
obtained from BD Transductions Laboratories (Franklin Lakes, NJ).
Microarray
RIE:iRas cells were plated at 0.5x106 cells per 10cm plate, allowed to attach
overnight, then cells left untreated or treated for 72 hours with 5mM IPTG (for H-
RasV12 induction), 3ng/ml TGF-! or IPTG and TGF-! together in DMEM containing
0.5% FBS. RNA was collected from 3 (IPTG and TGF-!) or 4 (untreated and
IPTG+TGF-!) independent cultures and purified using the RNeasy® kit from Qiagen
(Valenica, CA) according to manufacturer’s protocol, except no !-mercaptoethanol was
added to lysis buffer. RNA was eluted with 10mM Tris/DEPC H2O at pH 8.0 samples
were submitted to the Vanderbilt Microarray Shared Resource (VMSR, www.vmsr.net).
RNA quality was assessed with an Agilent 2100 bioanalyzer (Foster City, CA), then
hybridized to Affymetrix Rat Genome 230 2.0 GeneChip Expression arrays (Santa Clara,
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CA) according to manufacturer’s instructions. Data sets were normalized and background
subtracted by the Robust MultiChip Analysis (RMA) method (Irizarry et al., 2003). For
each replicate, samples treated with IPTG and/or TGF-! were compared with the
matched untreated sample. Gene expression increases or decreases were defined by a
log2 ratio (treated/untreated) greater than 1 or less than –1, respectively, using
GeneSpring software (Agilent Technologies, Santa Clara, CA). Synergistic regulation is
defined as IPTG and TGF-! together showing a more than additive increase or decrease
in expression compared to IPTG and TGF-! alone in at least two of three replicates.
Significance of differentially expressed genes was determined using the Benjamini-
Hochberg multiple testing comparison with a p-value <0.05.
RNA isolated from human CRC samples (5 adenomas and 19 stage 4 colon
adenocarcinomas) were hybridized to Affymetrix U133 Plus 2.0 GeneChip Expression
arrays (Santa Clara, CA) according to manufacturer’s instructions. Analysis of
microarray results was performed as described for the rat arrays using the Affymetrix
analysis functions in Bioconductor (http://www.bioconductor.org). Genes differentially
expressed between adenomas and stage 4 adenocarcinomas were identified by a two-
sample t-test and probes with a q-value<0.05 were selected for further analysis (Storey
and Tibshirani, 2003).!
Network and functional analysis
Rat microarray data were analyzed through the use of Ingenuity Pathway Analysis
(Ingenuity® Systems, www.ingenuity.com). Functional analysis of differentially
regulated genes identified the biological functions and/or diseases that were most
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significant (p<0.05) to the data set. Fischer’s exact test was used to calculate a p-value
determining the probability that each biological function and/or disease assigned to the
data set is due to chance alone.
The WebGestalt toolkit (http://bioinfo.vanderbilt.edu/webgestalt) was used for the
orthologous mapping, boolean operation, and functional annotation of the differentially
expressed gene sets (Zhang et al., 2005). Rat and human Affymetrix probe set IDs were
uploaded into WebGestalt for the analyses.  Rat genes were mapped to human orthologs
to allow a direct comparison with the human gene sets.
Identification of AU-rich elements
Human and rat RefSeq mRNAs with complete 3$UTR were processed to
computationally extract their 3$UTRs; the ARE motifs were searched as previously
described (Bakheet et al., 2001). Rat genes from the synergy list containing AREs were
identified by a second independent approach, for those with incomplete 3$UTR or
missing 3$UTR from rat GenBank mRNA records, AREs were defined from the human
sequence homologs since AREs are conserved among mammalian species (Khabar et al.,
2005). This was accomplished by using BLAST to human mRNA records and retrieval of
data from HomoloGene database at NCBI. In order to assess the statistical significance of
ARE gene representation, we used the stringent ARED-Organism (Halees et al., 2008),
which is based on the HomoloGene database, to examine the lists of differentially
expressed rat genes (individual, combined, and synergistic conditions) and human
adenoma compared to adenocarcinoma or each individual stage. The Chi-squared test
was used to determine statistical significance.
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Real time RT-PCR
RIE:iRas cells were plated at 0.5x106 cells per 10cm plate, allowed to attach
overnight, then cells left untreated or treated for 72 hours with 5mM IPTG (for H-
RasV12 induction), 3ng/ml TGF-! or IPTG and TGF-! together in DMEM containing
0.5% FBS. RNA was isolated and purified via RNeasy® kit (Qiagen, Valenica, CA)
according to manufacturer’s instructions. For time course experiments, RNA was isolated
from RIE:iRas cells treated for 0, 24, 48, 72, or 96 hours with IPTG and/or TGF-! under
similar conditions as above.
cDNA synthesis was performed using 300ng RNA with SuperScript III Reverse
Transcriptase from Invitrogen (Carlsbad, CA) and one gene specific primer (COX-2,
Wnt5a, Spp1, CUGBP2, TGF-", or hnRNP A/B) at 50oC. Primers were designed in our
laboratory and ordered from IDT Technologies (Coralville, IA); see Table 1 for
sequences. Real Time SYBR Green/Fluorescein PCR Master Mix was obtained from
SuperArray (Frederick, MD). PCR reactions were prepared according to SYBR Green
Master Mix protocol (SuperArray) and analyzed using a Bio-Rad iCycler under the
following conditions: 95!°C for 13:30m (1 cycle), 95!°C for 15s, 55!°C for 30s , 72!°C for
30s (45 cycles); 72!°C for 7m (1 cycle), melt curve 50!°C for 10s and increase
temperature by 0.4°C for each cycle (100 cycles). Real Time PCR was performed on a
minimum of three biological replicates. All samples were set up in quadruplicate with
efficiencies for each well calculated from the slopes of the exponential phase of the log
transformed reaction curves.  Fold changes were calculated according to the  methods of
Schefe et al. (Schefe et al., 2006). Reactions using phosphomannomutase 1 (Pmm1)
housekeeping gene were used to normalize all data sets (Rubie et al., 2005). Analysis of
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variance (ANOVA) with Bonferroni correction was used to examine differences between
mean fold change in gene expression among 3 treatment groups. Statistical analyses were
performed using Kaleidagraph version 4.03.
For Itgb1, Itga5, and Axin2, real time PCR was performed similar to the above
procedure with the following changes. RNA was DNase treated with RQ1 RNase-Free
DNase (Promega, Madison, WI) according to manufacturer’s instructions prior to
purification. Xpress-Ref Universal Rat RNA (SuperArray) was obtained for standards.
cDNA synthesis was performed using1.5µg RNA with M-MLV Reverse Transcriptase
(Promega) and Oligo(dT) primers according to manufacturer’s guidelines. Primers were
ordered from SuperArray. Standard curves were constructed using cDNA from Universal
Rat RNA in at least 6 serial dilutions. All reactions were run in triplicate. Standard curves
were used to derive starting quantities of cDNA in each unknown.
Table 1: Real time PCR primers
COX-2 Forward
Reverse
5’- CCACTTCAAGGGAGTCTGGA -3’
5’- AAGGGCCCTGGTGTAGTAGG -3’
Wnt5a Forward
Reverse
5’- TGAATAACCCTGTTCAGATGTCA -3’
5’- TGTACTGCATGTGGTCCTGA -3’
Spp1 Forward
Reverse
5'- GACCCATCTCAGAAGCAGAA -3'
5'- TTCGTCAGATTCATCCGAGT -3'
CUGBP2 Forward
Reverse
5’- ATGCAACAGCTCAACACTGC -3’
5’- CAGCGTTGCCAGATTCTGTA -3’
TGF-" Forward
Reverse
5’- CACTCTGGGTACGTGGGTG –3’
5’- CACAGGTGATAATGAGGACAGC –3’
hnRNP A/B Forward
Reverse
5’- GAGGTGTACCAGCAACAGCA –3’
5’- AGTAGTTGCCGTAGCCCTGA –3’
Luciferase-reporter assay
RIE-H-RasV12 cells (1x105/well) were transiently transfected with  pGL3-basic
firefly luciferase reporters (250ng) with or without the VEGF promoter and co-
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transfected with a renillia luciferase reporter (15ng) to control for transfection efficiency.
Full length VEGF promoter-reporter construct was a gift from Dr. Keping Xie (Shi et al.,
2001). Plasmids were combined with Lipofectamine Plus (Invitrogen, Carlsbad, CA)
transfection reagent, according to manufacturer’s instructions, and incubated in Opti-
mem media (Invitrogen, Carlsbad, CA). After six hours, cells were treated with or
without 3ng/ml TGF-! in complete DMEM with 10% FBS for 48 hours. Dual luciferase
assay was performed according to manufacturer’s instructions (Promega, Madison, WI).
All transfections and treatments were performed in triplicate wells for each of seven
independent experiments. Firefly luciferase activity was normalized to renilla luciferase
activity for each sample. Average VEGF-promoter luciferase units were normalized to
pGL3-basic for each experiment. Statistical analysis was performed by t-test using
Kaleidagraph version 4.03.
TGF-" RIA
RIE:iRas cells were treated with or without 5 mM IPTG and 3 ng/ml TGF-! for
24 hours in DMEM with 0.5% FBS. Media were collected and cells washed twice in PBS
then lysed in 1 ml lysis buffer (25 mM Tris-HCl (pH 8.0), 50 mM NaCl, 0.5% sodium
deoxycholate, 0.5% NP-40, 0.02% sodium azide, 2 mM PMSF, 5 µg/ml pepstatin, 5
µg/ml leupeptin, and 5 µg/ml aprotinin) on a rocker at 4C for 1 hour. RIA was performed
as described (Russell et al., 1993) to measure TGF-" levels in both the conditioned media
and lysates. Representative wells were trypsinized and cells were counted with a
hemacytometer to normalize the data. TGF-" was measured in LIM1863 cells as
described above except cells were grown for 48 hours in RMPI with 5% FBS and 1%
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ITS. LIM1863 organoids in suspension were pelleted, media collected from both
suspension and adherent cells, and cells lysed.
EGFR IP/western
Cells were treated and lysed in RIPA buffer, as above for Western blots. Lysate
(500µg) was incubated overnight at 4°C with 4µg of rabbit anti-EGFR (Upstate
Biotechnology). Protein G-sepharose (50µl of packed beads) was added and incubated
overnight at 4°C. Immunoprecipitations were washed 3 times in PBS and beads
resuspended in 2x Laemmli sample buffer. SDS-PAGE and immunoblot analysis were
performed as above using mouse anti-phospho-EGFR(tyr1068) antibody (Cell Signaling
Technology).
Matrigel invasion assay
A modified Boyden chamber assay was performed using Transwells (8 µm pore
size, 12 mm diameter) from Costar (Cambridge, MA) and Matrigel (BD Biosciences).
Each Transwell insert was first coated with 2.5 mg/ml Matrigel diluted in serum-free
media. RIE:iRas cells (5x104) or LIM1863 cells (approximately 3x104) were washed with
serum-free media twice, re-suspended in 0.2% bovine serum albumin serum-free
medium, then seeded in Transwell inserts, and grown in the presence of 10% fetal bovine
serum media in the lower chamber. Both cell lines were treated with DMSO or 10µM
EKI-785 and either with or without 5 mM IPTG and 3 ng/ml TGF-! (RIE:iRas) or with
and without 2 ng/ml TGF-! and 10 ng/ml TNF-" in both the upper and lower chambers.
After 72 hours of incubation, cells that had not invaded were removed with cotton swabs,
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and the cells that had invaded to the lower surface of the inserts were rinsed with PBS,
fixed in 4% formaldehyde for 30 min at room temperature, mounted on glass slides with
DAPI mounting media, and the invaded cells were counted under a light microscope
(200x). Five random fields on each insert were counted to determine the number of cells
invaded. The invasion assay was performed in triplicate. Analysis of variance (ANOVA)
with Bonferroni correction was used to examine differences between treatment groups.
Statistical analyses were performed using Kaleidagraph version 4.03.
RNA extraction and Northern blots
Total cellular RNA was extracted from RIE:iRas cells using Trizol (GibcoBRL,
Carlsbad, CA), following manufacturer’s instructions. RNA was separated on a
formaldehyde-agarose gel (10 µg/lane) and transferred to Hybond N (Amersham,
Piscataway, NJ). Membranes were hybridized for 16 hours at 42°C with a mouse
VEGF165 or HuR cDNA probe labeled with ["-
32P]-dCTP by random primer extension
(DECAprime II kit, Ambion, Austin, TX). Membranes were then washed and mRNA
levels examined by autoradiography and quantified by phosphor-imaging. Background
was subtracted from VEGF mRNA levels and RNA loading was normalized to 18S
ribosomal RNA visualized with ethidium bromide and quantified with a BioRad Gel Doc
(Hercules, CA). Where indicated, RIE:iRas cells were treated for 24 hours with TGF-!,
IPTG, or both and then transcription was inhibited by treatment with 5 µg/ml
actinomycin D (Sigma-Aldrich, St. Louis, MO) for up to 4 hours. Mouse VEGF165 cDNA
was a gift from Charles Lin (Vanderbilt University, Nashville, TN). VEGF mRNA half-
life was estimated from a log-linear plot of VEGF/18S ratio versus time and least squares
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regression analysis. VEGF mRNA stability was modeled on a log scale via multiple
linear regression with effects for time, TGF-!, IPTG, and interactions between treatments
and between treatments and time, controlling for differences in three biological
replicates.
VEGF ELISA
RIE:iRas or YAMC cells were treated with TGF-! and/or IPTG for 24 hours in
serum-containing media, conditioned media were collected and cells lysed in RIPA
buffer (150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 50mM Tris-HCl
pH 8.0, 2mM EDTA, 1mM PMSF, 3µg/ml aprotinin, 10µg/ml leupeptin, 0.25mM
vanadate and 10mM NaF). Media and lysates were stored at -80°C until use. Samples
were thawed and an ELISA performed using the rat/mouse VEGF Duoset kit (R&D
Systems, Minneapolis, MN), according to manufacturer’s instructions. VEGF
concentration (ng/ml) was normalized to total protein levels in cell lysates as determined
by BCA protein assay (Pierce, Rockford, IL). ANOVA was used to examine differences
between mean VEGF protein expression levels among 4 treatment groups.  Statistical
analyses were performed using SAS version 9.1 and R version 2.1.1. VEGF dose
response was modeled via multiple linear regression with terms for linear, quadratic, and
interactions between log IPTG and log TGF-! concentration.
Prostaglandin analysis
RIE:iRas cells were pretreated for 15 minutes with 10µM NS398, 10µM
celecoxib, or an equal volume of DMSO vehicle in DMEM with 0.5% FBS, then 5mM
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IPTG and/or 3ng/ml TGF-! were added for an additional 24 hours. Prostaglandins
(PGF1" and PGE2) in conditioned media were quantified by the mass spectrometric
method developed by the Morrow laboratory, as previously described (DuBois et al.,
1994).
Immunofluorescence
RIE:iRas cells (1 x 105 cells) were grown on cover slips and were subsequently
left untreated or incubated with 5mM IPTG, 5 ng/ml TGF-!, or both IPTG and TGF-!
for 24 hours. The cells were fixed in 4% paraformaldehyde for 15 minutes at RT, washed
in PBS, and permeabilized with 0.2% Triton X-100 in PBS containing for 5 minutes.
Cells were then blocked with 1% bovine serum albumin (BSA) and 10% horse serum in
PBS for 30 min at RT. HuR expression was detected with an anti-HuR monoclonal
antibody (3A2; 1:250) diluted in PBS containing 3% BSA. The cells were incubated with
the anti-HuR antibody for 1 hour at RT, washed, and then incubated with anti-mouse
FITC-conjugated secondary antibody (1:100, Vector Labs, Burlingame, CA) for 1 h at
RT. Images were obtained using a Zeiss Axiovert 200 inverted microscope equipped with
an AxioCam Mrc5 camera. Anti-HuR and anti-tubulin were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Anti-nucleoporin was purchased from BD Biosciences
(San Diego, CA).
Nuclear and cytoplasmic fractionation
RIE:iRas cells were plated at 500,000 cells per dish in p60 plates and subsequently
treated with IPTG, TGF-!, or both for 24 hours. The cells were then trypsinized,
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centrifuged, washed with PBS, centrifuged, and 250 µl cytoplasmic lysis buffer (10mM
HEPES pH 8, 3mM MgCl2, 4 mM KCl, 0.2% NP-40, 10% Glycerol, 0.1 mM DTT) was
added to each cell pellet. Cells were incubated on ice 15 minutes then centrifuged at
10,000 rpm for 2 minutes. Supernatant (cytoplasmic fraction) was transferred to new
tubes. Remaining pellets were washed with 100 µl cytoplasmic lysis buffer, centrifuged
again, and nuclei were lysed in 150 µl RIPA with protease inhibitors. Western blots were
performed on nuclear and cytoplasmic fractions as described above.
HuR siRNA
RIE-1 cells were transfected with varying concentrations of control siRNA or
siRNA against HuR (Ambion, Austin, TX) using siQuest reagent (Mirus Bio, Madison,
WI), according to manufacturers instructions. After 24 hours of transfection, media was
changed and cells were grown for another 24 hours. Media were then collected for VEGF
expression analysis by ELISA and cell lysates were analyzed for HuR expression by
SDS-PAGE, as described above. VEGF production was normalized to total cell protein
and is expressed relative to control siRNA. Three independent experiments were
performed.
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CHAPTER III
EFFECTS OF ONCOGENIC RAS AND TGF-! ON GLOBAL GENE EXPRESSION
Introduction
Although cooperation between activated Ras and TGF-! signaling in the process
of EMT has been well established, the molecular mechanisms by which changes in
cellular behavior occur are not well understood. The cooperative interaction between
oncogenic Ras and TGF-! activity could occur at several different levels, from
transactivation of immediate downstream effectors, such as Smad2/3/4 and Raf-MEK-
ERK, to interaction between secondary gene products, such as COX-2 . Rat intestinal
epithelial cells stably transfected with an inducible activated H-RasG12V construct
(RIE:iRas cells) were utilized to examine the interaction between oncogenic Ras and
TGF-! signaling. In these cells, oncogenic Ras expression induces EMT and invasion,
which is further augmented by treatment with TGF-! (Fujimoto et al., 2001; Sheng et al.,
2000). In order to validate that this phenotypic transformation is specific for Ras
activation and TGF-! treatment, both immediate downstream effectors (i.e., Smads and
MEK) as well as targets further downstream, such as COX-2, were examined in the
RIE:iRas cells.
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Results
Ras and TGF-! specifically activate downstream effectors in RIE:iRas cells
The first goal of this study was to verify that oncogenic Ras and TGF-!
specifically activate downstream signaling as expected and then to determine whether
RasV12 and TGF-! together augment the activation of their immediate downstream
effectors.
TGF-! signaling. TGF-!-induced activation of its primary downstream effector,
Smad2, was examined by western blotting for phosphorylated Smad2. Treatment of
RIE:iRas cells for 24 hours with TGF-! induced robust phosphorylation and activation of
Smad2 in the presence or absence of Ras induction (Figure 4A), while oncogenic Ras
alone did not activate Smad2. An inhibitor of the kinase activity of TGF-! type I receptor
(T!RI), which blocks its ability to activate downstream effectors, was used for two
purposes: first, to confirm the specificity of TGF-! treatment and second, to determine
whether oncogenic Ras expression induces expression of TGF-! in the RIE:iRas cells and
whether this TGF-! then acts alone or in concert with RasV12 to activate downstream
signaling. Inhibition of T!RI activity with LY364947 (TRKi) blocks TGF-!-induced
phosphorylation of Smad2 (Figure 4A). When RIE:iRas cells were treated with TRKi to
inhibit TGF-! signaling, TGF-!-induced expression of COX-2, a known downstream
effector of TGF-! (Sheng et al., 2000) was completely blocked and the cooperative
induction of COX-2 by Ras and TGF-! together was reduced to the level of COX-2
expression induced by Ras alone (Figure 4A).
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Ras/MEK/ERK signaling. Phosphorylation and activation of the MEK/ERK
signaling pathway by oncogenic Ras and TGF-! was examined by western blot using
antibodies specific for phosphorylated ERK or total ERK. After treatment of RIE:iRas
cells for 24 hours with IPTG, TGF-! or IPTG and TGF-! together, ERK was
A phospho-Smad2
TRKi
RasV12
TGF-!
- ++-
- ++-
- ++-
- ++-
Smad2
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- ++-
- ++-
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!-actin
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- +-+
+ +--
- +-+
+ +--
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COX-2
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TGF-!
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- +-+
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Figure 4: Ras and TGF-! activate their downstream effectors in RIE:iRas cells.
RIE:iRas cells were pretreated for 15 minutes with (A) a TGF-! receptor kinase
inhibitor (2µM LY364947/TRKi) or (B) a MEK inhibitor (10µM U0126), then treated
for 24 hours with 5mM IPTG to induce RasV12 and/or 3ng/ml TGF-!. Western
blotting was performed for phospho-Smad2, total Smad2, phospho-ERK, total ERK,
COX-2 and !-actin.
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phosphorylated in the RasV12 expressing cells. Although TGF-! alone transiently
activates ERK within the first few hours of treatment (data not shown), MEK/ERK was
not active after 24 hours of TGF-! treatment alone in these cells (Figure 4B). No marked
difference in ERK phosphorylation was seen with RasV12 and TGF-! together compared
to RasV12 alone. Pretreatment of RIE:iRas cells with U0126, a MEK inhibitor, blocked
both basal and Ras-induced phosphorylation of ERK. Inhibition of MEK/ERK signaling
with U0126 blocked Ras-induced and slightly reduced TGF-!-induced COX-2
expression in the presence or absence of oncogenic Ras (Figure 4B). These results show
that oncogenic Ras and TGF-! do not appear to cooperate through augmented activation
of immediate downstream effectors.
Characterization of Oncogenic Ras and TGF-! cooperation and global gene expression
Gene expression profiling was used to identify the gene expression changes that
occur during Ras and TGF-!-induced EMT. Examination of gene expression patterns,
molecular pathways, and biological functions have the potential to identify important
molecules, signaling pathways, and novel mechanisms that mediate the cooperative
interaction between oncogenic Ras and TGF-!.
Microarray analysis reveals a cooperatively regulated gene signature. In order to
assess global changes in gene expression related to the cooperative interaction of Ras and
TGF-! in transformation, we conducted microarray analysis of RIE:iRas cells at 72 hours
post induction of H-RasV12 expression and/or TGF-! treatment. At this time point, the
cells have undergone the molecular and morphological changes associated with EMT and
acquired an invasive phenotype (Fujimoto et al., 2001). RNA from RIE:iRas cells left
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untreated, induced to express oncogenic Ras with IPTG treatment, treated with TGF-!, or
after both Ras induction and TGF-! treatment together were hybridized to a 28,000 gene
rat-specific oligonucleotide microarray and analyzed. At least three independent
biological replicates were analyzed for each condition. Each treatment group yielded both
unique and overlapping gene signatures (Figure 5). Analysis of the gene expression
profile containing the set of genes that showed a more than additive, or synergistic,
change with combined RasV12 expression and TGF-! treatment over either treatment
alone was conducted next. We found that RasV12 induction and TGF-! treatment
significantly (p<0.05, Benjamini-Hochberg multiple testing comparison) induced the
expression of 553 transcripts, of which 194 showed a synergistic increase. Similarly, Ras
activation and TGF-! treatment together significantly (p<0.05, Benjamini-Hochberg
multiple testing comparison) downregulated 619 transcripts, including 185 that were
synergistically decreased. In total, Ras activation and TGF-! treatment synergistically
regulated 379 transcripts on the oligonucleotide arrays. After removal of ESTs (expressed
IPTG
(578)
TGF-!
(57)
IPTG+TGF-!
(619)
24
149
182
25
405
0
8
Decreased
IPTG
(557)
TGF-!
(106)
IPTG+TGF-!
(553)
205 46
173
32
320
0
28
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Figure 5: Summary of microarray results. Venn diagrams demonstrating the
distribution of genes upregulated or downregulated in RIE:iRas cells after treatment
with 5mM IPTG to induce RasV12 expression, 3ng/ml TGF-! treatment or combined
IPTG and TGF-! treatment for 72 hours. The total number of genes with altered
expression above 2-fold (p<0.05, Benjamini-Hochberg multiple testing comparison)
in at least two of three biological replicates is given for each treatment.
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sequence tags) and taking into account genes with multiple probes, this represents 191
unique, annotated rat genes. A complete list of synergistically regulated genes is found in
Appendix Table 5. Oncogenic Ras expression and TGF-! treatment together display a
novel gene expression profile that was distinct from either stimulus alone, indicating the
cooperative regulation of a cohort of genes, collectively referred to hereafter as the “Ras
and TGF-! signature”.
Ras and TGF-! target genes involved in cell growth and movement. The Ras and
TGF-! gene signature was subsequently subjected to WebGestalt and Ingenuity Pathway
Analysis (Pertovaara et al.) to examine the signaling pathways, cellular and molecular
functions, and biological processes in which these genes are involved based on the
published literature. This analysis demonstrated that one interaction network was linked
through TGF-! as a central node and contained 29 genes involved in tissue morphology,
cell cycle, and cellular development. Another network contained H-Ras as a central node
for 13 genes with known roles in cellular movement, cancer and cell morphology.
The 379 synergistically regulated probe IDs were loaded into WebGestalt and
map to 189 human orthologs with annotation for gene identity and function. Overall, the
Ras and TGF-! signature was significantly enriched for genes associated with cell
movement (27% or 52 genes; p-value<0.002), development (31% or 59 genes; p-
value<0.002), and cell growth and proliferation (42% or 80 genes; p-value<0.002). The
Ras and TGF-! signature also contains several transcription factors (Zfp36l1, Fosb, Tcf7,
Dmrt2, Klf4, Stat1, Id2, Smarca2), extracellular matrix-related genes (Col5a3, Col14a1,
Timp2, Adamts1, Mmp13, Mmp10, Lamb3, Lamc2, Itga5) as well as genes involved in
cell adhesion and cytoskeletal organization (Ctnnal1, Marks, Fhl3, Tns4, Frmd4a,
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Map1b, Ocln, Cav1, Cadm1), angiogenesis (Vegfa, Edn1, Fgf1, Sphk1), and several
members of the TGF-! (Id2, Bmp2, Inhba, Tgfb1, Bmp4, Fst, Pai1) and Wnt (Wnt5a,
Fzd1, Axin2, Wnt2) signaling pathways. In addition, the Ras and TGF-! signature is
enriched for several genes with known roles in cancer (67 genes; p-value<0.002).
Validation. We have previously shown that oncogenic Ras and TGF-! cooperate
to synergistically increase COX-2 expression (Sheng et al., 2000). Independent and
quantitative validation of the Ras and TGF-! signature was conducted in RIE:iRas cells
for both mRNA and protein expression. The synergistic upregulation of several genes
implicated in tumor progression, such as COX-2, osteopontin (Spp1), integrin "5 and
integrin !1 were validated by quantitative real-time RT-PCR (Figure 6A). Additional
validation at the protein level was determined by western blot for Id2 and Follistatin, two
genes involved in TGF-!/BMP signaling during EMT and development (Figure 6B). For
each of these genes, oncogenic Ras expression combined with TGF-! treatment resulted
in synergistic regulation of gene expression levels compared to each condition alone. The
synergistic regulation of genes involved in EGFR signaling as well as regulation of the
angiogenic factor VEGF, both of which play important roles during EMT and cancer
progression, is described in detail in the following sections.
Examination of the Ras and TGF-! signature from transformed RIE:iRas cells
revealed changes in several genes involved in TGF-! superfamily signaling. As previous
studies from our lab have shown, Ras and TGF-! cooperate to increase the expression of
TGF-!1 ligand and the TGF-! target gene Pai-1 (Fujimoto et al., 2001; Sheng et al.,
2000). Oncogenic Ras and TGF-! also cooperatively regulated Bmp-1, Bmp-2, Bmp-4,
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Id2, follistatin, and inhibin!A (Appendix Table 5). The synergistic increase in secreted
Follistatin was confirmed at the protein level by western blotting of RIE:iRas conditioned
media after either 24 or 72 hours of induction of Ras expression and TGF-! treatment
(Figure 6B). The observed increase in follistatin mRNA levels in RIE:iRas cells could
regulate EMT by blocking BMP-2 (increased 28-fold) signaling and encourage the
retention of an epithelial phenotype. RIE:iRas cells undergoing Ras and TGF-!-mediated
EMT also showed a decrease in Id2 expression (Appendix Table 5), which was
confirmed by RT-PCR and decreased Id2 protein was observed after both 24 and 72
hours of treatment (Figure 6A-B). These Ras and TGF-!-induced changes in follistatin
and Id2 expression we see in the RIE:iRas cells are consistent with a model of TGF-!-
induced EMT and BMP-induced mesenchymal to epithelial transition (Lee et al.),
respectively.
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Figure 6: Validation of synergistic gene expression. (A) RNA was isolated from
RIE:iRas cells treated for 72 hours with 5mM IPTG, 3ng/ml TGF-!, or IPTG and
TGF-! together and expression of COX-2, Spp1, "5 integrin, !1 integrin, Axin2, and
Wnt5a quantified by real time RT-PCR. Changes in gene expression under treated
conditions were calculated relative to untreated samples and all values were
normalized to the housekeeping gene Pmm1. Dotted lines show mean expression for
each treatment. Significance was determined by ANOVA with Bonferroni correction.
RT-PCR for Id2 and cyclophilin. (B) Western blotting for Follistatin in conditioned
media or Id2 in cell lysates from RIE:iRas cells treated for 24 or 72 hours with or
without 5 mM IPTG and 3 ng/ml TGF-!.
B
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Summary
Treatment with specific inhibitors of TGF-! receptor tyrosine kinase activity or
MEK signaling demonstrate the specificity of TGF-! to activate downstream signaling in
RIE:iRas cells through activation of the primary effector Smad2 and increased expression
of the COX-2 target gene and show that induction of RasV12 expression in RIE:iRas
cells specifically activates downstream signaling through MEK and ERK to increase the
expression of target genes such as COX-2. Taken together, these results indicate that the
cooperation between oncogenic Ras and TGF-! does not occur at the level of primary
signal transduction through ERK and Smads since the combination of Ras activation and
TGF-! treatment does not modify the activation of ERK or Smad2 compared to either
alone. Rather, these data suggest that Ras and TGF-! signaling events intersect further
downstream. Microarray analysis of gene expression patterns indicate that oncogenic Ras
expression and TGF-! treatment together display a novel gene expression profile that
would not have been predicted from either stimulus alone. The synergistic regulation of a
set of genes, many of which have known roles in cellular functions such as mitogenesis,
migration and invasion, is associated with oncogenic Ras and TGF-!-induced EMT.
Detailed examination of the molecular mechanisms involved in the synergistic regulation
of specific genes, pathways, and gene families will provide insights into the molecular
events that contribute to the oncogenic process.
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CHAPTER IV
EGFR SIGNALING IS NECESSARY FOR TGF-!-INDUCED EMT
Introduction
Growth factor signaling has long been known to play a crucial role in cancer
development and progression. As tumors develop, cell growth becomes independent of
exogenous growth factors through mechanisms including increased autocrine growth
factor production and increased growth factor receptor expression, enhancing the
sensitivity of the tumor cells to low concentrations of host- or tumor-derived factors.
Increased signaling driven by growth factors like epidermal growth factor (EGF) has
been well characterized to increase cell growth and proliferation and enhance cell
survival.
EGFR family and signaling
The EGF receptor (EGFR) family, also known as ErbB tyrosine kinase receptors,
is composed of four members: EGFR, ErbB2, ErbB3, and ErbB4 (Figure 7). A diverse
array of ligands that are synthesized as transmembrane precursors that are cleaved by
metalloproteinases into mature growth factors that bind and activate the ErbB receptors
(Dong et al., 1999). Among these, EGF, transforming growth factor " (TGF-") and
heparin binding-EGF (HB-EGF) specifically bind EGFR, while epiregulin, !-cellulin,
and amphiregulin (AR) are able to bind both EGFR and ErbB4 (Yarden, 2001). Ligand
39
binding stimulates homo- or heterodimerization of the receptors, activation of the
tyrosine kinase domain, and receptor phosphorylation, allowing the recruitment of
adaptors and signaling molecules (Olayioye et al., 2000).  EGF receptor stimulation
activates signaling pathways such as Ras-MAPK, PI3K-Akt, and PLC# to promote
cellular proliferation, survival, and migration, respectively (Jorissen et al., 2003).
Figure 7: EGF family of receptors and ligands. Illustration shows members of the
EGF family of receptors and ligands. Listed above each receptor are known ligands.
Epidermal growth factor (EGF). Transforming growth factor ! (TGF-!). Heparin-
binding epidermal growth factor (HB-EGF).
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Role of EGFR in cancer
The epidermal growth factor family of ligands and receptors play a central  role
during early embryonic development in the pathogenesis and progression of carcinomas
in the gastrointestinal tract. TGF-" and EGFR expression is observed in the fetal colon,
particularly at the base of fetal human colonic crypts in regions with high proliferative
activity (Hormi and Lehy, 1994; Menard and Pothier, 1991). While TGF-" continues to
be expressed in adult colonic tissue, EGFR expression decreases to low levels in normal
adult colonic mucosa (Borlinghaus et al., 1993; Hormi and Lehy, 1994). However,
increased expression of EGFR, TGF-", and HB-EGF is observed in premalignant,
hyperproliferative aberrant crypt foci, along with subsequent activation of Ras and ERK
(Cohen et al., 2006) and several EGF receptors and ligands are overexpressed in colon
cancer compared to adjacent normal mucosa, including EGFR, ErbB3, AR, TGF-", and
EGF (Ciardiello et al., 1991; Messa et al., 1998; Saeki et al., 1995). Overexpression of
ErbB2 and its role in cancer has been extensively characterized, particularly in breast
cancer; however, increased ErbB2 expression occurs less frequently in colon cancer
(Normanno et al., 2003). Furthermore, increased TGF-" expression may correlate with
increased stage and lymph node metastasis in colorectal cancer (Saeki et al., 1995).
Several studies in transgenic mice have demonstrated the importance of EGFR
signaling in normal gut development as mice carrying triple null mutations in the EGF-
related ligands, AR, EGF, and TGF-" show defects in the gastrointestinal tract, such as
reduced proliferation of crypt cells (Troyer et al., 2001). Similarly, EGFR null mice show
disorganized crypt formation (Threadgill et al., 1995). The transforming properties of
EGF receptors and ligands are also seen in transgenic animals where EGFR
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overexpression in the mammary gland induced hyperplasia, but these only progressed to
dysplasias and adenocarcinomas in lactating animals (Brandt et al., 2000). TGF-"
overexpression also induces marked hyperplasia in several organs, including the liver and
gastrointestinal tract (Sandgren et al., 1990). The activated form of ErbB2 however, is
able to stimulate mammary tumors when overexpressed (Muller et al., 1988). These
studies suggest that overexpression of EGF receptors or ligands, other than activated
ErbB2, are not alone able to induce carcinomas and that other events such as proto-
oncogene activation are required.
Clinical trials of a monoclonal antibody directed against EGFR show efficacy in
about 10% of patients with chemotherapy-resistant metastatic colorectal cancer
(Cunningham et al., 2004; Saltz et al., 2004), particularly in patients with increased
EGFR gene copy number (Moroni et al., 2005). Although EGFR is a promising
therapeutic target for colorectal cancer, it may only be effective in a subset of patients.
Therefore, a more detailed understanding of the molecular mechanisms of EGFR
signaling in the gastrointestinal tract is necessary to take full advantage of EGFR
inhibiting therapeutic agents.
EGFR signaling in EMT
Normal epithelial cells are growth inhibited by TGF-!, often undergoing
apoptosis, while neoplastic epithelial cells are resistant to these inhibitory effects in part
through increased EGFR signaling. TGF-! induces TGF-" transcription in Fet-1 cells, a
well differentiated colon adenocarcinoma cell line, that undergo TGF-!-induced growth
inhibition but not apoptosis (Lynch et al., 1993). During TGF-!-induced EMT in fetal rat
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hepatocytes, TGF-" and HB-EGF expression increases (Del Castillo et al., 2006). EGFR
activity is necessary for resistance to TGF-!-induced apoptosis in these cells through a
PI3 kinase-mediated mechanism inhibiting cytochrome C release and caspase-3
activation (Fabregat et al., 2000). Although the involvement of EGFR in EMT remains
elusive, EGFR signaling down regulates E-cadherin expression and cell adhesion in
tumor cells. EGF or TGF-" treatment of breast cancer cells decreases E-cadherin
expression and increases expression of Twist, a transcriptional repressor of E-cadherin
(Lo et al., 2007). In human tumor cells, EGF treatment decreased E-cadherin expression
and cell adhesion through a mechanism involving caveolin-1-mediated endocytosis of E-
cadherin at early times after EGF treatment and through decreased E-cadherin
transcription, correlating with increased expression of the transcriptional repressor Snail,
at later time points (Lu et al., 2003). These studies suggest that EGFR contributes to EMT
by increasing cell survival and disrupting cell-cell adhesion.
Although Ras is activated by EGFR signaling and is generally considered to be
part of the downstream signaling, several studies have shown that TGF-" mRNA and
protein expression increase in RasV12 transformed cells (Buick et al., 1987; Ciardiello et
al., 1990). EGFR signaling is necessary for oncogenic RasV12-induced transformation,
as an anti-TGF-" antibody partially inhibits Ras transformation, while specific inhibition
of EGFR activity completely attenuated the Ras transformed phenotype in RIE cells
(Gangarosa et al., 1997). However, another study in keratinocytes deficient in TGF-"
expression showed that TGF-" is not necessary for Ras-mediated transformation and
tumor formation in nude mice, suggesting that other EGFR ligands, such as HB-EGF,
amphiregulin, and !-cellulin, may be able to substitute for TGF-" in Ras transformed
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keratinocytes (Dlugosz et al., 1995). Together, these studies suggest a role for EGFR
activation during Ras transformation, although the role of specific ErbB ligands remains
unclear.
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Results
Cooperative regulation of EGFR ligands and receptors
Analysis of the RIE:iRas microarray data reveals that oncogenic Ras and TGF-!
regulate the expression of several EGFR family ligands and receptors (Table 2). Together
Ras and TGF-! synergistically increase neuregulin and decrease !-cellulin and ErbB3
mRNA. While Ras and TGF-! together increased the expression of EGFR and HB-EGF
mRNA more than either Ras or TGF-! alone, their effects were not more than additive.
In addition, oncogenic Ras expression significantly increased amphiregulin and TGF-"
mRNA expression, although TGF-! was able to block the Ras-mediated amphiregulin but
not TGF-" expression.
Table 2: EGFR family genes differentially regulated by oncogenic Ras and TGF-!
Gene
TGF-!
(Fold)
RasV12
(Fold)
RasV12 + TGF-!
(Fold)
Amphiregulin nc 3.75 nc
!-cellulin nc -8.23 -12.41
EGFR nc nc 2.13
ErbB3 nc nc -3.25
HB-EGF 5.68 5.61 6.03
Neuregulin nc 3.72 5.08
TGF-" nc 29.22 28.32
Microarray analysis of RIE:iRas cells treated for 72 hours with 5mM IPTG, 3ng/ml TGF-!, or IPTG and
TGF-! together. Table lists EGF receptors and ligands affected by Ras expression or TGF-! treatment.
Fold change represents expression in Ras expressing and/or TGF-! treated samples compared to untreated;
numbers are the average of at least three biological replicates. nc = no change, defined as < 2-fold change
in expression compared to untreated.
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Figure 8: Oncogenic Ras and TGF-!  cooperatively increase TGF-" mRNA
expression. (A) TGF-" mRNA expression. Microarray intensity values. RNA was
isolated from RIE:iRas cells treated for 72 hours with 5mM IPTG, 3ng/ml TGF-!, or
IPTG and TGF-! together and expression of TGF-" quantified by real time RT-PCR.
Changes in gene expression under treated conditions were calculated relative to
untreated samples and all values were normalized to the housekeeping gene Pmm1.
Dotted lines show mean expression for each treatment. Significance was determined
by ANOVA with Bonferroni correction. Box plot shows data from three independent
experiments. (B) Quantitation of TGF-" mRNA induction by real time RT-PCR, as
above. Bar graph shows data from one representative experiment.
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Validation of this increase in TGF-" expression after 72 hours of Ras induction or
TGF-! treatment was confirmed by qRT-PCR (Figure 8A). Although the increase in
TGF-" expression occurs primarily in response to oncogenic Ras expression, treatment
of Ras expressing cells with TGF-! modestly increases TGF-" mRNA levels. The
kinetics of TGF-" induction were measured by qRT-PCR after 24 to 96 hours of
treatment with TGF-! and/or induction of RasV12 (Figure 8B). TGF-! did not induce
TGF-" at any time point, as noted after 72 hour of treatment. Oncogenic Ras induction of
TGF-" peaks within 48 hours and remains elevated for more than four days. In this
representative experiment TGF-! treatment did not augment Ras induction of TGF-"
Figure 9: Oncogenic Ras and TGF-!  cooperatively increase TGF-" protein
expression. TGF-" protein expression in RIE:iRas cell lysates treated with 5 mM
IPTG and/or 3 ng/ml TGF-! for 24 hours was measured by RIA. Box plot shows data
from 3 independent experiments. *p-value<0.004 compared to all other treatments
(ANOVA).
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mRNA. Regulation of TGF-" expression was also examined at the protein level (Figure
9), as detectable in cell lysates using a highly sensitive ELISA developed by Dr. Robert
Coffey (Vanderbilt University). Oncogenic Ras expression induced a 3-fold increase in
TGF-" protein compared to untreated cells while TGF-! alone did not affect TGF-"
expression, similar to the mRNA expression pattern. TGF-! treatment and RasV12
expression together synergistically increased TGF-" expression more than 8-fold.
Based on the observation that Ras and TGF-! synergistically upregulate TGF-"
expression in RIE:iRas cells, a potential role for TGF-" in the EMT response to TGF-!
was extended to the human colon cancer cell line, LIM1863, developed Dr. Robert
Whitehead (Whitehead et al., 1987). LIM1863 cells are well-differentiated colon
carcinoma cells that grow in suspension as organoids around a central lumen. TGF-!
induces nearly 100% of the floating organoids to attach to the plastic substrate and begin
to spread into a monolayer exhibiting phenotypic characteristics of EMT (Figure 10A)
(Bates and Mercurio, 2003). While TGF-!-induced attachment occurs within 24 hours of
treatment, migration into a monolayer and loss of E-cadherin occur over a period of 3-7
days, a process which is dramatically accelerated by treatment with tumor necrosis factor
" (TNF") (Bates and Mercurio, 2003). TGF-!-induced attachment is specific, as
demonstrated by the ability of a T!RI tyrosine kinase inhibitor, LY364947 (TRKi), to
block attachment of LIM1863 cells (Figure 10B). Furthermore, TGF-! treatment of
LIM1863 cells induced a significant increase in TGF-" protein expression (Figure 10C),
consistent with our data from RIE:iRas cells.
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EGFR activity during EMT
Activation of EGFR during TGF-!-induced EMT. In order to determine whether
TGF-", or other EGFR ligands, activate EGFR during TGF-!-induced EMT,
phosphorylation of EGFR was examined. RIE:iRas cells were pretreated with or without
EKI-785 and then treated for 24 hours with IPTG and/or TGF-!. Western blotting for
EGFR phosphorylation at tyrosine 1068 revealed that TGF-! and Ras expression, alone
or together, induce transient phosphorylation of EGFR (Figure 11A).
EGFR phosphorylation was also examined in LIM1863 cells.
Immunoprecipitation of EGFR and western blotting for phospho-EGFR showed that
EGFR is phosphorylated and activated within 4 days of TGF-! treatment, at a time when
Figure 10: TGF-! induces EMT and TGF-" expression in LIM1863 cells. (A)
Diagram of TGF-!-induced attachment and EMT from Bates et al., 2007 Cells
Tissues Organs 185:29. (B) LIM1863 cells  were treated with or without 2 ng/ml
TGF-! and/or 10 ng/ml TNF-" for 48 hours. Phase-contrast photomicrographs show
floating and attached cells (100x). (C) TGF-" protein expression in LIM1863 cell
lysates treated with or without 2 ng/ml TGF-! for 48 hours was measured by RIA.
Box plot shows data  from 5 independent experiments. # p-value = 0.003 (ANOVA).
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the cells are attached and spreading into a monolayer (Figure 11B). Phosphorylated and
total EGFR levels decrease over the following two days.
A
Figure 11: EGFR is phosphorylated during TGF-!-induced EMT. (A) RIE:iRas
cells were pretreated for 15 minutes with DMSO or 1 µM EKI, then treated for 24
hours with or without 5 mM IPTG and/or 3 ng/ml TGF-!. Western blotting was
performed on cell lysates for phospho and total EGFR. (B) LIM1863 cells were
treated 0 to 6 days with 2ng/ml TGF-!. EGFR was immunoprecipitated from cell
lysates and Western blotting performed for total EGFR and phospho-Tyr1068 EGFR.
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Blocking EGFR activity prevents TGF-!-induced EMT. To determine whether
TGF-" expression and subsequent activation of EGFR is necessary for TGF-!-induced
EMT, cells were treated with an EGF receptor tyrosine kinase inhibitor (EKI-785).
RIE:iRas cells were pretreated with EKI-785 then treated with TGF-! or IPTG to induce
RasV12 expression. After 72 hours, combined Ras expression and TGF-! treatment
induced a spindle-shaped phenotype and EMT in RIE:iRas cells (Figure 12). Although
the EKI-785, IPTG, and TGF-! treated cells were less organized and cuboidal than
untreated cells, treatment with EKI-785 blocked the Ras and TGF-!-induced transition to
a fibroblastoid phenotype and prevented the cells from piling up on each other to form
foci.
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Figure 12: EGFR activity required for TGF-!-induced EMT in RIE:iRas cells.
Cells were pretreated for 15 minutes with DMSO or 1 µM EKI, then treated for 72
hours with or without 5 mM IPTG and/or 3 ng/ml TGF-!. Phase-contrast
photomicrographs show cell morphology (100x).
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Similar results were observed in LIM1863 cells. The organoids were pretreated
with or without EKI-785, treated with or without TGF-! for 24hrs, and then the cells
were photographed before and after through washing with PBS to remove any floating
cells. Treatment with EKI-785 prevented TGF-!-induced attachment of LIM1963 cells to
the plastic substrate (Figure 13). The Ras-MEK-ERK pathway is activated downstream of
EGFR signaling. LIM1863 cells were pretreated with the MEK inhibitor U0126 and then
treated with TGF-!. Blockade of MEK-ERK signaling prevented TGF-!-induced
attachment of LIM1863 cells (Figure 14). Interestingly, while activation of EGFR
signaling is required for TGF-!-induced EMT in these cells signaling, addition of
exogenous EGFR ligands, amphiregulin, TGF-", or EGF, is not able to accelerate TGF-
!-induced attachment of LIM1863 cells (Figure 15), suggesting that EGFR ligand
endogenous ligand production is sufficient to saturate receptor signaling.
EGFR activity is necessary for TGF-!-induced invasion. The role of EGFR
signaling plays in malignant cells behaviors, such as invasion and migration, was
examined. RIE:iRas cells were treated with or without EKI-785 and in the presence or
absence of IPTG and TGF-!. Cell invasion through matrigel coated transwells was
quantified after 72 hours of treatment. Untreated or EKI-785 treated cells were not
invasive, while oncogenic Ras expression and TGF-! treated cells were highly invasive
(Figure 16A). Inhibition of EGFR signaling with EKI-785 treatment significantly
decreased cell invasion. Similarly, LIM1863 cells are normally not invasive (Figure
16B). While TGF-! and TNF" transformed cells were highly invasive, EKI-785
treatment blocked cell invasion.
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Figure 13: EGFR activity required for TGF-!-induced EMT in LIM1863  cells.
LIM1863 cells were treated with or without 2 ng/ml TGF-! and 10 ng/ml TNF-" for
48 hours. Floating were collected, including two PBS washes, and attached cells were
detached with  trypsin. Phase-contrast photomicrographs show floating and attached
cells before (400x) and after PBS washing (100x). Both floating and attached cells
from untreated and TGF-! treated samples were disrupted into single cell suspensions
and counted on a hemocytometer. Bar graph represents the average of three
independent experiments +/- SD. p-value<0.0001 (ANOVA).
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Figure 14: MEK-ERK activity required for TGF-!-induced EMT in LIM1863
cells. Cells were pretreated with 10 µM U0126 for 30 minutes, then treated with or
without 2 ng/ml TGF-! for 48 hours. Phase-contrast photomicrographs show floating
and attached cells (200x).
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Figure 15: Exogenous EGFR ligands do not augment TGF-!-induced EMT in
LIM1863  cells. Cells were left untreated or treated with EGFR ligand (AR, TGF-",
or EGF) and simultaneously treated with or without 2 ng/ml TGF-! for 48 hours.
Phase-contrast photomicrographs show floating and attached cells (200x).
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Summary
Microarray analysis reveals that oncogenic Ras and TGF-! cooperate to alter the
expression of the EGF receptor and several EGF-related ligands. In addition, an increase
in EGFR phosphorylation and activation was observed in both RIE:iRas cells and the
LIM1863 colon cancer cell line during TGF-!-induced EMT. TGF-" is one potential
mediator of increased EGFR activity in these cells. While treatment with TGF-!
Figure 16: EGFR activity required for TGF-!-induced cell invasion. Cells were
plated Matrigel coated Transwells and treated. After 72 hours, cells were removed
from the top of the filter, then the bottom was fixed and mounted with DAPI mounting
media. (A) RIE:iRas cells were grown in the presence of DMSO, 1 µM EKI,  5 mM
IPTG and 3 ng/ml TGF-!, or IPTG, TGF-!, and EKI. (B) LIM 1863 cells were grown
in DMSO, 1 µM EKI, 10 ng/ml TNF-" and 2 ng/ml TGF-!, or TNF-", TGF-!, and
EKI. Five high power fields (hpf) of cells were counted per filter.  *p-value < 0.05 for
TGF-! + Ras/TNF-" vs. all other treatments (ANOVA).
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modestly augments the oncogenic Ras-induced increase in TGF-" mRNA expression,
TGF-! show marked synergy with RasV12 in increasing TGF-" protein expression,
suggesting that the cooperation between Ras and TGF-! signaling occurs through a post-
transcriptional mechanism by increasing TGF-" mRNA stability, translation efficiency,
or TGF-" protein stability. Similar increases in TGF-" expression were observed in
LIM1863 cells after TGF-! treatment, demonstrating that increased TGF-" expression is
associated with TGF-!-induced EMT in multiple model systems. Increased EGFR
activity has profound effects on cell behavior since blocking EGFR signaling with the
small molecule EKI-785 inhibited the phenotypic transformation of both RIE:iRas and
LIM1863 cells. Furthermore, EGFR inhibition was able to block TGF-!-induced invasion
of both cell lines. These results provide evidence of an important role for EGFR signaling
during the malignant transformation of intestinal epithelial cells.
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CHAPTER V
ONCOGENIC RAS AND TGF-! REGULATE VEGF AND OTHER GENES BY A
POST-TRANSCRIPTIONAL MECHANISM
Introduction
mRNA stability
Gene expression is tightly regulated at multiple levels including transcription,
mRNA stability, translation efficiency, and protein stability. There is growing evidence
that mRNA turnover plays a central role in the regulation of gene expression. The rate at
which RNA is degraded is a key point of regulation, particularly for immediate early
genes, such as myc, which are tightly regulated and often have unstable RNAs. Many of
these same factors are known mediators of oncogenic transformation, whose expression
is significantly enhanced in cancer, partially through mRNA stabilization, including
proto-oncogenes, growth factors and cytokines (Audic and Hartley, 2004).
The two main components responsible for regulating RNA stability and
translation efficiency are cis-elements and trans-acting factors. One of the most important
cis-acting elements in mRNA is the adenylate/uridylate-rich regions, or AU-rich elements
(ARE), in the 3’ untranslated region (3’UTR) of messenger RNA molecules (Caput et al.,
1986; Shaw and Kamen, 1986). AREs contain multiple adenylate-uridylate AUUUA
repeats and often have a high uridylate content (Figure 17).  The ARE targets mRNA for
rapid and selective degradation and can inhibit translation (Akashi et al., 1994; Chen et
al., 1994; Shaw and Kamen, 1986). Trans-acting factors also play an important role in
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regulating mRNA stability.  There are many RNA-binding proteins that bind the
AUUUA motif and are able to modulate mRNA decay (Bevilacqua et al., 2003). These
RNA-binding proteins can function as positive or negative regulators of mRNA stability
or translational efficiency, in part by regulating the subcellular localization of mRNA
(Hollams et al., 2002; Perrotti and Calabretta, 2002).
Altered mRNA stability is important in regulating tumor-associated genes that
participate in cancer progression. For example, general mRNA turnover and RNase
activity are higher in host livers than in transplanted hepatomas (Sidransky et al., 1978).
Importantly, the mRNA of several normally unstable genes, such as cytokines and cell
cycle regulators, are preferentially stabilized in tumor cells compared to normal cells
(Lee et al., 1998; Ross et al., 1991). Rapid decay of c-myc mRNA is mediated by cis-
elements in the 3’UTR, yet in certain cases of myeloma and leukemia, the c-myc 3’UTR
is translocated or lost leading to increased c-myc mRNA stability (Hollams et al., 2002).
AAAAn
3´ UTR
UUAUUUA(A/U)(A/U)
Coding region5´ UTR
RNABP
Figure 17: AU-rich element and mRNA structure. Illustration shows 5’
untranslated region (5’ UTR), coding region, and 3’ untranslated region (3’ UTR) of
messenger RNA. Blue circles denote adenylate/uridylate rich elements (AREs)
consisting of at least two ARE consensus sequences (AUUUA). Trans-acting factors,
or RNA binding proteins (RNABPs) bind AREs and modulate mRNA stability and
translation.
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An mRNA binding protein, CRD-BP, thought to stabilize c-myc mRNA, is amplified in
35% of breast cancers (Doyle et al., 2000). We have recently shown that COX-2, an
important factor in inflammation and carcinogenesis, is regulated on a post-
transcriptional level through its relatively long AU-rich 3’UTR which contains numerous
AREs sequences that are necessary for stabilization of COX-2 by oncogenic Ras and
TGF-! (Sheng et al., 2000). Furthermore, activity of the RNA binding protein HuR has
been associated with stabilization of COX-2 mRNA in ovarian cancer, brain tumors, and
colon cancer (Denkert et al., 2004; Dixon et al., 2001; Nabors et al., 2001).
VEGF
Angiogenesis is an essential process of endothelial cell proliferation, migration
and vessel formation that occurs during development and is necessary for tumor growth
and progression, when the formation of nutrient supplying blood vessels is vital for
tumors grow beyond 1-2mm in size (Folkman, 2002). Over-expression of VEGF has been
observed in several different cancers including pancreatic and colon, where it is often
highly expressed at an early stage and associated with tumor progression and metastasis
(Fujimoto et al., 1998; Konno et al., 1998; Takahashi et al., 1995; Wong et al., 1999).
Expression of VEGF is stimulated by a variety of conditions and factors, such as hypoxia,
nitric oxide, several cytokines and growth factors and by the expression of oncogenes like
myc (Gale and Yancopoulos, 1999; Hanahan and Folkman, 1996; Rak et al., 2000). In
addition, oncogenic Ras and TGF-! have each independently been shown to increase
steady state levels of VEGF mRNA and protein in a variety of cell types. TGF-!
increases VEGF expression in lung, breast, and kidney cancer cell lines (Donovan et al.,
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1997; Pertovaara et al., 1994; Wang et al., 2004) and oncogenic Ras increases VEGF
expression in intestinal epithelial cells, endothelial cells, and keratinocytes (Arbiser et al.,
1998; Rak et al., 2000; Segrelles et al., 2004).
VEGF regulation and mRNA stability
The transcriptional regulation of VEGF by oncogenes and growth factors has
been well characterized, however recent evidence suggests that changes in VEGF mRNA
stability contribute significantly to the regulation of VEGF expression. Stabilization of
VEGF mRNA was first observed in response to low oxygen conditions, or hypoxia
(Finkenzeller et al., 1995; Ikeda et al., 1995; Levy et al., 1995; Shima et al., 1995; Stein
et al., 1995). This stabilization of VEGF mRNA requires the binding of RNA binding
proteins, such as HuR and hnRNP L,  to the ARE region of the VEGF mRNA 3’UTR
(Dibbens et al., 1999; Levy et al., 1998; Shih and Claffey, 1999). In addition to hypoxic
conditions, VEGF mRNA is stabilized by RasV12 expression in fibroblasts (White et al.,
1997). VEGF mRNA was not stabilized by TGF-! in renal proximal tubular epithelial
cells (Kitamura et al., 2003). However, these results should be viewed with some caution
since the kinetics examined were not optimized for elucidating the stabilizing effects of
TGF-!. Although it is clear that oncogenic Ras expression and TGF-! treatment are each
able to induced VEGF expression, the mechanisms by which they regulate VEGF
expression and their combined effects on VEGF are not well understood.
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Results
Oncogenic Ras and TGF-! synergistically increase VEGF expression
One of the genes synergistically regulated by oncogenic Ras and TGF-! in the
microarray experiment was VEGF, showing no change after TGF-! treatment, a 5.9-fold
increase with RasV12 expression, and combined RasV12 and TGF-! further increased
VEGF mRNA expression to 7.5-fold. Since the angiogenic factor VEGF has a well-
established role in promoting cancer progression and metastasis (Fujimoto et al., 1998;
Konno et al., 1998; Takahashi et al., 1995; Wong et al., 1999), we conducted a thorough
and in depth analysis of VEGF mRNA and protein levels induced by activated Ras in
combination with TGF-! exposure. First, VEGF mRNA expression patterns were
validated by Northern blotting mRNA from RIE:iRas cells treated for 24 hours with
IPTG to induce oncogenic Ras expression, TGF-!, or both IPTG and TGF-!. Steady state
VEGF mRNA levels are very low in untreated RIE:iRas cells and increase 6- and 4-fold
after IPTG induction of RasV12 or TGF-! treatment, respectively, but increase more than
13-fold with RasV12 expression and TGF-! together (Figure 18A). TGF-! maximally
induces VEGF mRNA within 24 hours, after which VEGF is still expressed, albeit at
lower levels (Figure 18B). Oncogenic Ras induces VEGF expression more slowly,
delayed in part due to the lag between IPTG treatment and RasV12 expression, and
steadily increases between 12 and 72 hours. The profound cooperative effect of Ras and
TGF-! together on VEGF mRNA expression can be seen within 12 hours and is
sustained for more than 72 hours.
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Likewise, VEGF levels were determined by ELISA in conditioned media from
RIE:iRas cells treated for 24 hours with IPTG, TGF-!, or both IPTG and TGF-!.
Untreated RIE:iRas cells produce low levels of VEGF protein. Treatment of RIE:iRas
cells with TGF-! or expression of oncogenic Ras alone increased VEGF protein levels in
the media by 3-4 fold, whereas oncogenic Ras and TGF-! together synergistically
increased VEGF protein levels more than 15-fold (Figure 19A). Similar results were
observed after 72 hours of treatment (data not shown). The cooperative effects of RasV12
and TGF-! on VEGF protein expression were confirmed independently in young adult
mouse colonocyte (YAMC) cells and YAMC cells stably transfected with RasV12
(YAMC-Ras). Oncogenic Ras expression increased VEGF expression in YAMC-Ras
cells compared to parental cells and TGF-! treatment cooperated with RasV12 to further
RasV12
TGF-!
+
-
+
+
-
+
-
-
18S
VEGF
RasV12
TGF-!
RasV12 + TGF-!
0      6     12    24    48    72
Time (hours)
untreated
Figure 18: Oncogenic Ras and TGF-! synergistically increase VEGF mRNA
expression in RIE:iRas. RIE:iRas cells were treated with either vehicle, 5mM IPTG,
3ng/ml TGF-!, or both IPTG and TGF-!. VEGF mRNA levels in RIE:iRas cells were
visualized by Northern blot using a mouse VEGF165 cDNA probe and 18S rRNA
visualized with ethidium bromide. Northern blot is representative of at least three
separate experiments. (A) VEGF mRNA expression after 24 hours of treatment. (B)
Time course of VEGF mRNA expression.
A B
65
increase VEGF expression (Figure 19B). These data demonstrate that oncogenic Ras and
TGF-! cooperatively regulate VEGF expression in multiple gastrointestinal epithelial cell
lines.
Induction of VEGF by TGF-! treatment is dose-dependent, leveling out at
0.2ng/ml TGF-! (Figure 19C). IPTG-induced oncogenic Ras expression also stimulated
VEGF in a dose dependent manner (Figure 19D), however the nature of the lac operon
controlled inducible system relies more on a threshold IPTG dose to induce Ras
expression than on a gradient response. However, TGF-!  treatment and RasV12
induction together have a synergistic interaction on the production of VEGF (all
p<0.0001, test for interaction in regression). These results demonstrate the dose-
dependent and synergistic induction of VEGF expression stimulated by Ras and TGF-!
together compared to each alone.
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Figure 19: Oncogenic Ras and TGF-! synergistically increase VEGF protein expression in
RIE:iRas and YAMC cells. (A) RIE:iRas cells were treated with either vehicle, 5mM IPTG, 3ng/ml
TGF-!, or both IPTG and TGF-! for 24 hours. VEGF protein levels were measured in conditioned
media by ELISA and normalized to total protein concentrations. Box plot shows data summarized from
seven independently replicated experiments. *p-value <0.004 compared to untreated. **p-value <0.03
compared to untreated. #p-value <0.002 compared to all treatments. (B) YAMC and YAMC-Ras cells
were treated with or without 5ng/ml TGF-! for 24 hours then VEGF levels were measured in
conditioned media by ELISA and normalized to total protein concentrations. Box plot shows data from
eight independently replicated experiments. #p-value <0.0001 compared to all samples. (C-D) RIE:iRas
cells were treated with IPTG and/or TGF-! at varying doses for 24 hours and VEGF levels were
measured in conditioned media by ELISA and normalized to total protein concentrations. Cells were
treated with or without 5mM IPTG and 0, 0.04, 0.2, 1, 5, or 10 ng/ml TGF-! or cells were treated with
or without 3ng/ml TGF-! and 0, 0.001, 0.01, 0.1, 1, or 5 mM IPTG. Graphs show average of three
independent experiments +/- SE. Dose-dependence and synergistic interaction was confirmed via
multiple linear regression (all p<0.0001).
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Signaling pathways involved in VEGF regulation
TGF-! and MEK-ERK signaling. An inhibitor of the kinase activity of TGF-!
type I and type II receptors, which blocks their ability to activate down stream effectors,
was used for two purposes: first, to confirm the specificity of TGF-! treatment and
second, to determine whether oncogenic Ras expression induces expression of TGF-! in
the RIE:iRas cells and whether this TGF-! then acts alone or in concert with RasV12 to
increase VEGF expression. TGF-! treatment, alone or with Ras induction,
phosphorylates Smad2, and this phosphorylation is blocked by TRKi pretreatment.
Inhibition of the kinase activity of T!RI and T!RII with LY364947 (TRKi) blocks the
TGF-!-mediated increase in VEGF protein and mRNA expression (Figure 20A).
However, T!RI and T!RII activity is not necessary for the oncogenic Ras-mediated
increase in the expression of VEGF protein, but TRKi does decrease VEGF mRNA levels
slightly. The synergistic increase in VEGF protein and mRNA expression by
simultaneous induction of oncogenic Ras and TGF-! treatment is blocked by inhibition
of T!RI/II kinase activity, lowering it to the same level as oncogenic Ras induction alone
(Figure 20A). These data demonstrate that the TGF-!-receptors type I and type II (T!RI
and T!RII) are required for TGF-! but not RasV12 to increase VEGF expression.
The Raf-MEK-ERK signaling cascade is activated by oncogenic Ras and required
for Ras and TGF-!-induced EMT in keratinocytes (Janda et al., 2002). The MEK
inhibitor, U0126, was used to determine whether oncogenic Ras and TGF-! utilize
MEK/ERK signaling to increase VEGF expression. U0126 pretreatment prevents ERK
phosphorylation in response to oncogenic Ras expression or TGF-! treatment (Figure
20B). Inhibition of MEK with U0126 completely blocks VEGF protein and mRNA
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expression induced by oncogenic Ras and TGF-!, alone or in combination (Figure 20B).
Although ERK activity is required for either oncogenic Ras or TGF-! to induce VEGF,
there was no additional activation of ERK by RasV12 and TGF-! together, so ERK
activity may not be sufficient to account for the cooperative increase in VEGF expression
by oncogenic Ras and TGF-!.
PI3 kinase activity contributes to oncogenic Ras and TGF-! induction of VEGF.
The PI3 kinase-Akt signal transduction pathway is another of the prominent pathways
activated by oncogenic Ras and TGF-! (Rommel and Hafen, 1998; Zavadil and
Bottinger, 2005). To address whether oncogenic Ras and TGF-! increase VEGF
expression by signaling through PI3 kinase and its downstream effector, Akt, activation
status of PI3K/Akt was assessed in RIE:iRas cells. Oncogenic Ras and TGF-! induce
phosphorylation and activation of Akt, either alone or together (Figure 21). Inhibition of
PI3K with LY294002 blocks most of the oncogenic Ras-induced increase in VEGF
mRNA and protein but has no effect on the TGF-!-induced increase in VEGF expression
(Figure 21A). In the presence of the PI3K inhibitor, oncogenic Ras and TGF-! still
cooperatively increased VEGF expression, albeit not to the same level as in the absence
of the inhibitor. Similar results were obtained with YAMC and YAMC-Ras cells treated
with and without TGF-! and LY294002 (Figure 21B). This suggests that while the
PI3K/Akt pathway has a role in the cooperative increase in VEGF by oncogenic Ras and
TGF-!, there appears to be a PI3K-independent component.
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Figure 20: T!RII and ERK activity are necessary for oncogenic Ras and TGF-!
to increase VEGF expression in RIE:iRas cells. RIE:iRas cells were pretreated for
15 minutes with a (A) T!RII inhibitor (2µM TRKi) or (B) MEK inhibitor (10µM
U0126) then treated for 24 hours with 5mM IPTG and/or 3ng/ml TGF-!. VEGF
protein levels were assayed by ELISA and normalized to total protein levels. VEGF
Northern blot (with18S rRNA loading control band) is shown along with
corresponding Western blot of phosphorylated and total Smad2 or ERK. (A) Box plot
shows data from three independently replicated experiments. (B) Box plot shows data
from four independently replicated experiments. *p-value = 0.17 compared to TGF-!.
**p-value = 0.31 compared to Ras. #p-value <0.0001 compared to Ras + TGF-!.
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Figure 21: Synergistic induction of VEGF by oncogenic Ras and TGF-! is PI3
kinase and Akt dependent. (A) RIE:iRas cells were pretreated for 15 minutes with a
PI3K inhibitor (20µM LY294002) then treated for 24 hours with 5mM IPTG and/or
3ng/ml TGF-!. VEGF protein levels were assayed by ELISA and normalized to total
protein levels. Box plot shows data from four independently replicated experiments.
*p-value<0.08 compared to Ras. **p-value<0.0001 compared to Ras + TGF-!
(ANOVA). VEGF Northern blot (with18S rRNA loading control band) is shown
along with corresponding Western blot of phosphorylated Akt and total Akt. (B)
YAMC and YAMC-Ras cells were pretreated for 15 minutes with a PI3K inhibitor
(20µM LY294002) then treated for 24 hours with or without 5ng/ml TGF-!. VEGF
protein levels were assayed by ELISA and normalized to total protein levels. Dot plot
shows data from two independently replicated experiments. Western blot showing
phosphorylated Akt and total Akt.
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p38-independent induction of VEGF expression. Another candidate signaling
cascade that may contribute to the regulation of VEGF is the p38 MAPK signaling
pathway, which is activated during TGF-!-induced EMT in keratinocytes (Davies et al.,
2005). A recent study demonstrated that p38 signaling down regulates VEGF expression
in H-RasV12 transformed liver epithelial cells (Okajima and Thorgeirsson, 2000).
Expression of oncogenic Ras and treatment with TGF-! does not phosphorylate and
activate p38 MAPK in RIE:iRas cells (Figure 22). Inhibition of p38 activity with
SB203580 increases Ras and TGF-!-induced expression of VEGF mRNA and protein
(Figure 22).
EGFR signaling is required for increased VEGF expression. TGF-" treatment of
keratinocytes induces bioactive VEGF expression (Detmar et al., 1994). My previous
data demonstrate that RasV12 expression and TGF-! treatment activate EGFR signaling
in RIE:iRas cells (Chapter IV). To examine whether EGFR activation affects VEGF
expression, RIE:iRas cells were pretreated with EKI-785, treated with IPTG and/or TGF-
!, then conditioned media collected and levels of secreted VEGF were measured. EKI-
785 blockade of EGFR signaling inhibited TGF-! or Ras-induced VEGF expression
(Figure 23A). In addition, EKI-785 significantly reduced VEGF expression induced by
oncogenic Ras and TGF-! together. Similar results were observed in another colon
cancer cell line, YAMC cells (Figure 23B).
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Figure 22: Synergistic induction of VEGF by oncogenic Ras and TGF-! does not
require p38 activity. RIE:iRas cells were pretreated for 15 minutes with a p38
inhibitor (2µM SB203580) then treated for 24 hours with 5mM IPTG and/or 3ng/ml
TGF-!. VEGF protein levels were assayed by ELISA and normalized to total protein
levels. Dot plot shows data from two independently replicated experiments. VEGF
Northern blot (with 28S rRNA loading control band) is shown along with
corresponding Western blot of phosphorylated and total p38.
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VEGF induction by oncogenic Ras and TGF-! is independent of COX-2 activity.
Previous studies indicated a role for COX-2 in the induction of VEGF in tumor cells
(Abdelrahim and Safe, 2005; Kim et al., 2005b; Masunaga et al., 2000; Nishikawa et al.,
2004; Tsujii et al., 1998), therefore the secondary effects of COX-2 activity in RIE:iRas
cells were examined. A COX-2 specific inhibitor, NS398, was used at a concentration
(10µM) that completely inhibits COX-2-dependent prostaglandin production (Tsujii et
al., 1998). Inhibition of COX-2 activity and prostaglandin production at this dose had no
A B
Figure 23: EGFR signaling contributes to the synergistic induction of VEGF by
oncogenic Ras and TGF-!. (A) RIE:iRas cells were pretreated for 15 minutes with
an EGFR inhibitor (1µM EKI) then treated for 24 hours with 5mM IPTG and/or
3ng/ml TGF-!. VEGF protein levels were assayed by ELISA and normalized to total
protein levels. Box plot shows data from three independently replicated experiments.
(B) YAMC-Ras cells were pretreated for 15 minutes with an EGFR inhibitor (1µM
EKI) then treated for 24 hours with or without 5ng/ml TGF-!. VEGF protein levels
were assayed by ELISA and normalized to total protein levels. Box plot shows data
from six independently replicated experiments.
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effect on the synergistic induction of VEGF by oncogenic Ras and TGF-! (Figure 24A),
indicating that Ras and TGF-! signaling regulate VEGF expression independently of
COX-2. Prostaglandin levels, and thus COX-2 activity, were assessed by 6-keto-PGF1",
a stable metabolite of PGI2 and one of the major prostaglandins produced by COX-2
activity in these cells (Figure 24B). Similar results were obtained with the COX-2
inhibitor celecoxib and a similar response was observed for PGE2 levels (data not
shown).
These results were futher confirmed in another colon cancer model cell line,
YAMC, by activating Ras signaling with EGF treatment. Parental YAMC cells or COX-2
null YAMC cells (Figure 24C) were treated with or without TGF-! and EGF, then VEGF
protein levels in conditioned media were measured. TGF-! and EGF treatment together
cooperatively increased VEGF expression compared to either treatment alone, although
EGF cooperated to a lesser degree than oncogenic Ras expression (Figure 24D). COX-2
null YAMC cells showed the same VEGF expression pattern as the parental cells. These
data from two separate colon cancer model cell lines demonstrate that activation of Ras
and TGF-! signaling regulates VEGF gene expression through a COX-2-independent
mechanism.
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Figure 24: Ras and TGF-! -mediated increase in VEGF expression is COX-2 independent.
RIE:iRas cells were pretreated with DMSO or 10µM NS398 for 15 minutes then treated with vehicle,
5mM IPTG, 3ng/ml TGF-!, or both IPTG and TGF-! for 24hrs. (A) VEGF protein in conditioned
media was measured by ELISA and normalized to total protein concentration. Box plots show data
from four independently replicated experiments. (B) Prostacyclin (6-keto-PGF1") levels in conditioned
media were measured by gas chromatography-mass spectrometry. Box plots show data from four
independently replicated experiments. Significance between no inhibitor and NS398 treatment was
determined by ANOVA with Bonferroni correction. *p-value <0.0001 compared to TGF-!. **p-value =
0.09 compared to Ras. #p-value <0.0001 compared to Ras + TGF-!. (C) YAMC and COX-2 null
YAMC cells were treated for 24 hours with EGF and/or TGF-!. Western blotting for COX-2 and !-
actin. (D) YAMC and COX-2 null YAMC cells were treated for 24 hours with EGF and/or TGF-!.
VEGF protein in conditioned media was measured by ELISA and normalized to total protein
concentration. Box plots show data from three independently replicated experiments. * p-value = 0.02
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Oncogenic Ras and TGF-! cooperate to increase VEGF mRNA stability
Our previous work demonstrates that oncogenic Ras and TGF-! synergistically
increase COX-2 expression and mRNA stability through a mechanism involving AU-rich
elements (AREs) in the 3’untranslated region (UTR) of its mRNA transcript (Sheng et
al., 2000). VEGF mRNAs also contain AREs in their 3’UTR that target VEGF mRNA
for rapid degradation (Claffey et al., 1998; Levy et al., 1995; Levy et al., 1998; Shima et
al., 1995). The half-life of VEGF mRNA in the context of oncogenic Ras expression and
TGF-! treatment was examined and in untreated cells rapid decay was observed yielding
a half-life of 25 minutes for VEGF mRNA (Figure 25). Either Ras induction or TGF-!
treatment alone increased the stability of VEGF mRNA significantly (both p<0.0001),
extending the half-life to 50-55 minutes. Furthermore, combined Ras activation and TGF-
! treatment together also significantly increased VEGF mRNA stability (p<0.0001),
extending the half-life to 120 minutes. Although no interaction above the additive effects
of TGF-! and RasV12 were seen in mRNA stability (all p > 0.1788), combined
oncogenic Ras expression and TGF-!  markedly potentiated VEGF mRNA stability
compared to each alone (Figure 25).
Increased VEGF mRNA stabilization may not be the sole mechanism whereby
VEGF mRNA is increased. To determine whether oncogenic Ras and TGF-! increased
the transcription of VEGF, RIE-H-RasV12 cells were transiently transfected with a
VEGF promoter/luciferase reporter construct. TGF-! treatment did not enhance the
luciferase reporter activity of Ras expressing cells (Figure 26). These results demonstrate
that oncogenic Ras and TGF-! synergistically increase VEGF expression through
increased VEGF mRNA stability.
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Figure 25: Oncogenic Ras and TGF-! cooperate to synergistically stabilize VEGF mRNA.
Northern blot analysis of RIE:iRas cells after treatment for 24 hours with vehicle, 5mM IPTG,  3ng/ml
TGF-!, or both IPTG and TGF-! and then treatment with 10µg/ml Actinomycin D for up to 4 hours.
(A) VEGF Northern blot and 18S rRNA, as detected by ethidium bromide staining. (B) Percentage of
VEGF mRNA, normalized to 18S rRNA levels, remaining after actinomycin D treatment. Each
treatment group is highlighted in a separate graph and data are representative of three separate
experiments. ! untreated, " TGF-!, # IPTG, $ IPTG + TGF-!.
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A global mechanism of post-transcriptional gene regulation
Oncogenic Ras and TGF-! regulate ARE-containing genes. Based on the
observed regulation of both COX-2 and VEGF by a post-transcriptional mechanism, the
hypothesis that Ras and TGF-! cooperatively regulate global gene expression profiles
through a post-transcriptional mechanism involving AREs was formed. To test this
hypothesis, the Ras and TGF-! signature was examined for AU-rich element (ARE)
motifs that mediate post-transcriptional regulation of gene expression (Bakheet et al.,
2006) and function as binding sites for specific RNA binding proteins that regulate the
rate of RNA degradation and translation (Lee et al., 1998; Ross et al., 1991). ARE
analysis using a multiple search approach revealed that 39% of the 379 synergistically
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Figure 26: Ras activation of VEGF promoter-reporter is not affected by TGF-!.
RIE-H-RasV12 cells were transiently transfected with a VEGF promoter-luciferase
reporter or pGL3-basic control plasmid. Cells were treated with or without 3 ng/ml
TGF-! for 48 hours and luciferase activity measured. VEGF promoter activity was
normalized to pGL3 control plasmid. Box plot shows data from seven independent
experiments. p-value = 0.3 (t-test).
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regulated transcripts contained AREs in their 3’UTRs. Among the 191 unique genes in
this set with annotations, 105 (56%) contain AU-rich elements (Appendix Table 6). Since
only 5-8% of the transcriptome is estimated to contain such elements (Bakheet et al.,
2006), the Ras and TGF-! signature was found to be enriched more than 4-fold with
ARE-containing genes. In order to assess the statistical significance of ARE gene
representation, we employed the recently developed and stringent ARED-Organism
database (Halees et al., 2008). We observed a statistically significant 4-fold increase in
ARE-gene representation in the set of synergistically regulated genes (p=0.001).
Interestingly, we also observed a 4-fold enrichment of ARE-containing genes among
those genes differentially regulated in response to Ras expression (p=0.0001) or TGF-!
treatment (p=0.0002) alone or together (p=0.0001). It should be noted that the ARED-
Organism method is very stringent and non-comprehensive due to the high number of rat
genes with incomplete or missing 3’UTRs. Gene ontology and KEGG analysis of the list
of synergistic ARE-containing genes using IPA revealed that this list is significantly
enriched for genes associated with cell migration and invasion (p<0.002), cell growth and
proliferation (p<0.001), and cancer (p<0.004). The biological and molecular functions of
some of these genes are listed in Table 3. The over-representation of ARE-containing
genes in the Ras and TGF-! signature suggests that neoplastic transformation results in
profound changes in gene expression through post-transcriptional mechanisms.
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Table 3: Functions of ARE-containing genes synergistically regulated by oncogenic
Ras and TGF-!
Gene Symbol Gene Name Rat Ensembl GID Fold change
TGF-! RasV12
RasV12 +
TGF-!
Adhesion & Motility
Nrg1 neuregulin 1 ENSRNOG00000010392 -0.02 3.15 4.38
Podxl podocalyxin-like ENSRNOG00000012495 -1.34 -1.65 -2.90
Marcks myristoylated alanine rich protein kinase C substrate ENSRNOG00000000579 0.01 1.38 3.20
Vnn1 vanin 1 ENSRNOG00000016219 -2.09 -5.77 -7.94
Gne glucosamine ENSRNOG00000014365 1.77 4.11 6.52
Olr1 oxidized low density lipoprotein (lectin-like) receptor 1 ENSRNOG00000008375 -1.84 -4.26 -21.26
Col14a1 procollagen, type XIV, alpha 1 (predicted) ENSRNOG00000026415 -1.67 -8.14 -13.31
Igsf4a immunoglobulin superfamily, member 4A ENSRNOG00000018778 -1.33 -2.11 -4.23
Lamc2 lamimin, gamma 2 ENSRNOG00000002667 1.78 7.49 9.63
Cxadr coxsackie virus and adenovirus receptor ENSRNOG00000001557 -1.65 -7.32 -10.53
Ctnnal1 catenin (cadherin associated protein), alpha-like 1 (predicted) ENSRNOG00000010593 -2.57 -2.31 -7.18
Angiogenesis
Vegfa vascular endothelial growth factor ENSRNOG00000019598 1.45 5.90 7.52
Fgf13 fibroblast growth factor 13 ENSRNOG00000003523 -1.29 -7.46 -13.92
Growth & proliferation
Gas6 growth arrest specific 6 ENSRNOG00000018233 -2.08 -10.17 -27.00
Nppb natriuretic peptide precursor type B ENSRNOG00000008141 2.73 9.17 14.57
Fhl1 four and a half LIM domains 1 ENSRNOG00000000875 1.30 -11.85 -18.74
Dusp1 dual specificity phosphatase 1 ENSRNOG00000003977 1.85 -1.03 -3.36
Mycn v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) ENSRNOG00000006308 -1.58 -18.99 -67.66
Transcription
Klf4 kruppel-like factor 4 (gut) ENSRNOG00000016299 -1.29 1.04 -2.54
Id2 inhibitor of DNA binding 2 ENSRNOG00000007237 -3.40 -2.15 -6.66
Tcf7 transcription factor 7, T-cell specific (predicted) ENSRNOG00000005872 1.85 -1.10 20.51
Stat1 signal transducer and activator of transcription 2 ENSRNOG00000014079 -1.80 -1.28 -3.16
Nrg1 neuregulin 1 ENSRNOG00000010392 -0.02 3.15 4.38
ECM related
Adamts1 a disintegrin-like and metallopeptidse with thrombospondin type 1 motif, 1 ENSRNOG00000001607 -2.32 -12.63 -19.39
Col14a1 procollagen, type XIV, alpha 1 (predicted) ENSRNOG00000026415 -1.67 -8.14 -13.31
Mmp13 matrix metallopeptidase 13 ENSRNOG00000008478 2.18 3.23 23.10
Mmp10 matrix metallopeptidase 10 ENSRNOG00000032832 1.24 2.71 4.10
Cytoskeleton
Marcks myristoylated alanine rich protein kinase C substrate ENSRNOG00000000579 0.01 1.38 3.20
Map1b microtubule-associated protein 1b ENSRNOG00000017428 4.01 5.37 9.94
Ctnnal1 catenin (cadherin associated protein), alpha-like 1 (predicted) ENSRNOG00000010593 -2.57 -2.31 -7.18
Cav caveolin ENSRNOG00000006694 -1.68 -2.13 -5.01
RNA binding proteins
Zfp36l1 zinc finger protein 36, C3H type-like 1 ENSRNOG00000030024 -2.35 -2.13 -6.25
Cugbp2 CUG triplet repeat, RNA binding protein 2 ENSRNOG00000023661 -2.01 -2.58 -5.64
A2bp1 ataxin 2 binding protein ENSRNOG00000002827 -1.42 3.09 4.71
Growth factors & cytokines
Nrg1 neuregulin 1 ENSRNOG00000010392 -0.02 3.15 4.38
Bmp4 bone morphogenetic protein 4 ENSRNOG00000009694 -1.90 -10.34 -18.82
Bmp2 bone morphogenetic protein 2 ENSRNOG00000021276 1.81 20.10 25.40
Wnt5a wingless-type MMTV integration site 5A ENSRNOG00000015618 1.09 2.98 7.41
Wnt2 wingless-related MMTV integration site 2 ENSRNOG00000007843 2.49 1.16 7.79
Pdgfa platelet derived growth factor, alpha ENSRNOG00000001312 1.30 2.24 6.74
Vegfa vascular endothelial growth factor ENSRNOG00000019598 1.45 5.90 7.52
Il24 interleukin 24 ENSRNOG00000004470 1.30 2.95 23.63
Il1a interleukin 1 alpha ENSRNOG00000004575 1.08 1.46 16.17
Ccl2 chemokine (C-C motif) ligand 2 ENSRNOG00000007159 5.47 17.28 37.90
Btc betacellulin ENSRNOG00000002728 -1.58 -7.33 -11.47
Wnt signaling
Wnt5a wingless-type MMTV integration site 5A ENSRNOG00000015618 1.09 2.98 7.41
Wnt2 wingless-related MMTV integration site 2 ENSRNOG00000007843 2.49 1.16 7.79
Fzd1 frizzled homolog 1 (Drosophila) ENSRNOG00000016242 1.20 1.24 2.70
Axin2 axin2 ENSRNOG00000003612 1.42 2.26 4.26
TGF-! signaling
Bmp4 bone morphogenetic protein 4 ENSRNOG00000009694 -1.90 -10.34 -18.82
Bmp2 bone morphogenetic protein 2 ENSRNOG00000021276 1.81 20.10 25.40
Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 (PAI-1) ENSRNOG00000001414 33.57 4.60 57.69
All genes listed in the table are significantly and synergistically regulated by a combination of Ras induction and TGF-
! treatment and contain an ARE (AU-rich element) motif in the 3’UTR. Fold change represents expression in Ras
expressing and/or TGF-! treated samples compared to untreated. Gene expression increases and decreases are defined
as greater than 2-fold. Presence of an ARE was determined by analysis using the ARE database, ARED3.0 (Bakheet et
al., 2006).
Cooperative regulation of RNA binding proteins. Analysis of the RIE:iRas
microarray showed a synergistic change in the expression of two known mRNA binding
proteins in response to Ras and TGF-!. A 3.2-fold increase in heterogeneous nuclear
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ribonucleoprotein A/B (hnRNP A/B), a member of the hnRNP family of RNA binding
proteins involved in RNA trafficking and splicing, was induced by oncogenic Ras and
TGF-!. The cooperative increase in hnRNP A/B by oncogenic Ras and TGF-! at various
time points was confirmed by qRT-PCR, although synergy was only observed at the 48
hour time point (Figure 27B).
Another RNA binding protein, CUGBP2, has been shown to bind the COX-2
3’UTR and inhibit its translation in response to ionizing radiation (Mukhopadhyay et al.,
2003), consistent with our observed 4.3-fold decrease in CUGBP2 expression and
increase in COX-2 expression in response to oncogenic Ras expression and TGF-!
treatment. The synergistic decrease in CUGBP2 expression was confirmed at the mRNA
level by qRT-PCR (Figure 27A). Validation of endogenous CUGBP2 and hnRNP A/B
expression could not be confirmed at the protein level due to a lack of commercially
available antibodies.
Oncogenic Ras and TGF-! cooperate to alter HuR localization and expression.
Data indicating the synergistic effects of oncogenic Ras and TGF-! directly effect the
expression of ARE-containing genes and influence the stabilization of VEGF and COX-2
mRNA suggested that the ability of AREs to promote rapid decay was compromised.
Based on its ability to bind AREs and stabilize the mRNA of genes such as COX-2 and
VEGF (Dixon et al., 2001), involvement of the mRNA stability factor HuR was
examined. Under normal conditions HuR is primarily localized in the nucleus. However,
in response to cellular signaling, it can shuttle to the cytoplasm where it can influence
mRNA stabilization and translational efficiency (Brennan and Steitz, 2001). Based on
this, changes in cytoplasmic trafficking of HuR could account for the observed VEGF
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Figure 27: Ras and TGF-! regulate RNA binding protein expression. RNA was isolated from
RIE:iRas cells treated for 72 hours with 5mM IPTG, 3ng/ml TGF-!, or IPTG and TGF-! together and
expression of CUGBP2 and hnRNP A/B quantified by real time RT-PCR. Changes in gene expression
under treated conditions were calculated relative to untreated samples and all values were normalized to
the housekeeping gene Pmm1. Dotted lines show mean expression for each treatment. Significance was
determined by ANOVA with Bonferroni correction. (A) RNA was isolated from cells treated for 72
hours with 5mM IPTG, 3ng/ml TGF-!, or IPTG and TGF-! together. Dotted lines show mean
expression for each treatment. Significance determined by ANOVA with Bonferroni correction. (B)
RNA was isolated from cells treated 24, 48, 72, or 96 hours with 5mM IPTG, 3ng/ml TGF-!, or IPTG
and TGF-! together. Bar graph shows data from one representative experiment.
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mRNA stabilization and protein overexpression promoted by oncogenic Ras and TGF-!.
RIE:iRas cells were incubated with IPTG to induce Ras expression, TGF-!, or a
combination of both, and localization of HuR was examined by immunofluorescence
(Figure 28A). HuR was primarily detected in the nuclei of untreated RIE:iRas cells.
Expression of oncogenic Ras or treatment with TGF-! for 24 hours increased HuR levels
in the cytoplasm and cytoplasmic HuR was robustly detected by immunostaining after
oncogenic Ras and TGF-! treatment together. Similar results were obtained upon
examination of HuR subcellular localization by SDS-PAGE (Figure 28B). In addition to
the nuclear to cytoplasmic translocation of HuR, total levels of HuR protein, but not
mRNA, were cooperatively increased by oncogenic Ras and TGF-! (Figure 28C-D).
A role for HuR in the regulation of VEGF. To examine the role of HuR in the
regulation of VEGF expression, siRNA against HuR was transiently expressed in RIE
cells. A dose-dependent decrease in HuR expression was observed after HuR siRNA
transfection (Figure 29). A concomitant decrease in VEGF protein expression was also
seen (Figure 29). These results indicate that HuR is translocated from the nucleus to the
cytoplasm under conditions of oncogenic Ras and TGF-! signaling in intestinal epithelial
cells and suggest that this regulated translocation of HuR contributes to mRNA
stabilization and protein synthesis in these cells.
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Figure 28:  Oncogenic Ras and TGF-! influence subcellular localization and
expression of HuR in RIE:iRas cells. (A) RIE:iRas cells (1 x 105) were plated on
cover slips and were subsequently left untreated or incubated for 24 hours with 5mM
IPTG, 5 ng/ml TGF-!, or both IPTG and TGF-! followed by examination of HuR
localization by immunofluorescence. (B) Western blot analysis of nuclear (20 µg) and
cytoplasmic (40 µg) levels of HuR in RIE:iRas cells that were either untreated
(labeled NT) or treated as described above. Nucleoporin and "-tubulin served as
loading controls for nuclear and cytoplasmic preparations, respectively. (C) Western
blot analysis of total (30 µg) HuR levels that were either left untreated or treated as
stated above.  !-actin served as a loading control. (D) Northern blot analysis of HuR
mRNA levels. 18S ribosomal RNA served as a loading control.
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Figure 29: Inhibition of HuR expression attenuates VEGF expression in RIE
cells. RIE-1 cells were transfected with increasing concentrations of a control siRNA
(-) or a siRNA against HuR (siRNA). After 24 hr of transfection, media was changed
and cells were grown for another 24 hr. Cultured media was then collected for VEGF
expression analysis by ELISA (bottom panel) and cell lysates were analyzed for HuR
expression by SDS-PAGE (top panel). Relative VEGF production was assessed as
VEGF secretion in cultured media normalized to total cell protein. All values shown
are normalized to VEGF expression in cells transfected with the respective amount of
control siRNA and indicate the averages triplicate experiments.
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Summary
Oncogenic Ras and TGF-! cooperate in a dose-dependent manner to
synergistically increase VEGF expression in multiple gastrointestinal epithelial cell lines.
Several signaling pathways known to be activated by both Ras and TGF-! participate in
this synergistic increase in VEGF, as MEK/ERK and EGFR activity are necessary and
PI3K/Akt signaling also contributes. However, the cooperative interactions of Ras and
TGF-! increase VEGF expression independently of COX-2 activity and p38 signaling.
The synergistic increase in VEGF expression by oncogenic Ras and TGF-! occurs
through a mechanism of increased VEGF mRNA stability, while a cooperative increase
in VEGF promoter activity is not observed. Furthermore, this study suggests a global
mechanism of post-transcriptional regulation is involved in altering gene expression
during EMT. The set of synergistically regulated genes is enriched with gene containing
AU-rich elements and Ras and TGF-! cooperatively affect RNA binding proteins,
decreasing CUGBP2 (an inhibitor of translation) and increasing cytoplasmic HuR (a
mRNA stabilizing protein).
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CHAPTER VI
COLORECTAL CANCER MICROARRAY
Introduction
Recently, advances in gene array technology have made it possible to evaluate
gene expression patterns across much of the known genome. Microarray analysis of
colorectal tumors facilitates identification of genes that differentiate biological behavior
or response to therapeutic intervention. Due to the multitude of variables affecting in vivo
tumorigenesis, such as genetic background, patient history and diet, it is useful to inform
gene expression analyses of malignant transformation with those occurring in well-
controlled experiments through cell culture model systems. Such model systems have
demonstrated important mechanistic principles such as the loss of a growth inhibitory
response to TGF-! in the process of carcinogenesis and that TGF-! can promote tumor
progression, increase cell motility and invasiveness, and promote metastasis (Cui et al.,
1996; Friedman et al., 1995; Janji et al., 1999; Robson et al., 1996). Oncogenic Ras can
switch TGF-! from a growth suppressor to a growth promoter and TGF-! enhances the
transforming effects of oncogenic Ras (Filmus et al., 1992; Fujimoto et al., 2001; Oft et
al., 1996).
One objective of this study is to determine whether the our cell model of EMT is
applicable to human cancers. The approach described here is to perform combined
analysis of microarray data sets derived from cell culture model systems of colorectal
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cancer and clinical colorectal data sets. The Ras inducible rat intestinal epithelial
(RIE:iRas) cell culture model is used to examine the biological relevance of genes
involved in malignant transformation, such as is seen in the cooperation of TGF-! and
oncogenic Ras. The Ras and TGF-! signature was compared with expression patterns
seen in human colorectal tumors. The hypothesis of this study states that interrogation of
clinical microarray data sets using parallel data sets from cell culture model systems leads
to the identification of biomarkers and novel therapeutic targets for colon cancer.
Results
In order to determine whether the Ras and TGF-! signature derived from
RIE:iRas cells provides mechanistic insights into the human disease, global gene
expression profiles from human colorectal cancers were examined. Gene expression
profiles from colorectal cancer (CRC) samples were obtained using the Affymetrix U133
Plus 2.0 array. These profiles were examined for genes significantly (Q-value< 0.05)
changed in human stage 4 metastatic colorectal adenocarcinomas as compared with
adenomas and 7721 transcripts, corresponding to 3694 unique Ensembl gene IDs, were
differentially regulated.
Overlap between CRC and RIE:iRas microarray
The 379 transcripts synergistically up- or down-regulated by Ras and TGF-! in
RIE:iRas cells were mapped to human orthologs based on Ensembl annotation, resulting
in 189 genes. These synergistic genes were then intersected with the 3694 genes
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differentially expressed in stage 4 adenocarcinoma compared to adenomas (Figure 30).
Among the 44 genes in common between human CRCs and RIE:iRas cells are several
genes involved in TGF-! signaling (Bmp1, Bmp4, Follistatin, Inhibinba, Pai1, Tgfb1),
EGFR signaling (Erbb3, Epiregulin), and adhesion and migration (Col14a1, Col5a3,
7721 transcripts differentially expressed
3694 unique transcripts
379 transcripts
204 unique transcripts
189 Human orthologs
3650 44 145
23%1%
Human CRC
(3694)
Rat Synergy
(189)
Human CRC 
Adenoma vs. Stage 4
RIE:iRas 
RasV12 & TGF-! synergy
Figure 30: Molecular events in transformed RIE:iRas cells reflect gene
expression changes in human colorectal tumors. Flow chart and Venn diagram
show the intersection of genes differentially expressed in stage 4 human colorectal
cancer samples compared to adenomas (Q-value<0.05) with human homologs of the
RIE:iRas Ras-TGF-! signature genes using Webgestalt.
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Integrina5, Timp2) (Appendix Table 6). Annotation of the rat genome is less complete
than that of the human genome, thus gene overlap between the RIE:iRas and CRC lists is
likely incomplete.
Several ARE-containing genes that are differentially expressed between human
adenomas and stage 4 CRC overlap with genes that are also present in the Ras and TGF-!
gene signature derived from RIE:iRas cells. There is a high correlation (8/11) in the
direction of expression change in ARE-containing genes between the oncogenic Ras and
TGF-! signature and stage 4 CRC (Table 4). Several of the genes in common between
the rat cellular model and human CRC are involved in cell proliferation and adhesion,
such as Col14a1, Gne, Mbp, Pai-1, Tfp1, and Vegfa. Furthermore, three of these genes,
Vegfa, Pai-1, and Tfp1, have well established roles in cancer.
Table 4: Human and rat differentially expressed ARE-containing genes
Gene
Symbol Gene Name
Rat
RasV12 + TGF-!
vs. untreated
Human
Stage 4 vs.
adenoma
AKAP7 A-kinase anchor protein 7 isoform gamma down down
ANKH Progressive ankylosis protein homolog up down
ARL4C ADP-ribosylation factor-like protein 4C up up
CHSY1 Chondroitin sulfate synthase 1 up up
COL14A1 Collagen alpha-1(XIV) chain down up
GNE Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-
acetylmannosamine kinase
up down
MBP Myelin basic protein down down
RAB27A Ras-related protein Rab-27A down down
SERPINE1 Plasminogen activator inhibitor 1 (PAI-1) up up
TFPI Tissue factor pathway inhibitor up up
VEGFA Vascular endothelial growth factor A up up
All genes listed contain AU-rich elements, are synergistically regulated by oncogenic Ras
and TGF-! in RIE:iRas cells, and are significantly changed in human stage 4
adenocarcinomas compared to adenomas. Presence of an ARE (AU-rich element) was
determined by analysis using the ARE database, ARED3.0 (Bakheet et al., 2006).
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In addition to changes in specific genes that were synergistically regulated by Ras
and TGF-! in RIE:iRas cells, numerous genes involved in the signaling pathways
investigated here are differentially regulated in CRC. KEGG based pathway analysis of
human CRC microarray revealed that 11 genes associated with the EGF pathway are
differentially regulated in stage 4 adenocarcinomas compared to adenomas. Among these
are several signaling mediators, such as Grb2, HRas, Jak1 and Shc1, which have
increased expression in stage 4 adenocarcinomas and activate downstream signaling. In
addition, two separate oligo probe sets for the EGF receptor, Erbb1, are down regulated
in stage 4 adenocarcinomas compared to adenomas (Figure 31). Profound misregulation
of genes involved in TGF-! signaling was also observed in the human CRC microarray,
KEGG based pathway analysis revealed that 27 genes associated with the TGF-!
 
Figure 31: EGFR expression is significantly decreased in stage 4 CRC. Box plots
show microarray expression values for two oligonucleotide probe sets in adenomas
(n=5) and stage 4 adenocarcinomas (n=19).
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pathway are differentially regulated in stage 4 adenocarcinomas compared to adenomas.
Among these are several ligands (Bmp1, Bmp4, Bmp7, Tgfb1, Tgfb2, Nodal), inhibitors
(Inhibinba, Inhibinbb, Follistatin), receptors (Bmpr2, Tgfbr1, Acvr1, Acvr1c), and
signaling mediators (Smurf1, Smad7, Smad5). All of these genes, except Smad7 and
Acvr1c, show increased expression in stage 4 adenocarcinomas. Overall, these changes
suggest increased TGF-! signaling, through increased expression of ligands and type I
receptor and decreased expression of inhibitory Smad7, and decreased BMP signaling
due to increased expression of the BMP inhibitor Follistatin and increased expression of
Smurf1, which targets BMP specific Smad1/5 for degradation, despite increases in BMP
ligands.
Clinical significance of post-transcriptional gene regulation
ARE-containing genes in CRC progression. Previous studies have demonstrated
that dysregulation of mRNA stability may occur during the malignant transformation of
cancer cells through mutations in the cis-regulatory elements or by dysregulation of the
trans-acting proteins that bind these elements (Denkert et al., 2004; Dixon et al., 2001;
Hollams et al., 2002). These studies, together with the observation that ARE-containing
genes are enriched in the Ras and TGF-! signature, led to the hypothesis that a similar
ARE-mRNA enrichment occurs in human CRC samples. The set of 3694 genes
differentially regulated between adenomas and stage 4 adenocarcinomas were examined
for the presence of conserved ARE motifs (Bakheet et al., 2006). A 3- to 4-fold
enrichment in ARE-containing genes was observed, showing an increase in ARE-
mRNAs from 5-8% of the whole transcriptome to 20.2% within the differentially
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regulated transcripts (Appendix Table 7). To facilitate statistical analysis, we used the
stringent ARED database (Halees et al., 2008) and found that ARE representation in this
gene list was statistically significant (p-value = 0.001). Furthermore, we observed AREs
in 21-24% of the genes differentially expressed between adenomas and any stage of
adenocarcinoma, including stage 1 (p=0.001), 2 (p=0.001), or 3 (p=0.002), and all
adenocarcinomas combined (p=0.0002), representing a statistically significant
enrichment. A notable enrichment of ARE-containing genes (20.3%) was also observed
in the list of genes differentially regulated in late stage CRC samples that were analyzed
with the ABI microarray platform (data not shown). Taken together, these results indicate
that molecular events in transformed RIE:iRas cells reflect the gene expression changes
in human tumors and could provide mechanistic insights into the oncogenic process.
RNABPs in CRC. Among the genes differentially expressed in stage 4 CRC
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Figure 32: HuR expression is significantly increased in stage 4 CRC. Box plots
show microarray expression values for two oligonucleotide probe sets in adenomas
(n=5) and stage 4 adenocarcinomas (n=19).
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compared to adenomas are 151 RNA binding protein encoding genes, representing a
significant enrichment (p<0.0006) of genes with this molecular function. Among these
RNABPs, HuR is significantly increased in stage 4 adenocarcinoma as compared with
adenomas (Figure 32).  Furthermore, 17 genes involved in translation initiation,
elongation, and repression are differentially regulated in late stage CRC.
Summary
Analysis of microarray gene expression patterns in human colorectal cancer
samples suggest that stage 4 adenocarcinomas have increased signaling through Ras and
TGF-! and decreased BMP signaling, consistent with known roles of these pathways in
EMT and MET, respectively. In addition, several genes that are regulated by oncogenic
Ras and TGF-! in the RIE:iRas cells are also differentially regulated in stage 4
adenocarcinomas compared to adenomas, including increases in VEGF, an important
angiogenic factor, and PAI-1, a regulator of adhesion and migration. Furthermore, the list
of genes differentially expressed in stage 4 adenocarcinomas compared to adenomas is
enriched for genes with AU-rich elements and contains many RNA binding proteins,
such as HuR, suggesting a role for post-transcriptional gene regulation during colorectal
cancer progression. Together these results demonstrate that gene expression patterns in
transformed RIE:iRas cells grown under highly controlled conditions are reflective of
some of the gene expression changes that occur during tumor development and
progression, suggesting that this cell culture system could yield a better understanding of
the molecular mechanisms underlying carcinogenesis.
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CHAPTER VII
DISCUSSION AND FUTURE DIRECTIONS
The molecular mechanisms leading to the metastatic spread of cancer cells are
incompletely understood but critically important to the prevention of cancer-related
fatalities. Given the heterogeneity and complexity of human tumors, experimental models
of tumor cell behavior are invaluable for the elucidation of key regulators and
mechanisms contributing to malignancy. In this study, we used a rat intestinal epithelial
cell line under non-transforming and highly transforming conditions to characterize
pathway-specific gene expression signatures in well-controlled conditions, finding that a
global mechanism of post-transcriptional regulation of gene expression is important
during Ras and TGF-!-mediated EMT in vitro and represents a clinically relevant target.
Cooperation between Ras and TGF-!
TGF-! treatment enhances oncogenic Ras-induced transformation and invasion in
intestinal epithelial cells. One explanation for this is that Ras and TGF-! each moderately
activate the same pathways and that threshold effects are achieved when the two are
activated in combination. In this study, TGF-!-mediated activation of Smad2 was not
effected by Ras expression and Ras activation of ERK was not effected by TGF-!
treatment, though Ras and TGF-! together cooperate to induce COX-2 expression. These
results show that synergy between Ras and TGF-! occurs downstream or in parallel with
the primary effectors of Ras and TGF-! signaling. Thus, crosstalk between Ras and TGF-
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! may result in threshold activation of a downstream target that in turn uniquely regulates
a distinct set of genes important for EMT.
The purpose of this study is to examine the mechanism and effect of the
interaction of oncogenic Ras expression and TGF-! treatment. We used microarray
analysis to define a Ras and TGF-! expression signature consisting of genes that are
regulated in a more than additive, or synergistic, way in response to this unique
interaction. Quantitative validation of several genes in the Ras and TGF-! signature at the
mRNA and protein levels demonstrated that Ras and TGF-! interact to synergistically
regulate gene expression, which is of particular importance since microarray technology
is not purely quantitative.
The Ras and TGF-! signature revealed numerous cooperatively regulated genes
that are known to have relevance for EMT. For example, a synergistic increase in
expression of the transcriptional repressor Snail is consistent with the increase in Slug we
recently observed and reported during Ras-induced transformation and EMT in the
RIE:iRas cells (Schmidt et al., 2005). We have previously shown that oncogenic Ras and
TGF-! cooperate to synergistically increase COX-2, integrin !1 and PAI-1 expression
(Fujimoto et al., 2001; Saha et al., 2001; Sheng et al., 2000), validating our expression
profiling experiment.  TGF-! also cooperates with Ras-mediated transformation to
decrease E-cadherin and TGF-! type II receptor expression (Fujimoto et al., 2001). These
gene expression changes were also noted in our present gene expression array
experiment.
A model of the differing roles that members of the TGF-! superfamily play in the
regulation of epithelial to mesenchymal transition is emerging. As we and others have
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shown, TGF-! signaling through Smad 2/3 can promote epithelial to mesenchymal
transition. BMP-7 signaling through Smad 1/5/8 blocks TGF-!-induced EMT and
promotes a mesenchymal to epithelial transition (Lee et al.), particularly during the
process of renal fibrosis in response to injury (Zeisberg et al., 2003). Changes in the
expression of two genes, follistatin and Id2, from the microarray stood out for their
potential roles in regulating or mediating this balance between TGF-!-induced EMT and
BMP-induced MET. Follistatin was originally identified for its role in preventing Activin
from binding its receptor and has since been found to also bind BMP-2, BMP-4 and
BMP-7, blocking signaling through the Activin and BMP receptors. Upregulation of
Follistatin, as seen in these experiments, would be predicted to block BMP signaling,
promoting the transforming effects of TGF-! signaling.
The Id family of proteins play a role in EMT and inhibit differentiation by
antagonizing basic helix-loop-helix (bHLH) transcription factors (Ruzinova and Benezra,
2003). A recent study demonstrated that Id2 and Id3 are differentially expressed in
response to TGF-! and BMP-7. TGF-! treatment causes sustained inhibition of Id2 and
Id3, whereas BMP-7 treatment results in sustained upregulation of these two proteins
(Kowanetz et al., 2004). Forced overexpression of Id2 or Id3 by adenoviral infection in
this study was sufficient to block the downregulation of E-cadherin and "-smooth muscle
actin by TGF-! treatment of a clone of NMuMG cells (NMe cells), whereas knockdown
of Id2 enhanced EMT induced by TGF-! and enabled cells to undergo EMT in response
to BMP-7 (Kowanetz et al., 2004). The observed synergistic decrease in Id2 expression
observed in this study suggests that this is one of the mechanisms by which activated Ras
and TGF-! can collaboratively induce EMT.
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One important question raised by these studies is whether the observed
cooperation between oncogenic Ras and TGF-! on malignant behaviors in vitro also
occurs in vivo. To address this question, it would be of interest to determine whether cells
expressing both oncogenic RasV12 and active TGF-! signaling, through overexpression
of TGF-! ligand or constitutively active TGF-! type II receptor, are able to form more
aggressive tumors in mice. We would expect to see an increase in tumor size,
vascularization, and perhaps local invasion in tumors expressing Ras and TGF-! together
compared to either alone. It would be particularly interesting to determine whether
injection of these cells into the tail vain, spleen, or cecum led to increased metastases.
Role of EGFR signaling
Microarray analysis revealed that several EGF family ligands and receptors show
altered expression patterns in response to oncogenic Ras and TGF-!. Additional studies
validating these gene expression changes, beyond TGF-", and exploring the kinetics of
EGFR activation will provide important mechanistic insights into the role of this pathway
during TGF-!-induced EMT. Since EGF receptors homo- and heterodimerize, we cannot
exclude the possibility that other ErbB receptors are involved in EGFR mediated EMT. It
will also be important to determine whether expression of these receptors and ligands
requires additional transcription or translation.
Oncogenic Ras and TGF-! cooperate to increase TGF-" mRNA expression and
synergistically increase TGF-" protein, suggesting that Ras and TGF-! cooperate to
regulate TGF-" by a post-transcriptional mechanism. Furthermore, increased TGF-"
expression during TGF-!-induced EMT was confirmed in LIM1863 cells. ErbB ligands
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are synthesized as transmembrane precursors that are proteolytically cleaved to release
biologically active soluble growth factors. TACE (TNF-" converting enzyme)/ADAM17
(A disintegrin and metalloprotease 17) is the major convertase mediating cleavage and
release of ErbB ligands, such as TGF-", AR, and HB-EGF (Sunnarborg et al., 2002).
After secretion, EGFR ligands rapidly bind their receptors and are internalized into the
cells (Dempsey and Coffey, 1994), consistent with our observation of increased TGF-"
in cell lysates but not in conditioned media. It remains to be clarified whether EGF
ligands are acting in an autocrine, paracrine, or juxtacrine manner to contribute to TGF-
!-induced EMT.
Stimulation of EGFR ligand binding and activation can occur through several
different mechanisms, including changes in ligand production, ligand secretion, or
receptor expression. Upregulation of transcription, translation, and secretion of ErbB
ligands is one way to increase ligand availability to bind and activate receptors. In
addition, activation of TACE or ADAMs increases proteolytic cleavage of existing
transmembrane precursor ligands to release active growth factors. Transactivation of the
EGF receptor by G-protein coupled receptors has been well characterized and is mediated
by activation of ADAMs (Ohtsu et al., 2006). Recently, TGF-! was reported to stimulate
transactivation of the EGFR independent of ligand release, similar to G-protein coupled
receptors, (Joo et al., 2007). Another mechanism to increase ErbB activity involves
increased receptor expression, which can help overcome ligand-induced receptor
internalization and ubiquitin-mediated degradation (Sweeney et al., 2006). The data
presented here suggest that Ras and TGF-! activation of EGFR signaling could occur
through several of these mechanisms. Ras and TGF-! increase EGFR expression and
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increased TGF-" mRNA levels suggests that Ras and TGF-! stimulate transcription of
TGF-", but the synergy observed at the TGF-" protein level suggests a combination of
transcription and transactivation are responsible for increasing TGF-" expression.
These studies have shown that EGFR activity is required for TGF-!-induced
EMT and invasion of RIE:iRas and LIM1863 cells. Nearly 100% of LIM1863 cells attach
to the plastic substrate upon TGF-!-treatment and EGFR signaling seems to be required
for this process, however further quantitation of the effects of blocking EGFR signaling
on TGF-!-induced attachment need to be performed. An EGFR tyrosine kinase inhibitor
blocks the TGF-!-induced phenotypic transformation of RIE:iRas and LIM1863 cells,
but these studies would benefit from an examination of molecular markers of EMT, such
as E-cadherin, N-cadherin, "-smooth muscle actin, and vimentin expression and actin re-
arrangement to confirm EMT. Although the invasion assay results are preliminary and
further confirmation is needed, they suggest that EGFR signaling is necessary for TGF-!
to enhance cellular invasiveness.
As outlined in the introduction of chapter 4, the exact role of EGFR signaling in
cancer is unclear. EGFR expression is low in normal colon but increases in aberrant crypt
foci and colorectal cancer (Borlinghaus et al., 1993; Ciardiello et al., 1991; Cohen et al.,
2006). However, the prognostic value of EGFR expression remains controversial
(Overman and Hoff, 2007). A comparison of EGFR mRNA expression in adenomas and
stage 4 adenocarcinomas in this study shows that EGFR expression is decreased in later
stage colorectal cancers. Further examination of EGFR expression in normal colon and a
larger number of patients with early stage colorectal adenomas and adenocarcinomas
would clarify the pattern of EGFR expression during colorectal cancer progression.
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Based on our current knowledge of EGFR actions, we propose that EGFR plays a role in
early cancer development, increasing proliferation and acting in concert with other
oncogenic events to increase malignant behaviors, such as loss of cell-cell adhesion and
increased migration, but that EGFR activity becomes less important as tumors acquire
other mechanisms to grow independently of growth factors and invade.
Regulation of VEGF expression
The collaboration of Ras and TGF-! in regulating VEGF was of particular interest
to us since VEGF is known to play an important role in the angiogenesis necessary for
tumor growth and metastasis (Fujimoto et al., 1998; Konno et al., 1998; Takahashi et al.,
1995; Wong et al., 1999). Our results show that Ras and TGF-! synergistically regulate
VEGF mRNA and protein expression in RIE:iRas cells and in an independent colon
cancer cell line, demonstrating the universality of this response in intestinal cells. VEGF
is induced in a dose-dependent manner by both TGF-! and Ras induction and the
combination of Ras and TGF-! together induces VEGF expression more than predicted
from the effect of each alone.
COX-2 expression is rapidly induced by a variety of mitogens and tumor
promoters (DuBois et al., 1994). A key enzyme in the metabolism of arachadonic acid,
COX-2 increases the production of prostaglandins, which can promote survival and
growth of colorectal cancer cells. Increased expression of COX-2 is frequently observed
in colon cancer (Eberhart et al., 1994) and treatment with non-steroidal anti-inflammatory
drugs (NSAIDs) that inhibit COX-2 is associated with a decreased incidence of colon
cancer (Smalley and DuBois, 1997; Thun et al., 1991). High COX-2 expression in colon
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cancer has been correlated with increased VEGF expression and microvessel density
(Masunaga et al., 2000). Although COX-2 inhibitors clearly decrease tumor formation,
the direct effects of COX-2 activity on VEGF expression are less clear. In one study,
HCA-7 cells and Caco-2 colon cancer cells over-expressing COX-2 produced high levels
of VEGF that were decreased by COX-2 inhibitors (Tsujii et al., 1998). In another study,
colon cancer cells treated with a high dose of COX-2 inhibitors (60 µM), were shown to
exhibit COX-2-independent effects on cell growth and VEGF expression (Abdelrahim
and Safe, 2005). Other studies have demonstrated either no change or a slight increase in
VEGF expression following treatment with COX-2 inhibitors, consistent with the
observations presented here (Kim et al., 2005b; Nishikawa et al., 2004).  These studies
demonstrate the complex regulation of VEGF expression in colon cancer and suggest that
there are COX-2-dependent and independent mechanisms, determined in part by the
microenvironment and genetic factors.
The synergistic increase in VEGF expression during oncogenic Ras and TGF-!-
induced EMT may not be accounted for due to increased transcriptional activity of the
VEGF gene. The post-transcriptional regulation of COX-2 by Ras and TGF-! (Sheng et
al., 2000) and recent literature demonstrating that under certain conditions VEGF mRNA
stability may be altered (Claffey et al., 1998; Levy et al., 1995; Levy et al., 1998; Shima
et al., 1995) suggest that changes in post-transcriptional regulation are an important
determinant of VEGF expression in cancer cells. This study demonstrates that
cooperation between TGF-! and oncogenic Ras increased VEGF mRNA and protein
expression by stabilizing VEGF mRNA. However, we cannot eliminate the possibility of
a transcriptional contribution to the Ras and TGF-! cooperative increase in VEGF
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expression, as the VEGF promoter activity shown here is from a single representative
experiment and should be verified. VEGF mRNA stabilization under hypoxic conditions
is mediated by conserved ARE sequences in the 3’UTR (Claffey et al., 1998). One study
has also shown that destabilizing elements in the 5’UTR and coding region contribute to
the regulation of VEGF mRNA stability (Dibbens et al., 1999). It remains to be
determined which VEGF mRNA regions are necessary for regulating Ras and TGF-!-
mediated stabilization.
Global post-transcriptional mechanism
One goal of this study was to determine the precise molecular mechanism by
which oncogenic Ras and TGF-! synergistically regulate gene expression. The
synergistic regulation of both VEGF and COX-2 (Sheng et al., 2000) mRNA stability
suggested to us that post-transcriptional gene regulation is an important component of the
collaborative effects of oncogenic Ras and TGF-! signaling. The primary mechanism for
post-transcriptional regulation is through AU-rich elements that are located in the 3’UTR
of mRNA (Caput et al., 1986; Shaw and Kamen, 1986) and significantly, 39% of genes
synergistically regulated in this study contain AU-rich elements representing a greater
than 4-fold enrichment compared to the genome as a whole (Bakheet et al., 2006).
Among the genes increased or decreased by oncogenic Ras expression and TGF-!
treatment, alone or together, we also observed a 4-fold enrichment of ARE-containing
genes, suggesting that in addition to COX-2 and VEGF, a number of other genes known
to be involved in tumor progression may also be co-regulated by a similar post-
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transcriptional mechanism. This enrichment of ARE-containing genes indicates that the
regulation of mRNA stability is an important mechanism of gene regulation during EMT.
There is a growing body of evidence suggesting that defects in mRNA turnover
play a central role in cellular transformation. Specific immediate-early genes (proto-
oncogenes among them), growth factors, cytokines and genes encoding other
inflammatory mediators, such as COX-2 and VEGF, have been shown to be regulated
though mRNA stabilization (Audic and Hartley, 2004). For example, the rapid decay of
c-myc mRNA is mediated by cis-elements in the 3’UTR, yet in certain cases of myeloma
and leukemia, the c-myc 3’UTR is translocated or lost, leading to increased c-myc
mRNA stability (Hollams et al., 2002). Through specific interaction with AREs, RNA-
binding proteins can be either positive or negative regulators of stability and translation
(Bevilacqua et al., 2003). The Ras and TGF-! signature contains two known RNA
binding proteins. Heterogeneous nuclear ribonucleoprotein A/B (hnRNP A/B), a member
of the hnRNP family of RNA binding proteins involved in RNA trafficking and splicing,
increased more than 3-fold with combined Ras expression and TGF-! treatment. In
addition, CUGBP2, which has been shown to bind the COX-2 3’UTR and promote its
stability while inhibiting its translation in response to ionizing radiation (Mukhopadhyay
et al., 2003), decreased more than 4-fold in response to Ras expression and TGF-!
treatment. The altered expression of hnRNP A/B and CUGBP2 mediated by Ras and
TGF-! remains to be confirmed at the protein level. The role of these proteins in the
regulation of VEGF mRNA stability can be assessed through knockdown or
overexpression, respectively.
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Another important RNA binding protein that acts in trans with the 3’UTR AU
rich elements is HuR, a member of the ELAV family of RNA binding proteins. HuR is a
nuclear-cytoplasmic shuttling protein (Fan and Steitz, 1998a) and it is generally believed
that the ability of HuR to promote mRNA stabilization requires its translocation to the
cytoplasm (Fan and Steitz, 1998b; Peng et al., 1998) where it is able to stabilize ARE-
containing mRNA transcripts such as COX-2 (Dixon et al., 2001; Fan and Steitz, 1998b;
Peng et al., 1998). Furthermore, the increased expression and cytoplasmic localization of
HuR is correlated with elevated COX-2 expression and poor outcome in ovarian, breast,
and colon cancers (Denkert et al., 2004; Dixon et al., 2001; Erkinheimo et al., 2003;
Heinonen et al., 2005). In the present studies, oncogenic Ras and TGF-! cooperate to
increase both the total steady-state level of HuR and to increase the relative amount of
HuR in the cytoplasm. The increase in HuR protein expression after Ras induction and
TGF-! treatment was not associated with an increase in HuR mRNA, suggesting that
oncogenic Ras and TGF-! signaling may influence HuR expression through translation
or protein stabilization. It remains to be determined whether HuR directly interacts with
VEGF or COX-2 mRNA and if HuR expression is necessary for Ras and TGF-! to
stabilize mRNA.
These data suggest a possible mechanism by which oncogenic Ras and TGF-! can
cooperatively regulate ARE-containing genes, such as COX-2 and VEGF. Modulating
the expression, activity, and binding specificity of these trans-acting regulatory proteins
could change the RNA-protein complexes formed, profoundly affecting RNA decay and
protein translation. While beyond the scope of this study, resolving the role of RNA
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binding proteins during oncogenic Ras and TGF-!-mediated EMT could contribute
important insights into the mechanisms of malignant transformation.
Oncogenic Ras and TGF-! each activate numerous downstream signaling
pathways, including MEK/ERK, PI3K/Akt, JNK, and p38, that contribute to EMT. Many
of these signaling pathways regulate mRNA decay during inflammation and
transformation, such as p38, JNK, ERK, and PKC (Eberhardt, 2007 #187). Further
defining the signaling pathways that regulate RNA binding proteins and ARE-mediated
turnover is important for understanding the mechanisms underlying malignant cell
behavior and cancer progression. Although no drugs have yet been identified that target
ARE-binding proteins, the development of novel therapeutics effecting mRNA decay is a
promising approach to treating inflammatory disease and cancer.
Clinical relevance
During Ras and TGF-!-induced EMT and invasiveness, RIE:iRas cells model
aspects of human tumor cell behavior (Fujimoto et al., 2001; Sheng et al., 2000). We
found that several of the ARE-containing transcripts in the Ras and TGF-! gene signature
derived from RIE:iRas cells are also differentially regulated in metastatic tumors
compared to early adenomas, including VEGFA and PAI-1. To further determine
whether genes in the Ras and TGF-! signature are significant for human malignancy, we
analyzed human CRC gene expression profiles for the presence of RNA regulatory
elements. The genes that are differentially regulated in late stage carcinomas compared to
adenomas show a 3-fold enrichment in ARE-containing genes compared to the genome
as a whole (Bakheet et al., 2006) and a similar enrichment is seen as early as Stage 1,
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suggesting that post-transcriptional gene regulation could be an important regulatory
mechanism involved in early tumor progression from adenoma to invasive carcinoma.
Cross-platform comparison of large microarray data sets, such as the human
colorectal cancer and rat cell culture model system described here, will help to establish
standards and tools for selecting biologically relevant gene lists for further validation
studies. Such procedures will allow us to closely examine different genetic models and
molecular mechanisms of gene regulation that may be important in altering the
expression of genes necessary for tumor cell survival, growth, and metastasis. Future
experiments could include the analysis of the effects of other oncogenes and purified
growth factors, of pharmacological inhibitors of COX-2 activity and other biologically
relevant targets, and of the effects of the impact of co-cultured fibroblast and matrix
determinants. This type analysis will facilitate the discovery of novel intracellular
regulatory mechanisms, improve molecular classification of human cancers, and
identification of relevant cancer biomarkers and novel therapeutic targets.
The application of microarray technology to cancer research has the potential to
assist in the classification of different types of cancer and to predict clinical outcome and
survival. Microarray based gene expression profiling has already contributed to the
molecular classification of hepatocellular carcinomas (Lee and Thorgeirsson, 2004).
Genome-wide gene expression analysis of human colorectal cancers, transgenic mouse
models of colon cancer, and mouse embryonic development were combined in a large-
scale comparison revealing extensive similarities between the gene expression patterns in
mouse models and human cancers and early embryonic development (Kaiser et al.,
2007). In addition, several recent studies from the Thorgeirsson lab have utilized gene
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expression profiles generated from cell lines and mouse models to identify subsets of
hepatocellular carcinoma patients with poor prognosis (Kaposi-Novak et al., 2006; Lee et
al., 2004a; Lee et al., 2006). It would be interesting to perform similar analyses with the
gene expression profiles generated from Ras and TGF-! transformed intestinal epithelial
cells and the human CRC data from the GI SPORE.
Conclusion
These studies show that oncogenic Ras and TGF-! together regulate the
expression of a set of genes that includes members of the EGFR family, the TGF-! and
Wnt signaling pathways, and an important angiogenic factor, VEGF. Analysis of a Ras
and TGF-! gene signature reveals that these conditions enrich for ARE-containing
mRNA transcripts. Consistent with this effect, oncogenic Ras and TGF-! synergistically
increase the expression of VEGF through stabilization of its ARE-containing mRNA.
Furthermore, VEGF and other ARE-containing transcripts are differentially regulated in
stage 4 colorectal adenocarcinomas. The reflection of the Ras and TGF-! gene
expression profile and enrichment of AREs in human CRC cancers demonstrates that this
experimental model system can provide novel molecular explanations of EMT and cancer
progression, revealing important potential therapeutic targets. Thus, these studies
demonstrate that oncogenic Ras and TGF-! cooperate to induce EMT and malignant cell
behaviors by post-transcriptional regulation of a unique set of mRNA transcripts with
clinical relevance to human CRC.
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APPENDIX
Table 5: Genes synergistically regulated by oncogenic Ras and TGF-!
probe_id Gene Name Gene Symbol
AU-rich
element Fold change
TGF-! RasV12
RasV12 +
TGF-!
1368519_at serine (or cysteine) peptidase inhibitor, clade E, member 1 Serpine1 ARE 42.22 5.53 75.28
1373000_at sushi-repeat-containing protein, X-linked 2 (predicted) Srpx2 19.24 25.59 73.63
1383486_at Transcribed locus --- ARE 5.93 27.94 52.85
1367581_a_at secreted phosphoprotein 1 Spp1 2.46 19.28 49.76
1368359_a_at VGF nerve growth factor inducible Vgf 3.11 4.61 48.10
1392618_at Transcribed locus --- ARE 3.48 24.30 45.76
1398302_at prolactin-like protein F Prlpf ARE 1.39 3.29 45.23
1392264_s_at serine (or cysteine) peptidase inhibitor, clade E, member 1 Serpine1 ARE 24.92 3.67 40.09
1391022_at laminin, beta 3 Lamb3 2.13 3.31 38.15
1384605_at Transcribed locus --- 2.94 14.57 37.91
1367973_at chemokine (C-C motif) ligand 2 Ccl2 ARE 5.47 17.28 37.90
1369249_at progressive ankylosis homolog (mouse) Ank ARE 3.12 8.33 33.58
1398479_at ryanodine receptor 3 Ryr3 ARE 1.42 9.28 29.65
1371194_at tumor necrosis factor alpha induced protein 6 Tnfaip6 ARE 2.95 7.90 29.24
1386344_at Progressive ankylosis homolog (mouse) Ank 3.59 9.42 28.55
1368945_at bone morphogenetic protein 2 Bmp2 ARE 1.69 22.39 27.95
1398662_at Transcribed locus --- 8.35 12.74 26.27
1386552_at Transcribed locus --- 2.26 15.31 25.51
1368210_at interleukin 24 Il24 ARE 1.30 2.95 23.63
1388204_at matrix metallopeptidase 13 Mmp13 ARE 2.18 3.23 23.10
1398270_at bone morphogenetic protein 2 Bmp2 ARE 1.93 17.82 22.84
1383987_at Transcribed locus --- 2.63 10.44 22.11
1391083_at Rho GTPase activating protein 22 (predicted) Arhgap22 1.30 19.08 21.97
1393439_a_at progressive ankylosis homolog (mouse) Ank ARE 2.58 5.32 21.63
1384027_a_at --- --- 2.17 1.00 21.38
1382378_at cathepsin W Ctsw 6.39 -1.02 20.55
1376197_at transcription factor 7, T-cell specific (predicted) Tcf7 ARE 1.85 -1.10 20.51
1385709_x_at Progressive ankylosis homolog (mouse) Ank 2.30 5.15 20.45
1374594_at similar to RIKEN cDNA 1600029D21 LOC363060 1.40 16.93 19.30
1382603_at Similar to PD-1-ligand precursor (predicted) RGD1566211 1.13 1.95 19.09
1369081_at neuraminidase 1 Neu1 ARE 4.75 1.61 17.73
1378867_at Similar to CG32425-PA (predicted) RGD1307366 2.99 12.57 16.65
1390835_at similar to 1300013J15Rik protein RGD1311123 4.20 11.04 16.47
1368592_at interleukin 1 alpha Il1a ARE 1.08 1.46 16.17
1370047_at ectonucleotide pyrophosphatase/phosphodiesterase 1 Enpp1 7.78 5.19 15.56
1368564_at solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6 Slc17a6 ARE -1.02 5.74 15.25
1367616_at natriuretic peptide precursor type B Nppb ARE 2.73 9.17 14.57
1380028_at similar to ADP-ribosylation factor-like protein 4C (ADP-ribosylation factor-like 7) LOC367311 1.58 2.77 13.95
1375684_at neuraminidase 1 Neu1 3.74 1.40 13.81
1388972_at reticulon 4 receptor Rtn4r 3.90 1.16 13.72
1387548_at hyaluronan synthase 2 Has2 ARE 1.18 1.88 13.06
1378133_at Transcribed locus --- 1.80 13.18 13.01
1384028_at --- --- 2.26 1.08 12.94
1393314_at Transcribed locus --- 3.18 1.28 12.81
1387562_at peptidyl arginine deiminase, type III Padi3 2.40 1.16 12.57
1373008_x_at reticulon 4 receptor Rtn4r 3.33 1.18 12.43
1378556_at Transcribed locus --- 6.54 4.22 12.21
1393728_at Transcribed locus --- ARE 1.65 7.90 11.60
1375815_at Progressive ankylosis homolog (mouse) Ank 1.32 2.21 11.54
1386529_at Transcribed locus --- 3.71 3.88 11.53
1393927_at wingless-related MMTV integration site 2 Wnt2 3.02 1.08 11.51
1395357_at microtubule-associated protein 1b Map1b ARE 4.30 5.96 11.10
1389467_at similar to RIKEN cDNA 1810057C19 MGC108778 ARE 1.08 1.08 10.34
1382482_at Transcribed locus --- 1.41 2.17 10.01
1379340_at lamimin, gamma 2 Lamc2 ARE 1.78 7.49 9.63
1397729_x_at similar to RIKEN cDNA 1600029D21 LOC363060 1.18 8.10 9.30
1379284_at similar to RIKEN cDNA 2810457I06 (predicted) RGD1310357 1.59 3.68 9.23
1375014_at similar to ADP-ribosylation factor-like protein 4C (ADP-ribosylation factor-like 7) LOC367311 ARE 1.45 2.14 9.05
1373363_at microtubule-associated protein 1b Map1b ARE 3.72 4.77 8.78
1385738_at Transcribed locus --- 1.26 1.75 8.53
1385925_at Transcribed locus --- 4.65 2.63 8.46
1367723_a_at linker of T-cell receptor pathways Lnk ARE 1.21 3.78 8.02
1369008_a_at olfactomedin 1 Olfm1 1.14 2.08 7.91
1382375_at Wingless-type MMTV integration site 5A Wnt5a 1.17 3.04 7.85
1397769_at Similar to RIKEN cDNA 6330512M04 gene (predicted) RGD1563319 -1.16 6.18 7.59
1373807_at vascular endothelial growth factor A Vegfa ARE 1.45 5.90 7.52
1393003_at Transcribed locus --- ARE 2.43 2.99 7.28
1370427_at platelet derived growth factor, alpha Pdgfa ARE 1.31 2.28 7.17
1377365_at similar to hypothetical protein DKFZp434H2010 (predicted) RGD1311019 1.01 2.25 7.04
1370387_at cytochrome P450, family 3, subfamily a, polypeptide Cyp3a13 ARE 1.08 5.26 7.04
1368374_a_at gamma-glutamyltransferase 1 Ggt1 1.27 1.07 7.01
1369263_at wingless-type MMTV integration site 5A Wnt5a ARE 1.02 2.91 6.96
1373298_at Transcribed locus --- 1.16 2.56 6.90
1370336_at pregnancy-induced growth inhibitor Okl38 1.94 2.48 6.86
1392791_at Early growth response 3 Egr3 ARE 1.16 3.84 6.81
1388596_at coactosin-like 1 (Dictyostelium) (predicted) Cotl1 1.64 1.40 6.78
1373759_at Transcribed locus --- 1.14 5.17 6.76
1369012_at inhibin beta-A Inhba 1.57 2.87 6.76
1399032_at excision repair cross-complementing rodent repair deficiency, complementation group 1
(predicted)
Ercc1 1.32 4.16 6.70
1378522_at Transcribed locus --- 2.72 2.89 6.64
1375986_at Similar to BTEB3 protein (predicted) RGD1565099 2.29 2.95 6.59
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1368804_at leukemia inhibitory factor Lif 1.16 4.56 6.53
1368009_at glucosamine Gne ARE 1.77 4.11 6.52
1389463_at protein kinase, cAMP dependent regulatory, type I, beta Prkar1b 1.59 1.12 6.47
1392820_at Fibroblast growth factor 1 Fgf1 2.25 1.33 6.46
1370023_at gap junction membrane channel protein alpha 4 Gja4 1.29 4.14 6.39
1379598_at Transcribed locus --- 1.16 1.36 6.34
1379375_at Platelet derived growth factor, alpha Pdgfa 1.29 2.21 6.31
1374817_at Transcribed locus --- ARE -1.28 2.09 6.25
1387843_at follistatin Fst 2.83 2.69 6.16
1368350_at protein tyrosine phosphatase, receptor-type, Z polypeptide 1 Ptprz1 ARE -1.18 1.78 6.05
1369625_at aquaporin 1 Aqp1 1.08 1.34 5.95
1395715_at Transcribed locus --- 1.48 2.00 5.89
1368259_at prostaglandin-endoperoxide synthase 1 Ptgs1 ARE 1.15 4.07 5.81
1375320_at Similar to hypothetical protein DKFZp434H2010 (predicted) RGD1311019 1.30 2.12 5.81
1396208_at gamma-glutamyltransferase-like activity 1 Ggtla1 1.61 1.09 5.68
1376498_at similar to 2900002H16Rik protein (predicted) RGD1307973 ARE 1.26 1.70 5.62
1380410_at Similar to GLI pathogenesis-related 2 LOC679819 2.97 2.08 5.58
1385805_at --- --- 1.49 1.19 5.52
1393494_at Transcribed locus --- 1.22 1.88 5.48
1381243_at Transcribed locus --- ARE 1.24 3.69 5.45
1383096_at amyloid beta (A4) precursor-like protein 2 Aplp2 ARE 1.02 2.51 5.43
1388785_at dynein, axonemal, light chain 4 Dnalc4 ARE 1.34 3.05 5.35
1373751_at Transcribed locus --- ARE 1.81 2.01 5.31
1391563_at similar to melanoma associated antigen (mutated) 1-like 1 (predicted) RGD1565148 ARE 1.37 1.62 5.23
1390983_at Transcribed locus --- ARE 1.06 3.02 5.19
1385181_at Transcribed locus --- 1.05 2.39 5.16
1371211_a_at neuregulin 1 Nrg1 1.10 3.72 5.08
1380895_at Amyloid beta (A4) precursor-like protein 2 Aplp2 1.14 1.77 5.05
1368545_at CASP8 and FADD-like apoptosis regulator Cflar ARE 1.49 3.16 5.00
1385926_at Transcribed locus --- 2.76 1.79 5.00
1369683_at BH3 interacting domain death agonist Bid 1.23 1.62 4.93
1368254_a_at sphingosine kinase 1 Sphk1 1.78 2.19 4.83
1383883_at similar to Hypothetical protein KIAA0469 (predicted) RGD1309644 1.70 2.48 4.78
1370082_at transforming growth factor, beta 1 Tgfb1 1.73 2.35 4.78
1374920_at Transcribed locus --- 1.55 2.61 4.73
1378241_at --- --- 1.97 1.00 4.71
1385235_at bol, boule-like (Drosophila) (predicted) Boll ARE -1.42 3.09 4.71
1374537_at carbohydrate (chondroitin) synthase 1 (predicted) Chsy1 ARE 1.65 2.23 4.67
1390429_at Transcribed locus --- ARE 1.55 2.66 4.61
1377759_at Transcribed locus --- ARE 1.21 1.59 4.57
1375377_at Transcribed locus --- 1.43 2.25 4.56
1384238_at similar to Tweety homolog 2 (predicted) RGD1562969 ARE 1.10 2.40 4.45
1388121_at amyloid beta (A4) precursor-like protein 2 Aplp2 1.01 2.36 4.44
1393344_at Transcribed locus --- ARE 1.70 2.15 4.31
1387206_at UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 6 B4galt6 ARE 1.80 1.96 4.31
1387184_at axin2 Axin2 ARE 1.42 2.26 4.26
1378032_at nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta (predicted) Nfkbiz ARE 1.35 2.46 4.23
1382442_at similar to Septin-6 LOC682750 ARE 1.22 2.14 4.23
1391121_at similar to DNA segment, Chr 8, ERATO Doi 82, expressed (predicted) RGD1311793 ARE 1.35 1.94 4.19
1383257_at Transcribed locus --- ARE -1.81 2.79 4.14
1368713_at matrix metallopeptidase 10 Mmp10 ARE 1.24 2.71 4.10
1394361_a_at wingless-related MMTV integration site 2 Wnt2 ARE 1.97 1.24 4.07
1385706_at Transcribed locus --- 1.50 1.77 4.01
1368681_at parathyroid hormone-like peptide Pthlh ARE 1.12 1.95 4.00
1387301_at fibroblast growth factor 1 Fgf1 1.84 1.25 3.99
1372569_at four and a half LIM domains 3 (predicted) Fhl3 1.59 2.25 3.93
1369293_at reticulon 4 receptor Rtn4r 1.65 1.06 3.84
1387975_at UDP-glucose ceramide glucosyltransferase Ugcg ARE 1.27 2.47 3.81
1390249_at similar to DKFZP434H132 protein RGD1305464 1.06 1.48 3.80
1373970_at similar to RIKEN cDNA 9230117N10 RGD1311155 -1.12 3.64 3.72
1369783_a_at neuregulin 1 Nrg1 ARE -1.15 2.58 3.69
1393252_at Transcribed locus --- ARE 1.44 1.04 3.65
1370948_a_at myristoylated alanine rich protein kinase C substrate Marcks ARE 1.09 1.48 3.65
1378480_at Transcribed locus --- 1.01 1.86 3.64
1370817_at Sec11-like 3 (S. cerevisiae) Sec11l3 1.44 1.59 3.55
1368323_at tissue factor pathway inhibitor Tfpi ARE 1.36 1.06 3.55
1383286_at pleckstrin 2 (predicted) Plek2 1.34 1.49 3.54
1372277_at Taste receptor, type 1, member 2 Tas1r2 -1.33 1.74 3.51
1373226_at Transcribed locus --- 1.37 2.03 3.43
1383130_at Transcribed locus --- -1.24 2.38 3.42
1378009_at Transcribed locus --- ARE 1.06 2.00 3.35
1371696_at similar to G protein-coupled receptor 56 LOC682401 1.22 1.26 3.34
1384878_at N-myristoyltransferase 2 Nmt2 1.48 1.77 3.34
1399065_at Ring finger protein 167 Rnf167 1.42 1.32 3.33
1381121_at Basic helix-loop-helix domain containing, class B2 Bhlhb2 1.75 1.23 3.28
1373258_at cathepsin F Ctsf 1.89 -1.09 3.25
1371193_at tumor necrosis factor alpha induced protein 6 Tnfaip6 1.20 1.30 3.22
1376362_at neuronal pentraxin receptor Nptxr ARE 1.50 1.58 3.22
1379614_at Transcribed locus --- ARE 1.10 1.69 3.20
1393140_at zinc finger CCCH type containing 12A (predicted) Zc3h12a 1.05 1.57 3.20
1390386_at caspase 3, apoptosis related cysteine protease Casp3 ARE 1.20 1.94 3.16
1367905_at ectonucleotide pyrophosphatase/phosphodiesterase 3 Enpp3 1.02 2.02 3.10
1368347_at procollagen, type V, alpha 3 Col5a3 1.16 1.72 3.10
1371014_at phospholipase C, beta 1 Plcb1 ARE -1.02 1.30 3.09
1376799_a_at cytokine receptor-like factor 1 (predicted) Crlf1 1.95 1.10 3.07
1378262_at Transcribed locus --- 1.10 1.41 3.05
1372935_at Transcribed locus --- 1.95 -1.24 3.04
1368531_at prolactin-like protein C 1 Prlpc1 ARE 1.09 1.14 3.03
1369686_at double cortin and calcium/calmodulin-dependent protein kinase-like 1 Dcamkl1 ARE 1.19 1.38 2.99
1385649_at integrin alpha 5 Itga5 1.22 1.71 2.99
1393191_at similar to RIKEN cDNA 2610200G18 (predicted) RGD1561205 ARE 1.28 1.19 2.93
1390925_a_at Transcribed locus --- 1.17 1.56 2.91
1387121_a_at N-myc downstream regulated gene 2 Ndrg2 1.46 -1.19 2.86
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1373432_at similar to Myristoylated alanine-rich C-kinase substrate Marcks ARE -1.05 1.24 2.78
1377975_at Transcribed locus --- ARE -1.03 1.13 2.76
1370949_at myristoylated alanine rich protein kinase C substrate Marcks ARE -1.07 1.28 2.76
1367754_s_at heterogeneous nuclear ribonucleoprotein A/B Hnrpab 1.14 1.20 2.72
1370256_at frizzled homolog 1 (Drosophila) Fzd1 ARE 1.20 1.24 2.70
1386645_at similar to 2900002H16Rik protein (predicted) RGD1307973 1.06 1.22 2.67
1373786_at Transcribed locus --- 1.81 -1.52 2.64
1371127_at bone morphogenetic protein 1 Bmp1 1.64 -1.09 2.61
1374779_at Coagulation factor XIII, A1 subunit F13a1 1.06 1.00 2.61
1375957_at Transcribed locus --- 1.35 1.06 2.58
1382907_at similar to 4930431B09Rik protein LOC310721 1.03 1.05 2.57
1368916_at argininosuccinate lyase Asl ARE 1.12 1.15 2.52
1387651_at aquaporin 1 Aqp1 1.02 1.15 2.51
1389048_at bone morphogenetic protein 1 Bmp1 1.28 -1.25 2.48
1391399_at Transcribed locus --- 1.35 -1.13 2.46
1387729_at gamma-glutamyltransferase-like activity 1 Ggtla1 1.19 -1.00 2.45
1378947_at tensin 4 Tns4 -1.29 1.28 2.36
1374816_at similar to hypothetical protein FLJ30973 LOC363091 ARE 1.24 -1.06 2.31
1396445_at RIB43A domain with coiled-coils 2 Ribc2 1.08 -1.11 2.28
1389229_at acid phosphatase-like 2 Acpl2 ARE -1.45 1.07 2.07
1373657_at solute carrier family 31, member 2 Slc31a2 ARE 1.26 -1.34 -2.17
1375028_at Transcribed locus --- 1.05 -1.23 -2.22
1371131_a_at thioredoxin interacting protein Txnip ARE -1.12 -1.05 -2.27
1391458_at N-myc downstream regulated gene 1 Ndrg1 -1.03 -1.10 -2.38
1389142_at similar to Sulfide:quinone oxidoreductase, mitochondrial precursor LOC691966 -1.42 1.18 -2.42
1398582_at ribosomal protein S6 kinase, polypeptide 5 (predicted Rps6ka5 ARE -1.19 -1.20 -2.54
1387260_at Kruppel-like factor 4 Klf4 ARE -1.29 1.04 -2.54
1373079_at Transcribed locus --- 1.54 -1.84 -2.61
1398387_at Unknown (protein for MGC:72614) MGC72614 2.15 1.11 -2.61
1375716_at interferon gamma receptor 2 (predicted) Ifngr2 1.09 -1.05 -2.63
1376920_at similar to sterile alpha motif domain containing 9-like LOC500013 ARE -1.18 -1.25 -2.65
1371360_at N-myc downstream regulated gene 1 Ndrg1 ARE -1.04 -1.19 -2.69
1374142_at similar to RIKEN cDNA E130201N16 (predicted) RGD1311589 -1.10 -1.09 -2.72
1388791_at similar to 2810022L02Rik protein RGD1309930 ARE -1.37 -1.10 -2.72
1376319_at Transcribed locus --- -1.20 -1.50 -2.79
1384617_at Unknown (protein for MGC:72614) MGC72614 ARE 2.37 1.24 -2.80
1393653_at similar to putative protein product of HMFN2073 (predicted) RGD1560766 ARE 2.22 -1.31 -2.83
1385150_at Transcribed locus --- -1.50 1.59 -2.84
1369895_s_at podocalyxin-like Podxl ARE -1.34 -1.65 -2.90
1374544_at hypothetical protein LOC679150 LOC679150 -1.63 1.25 -2.90
1395336_at hypothetical LOC501207 LOC501207 -1.52 -1.20 -2.97
1383194_a_at CDNA clone IMAGE:7379585 --- -1.47 -1.51 -2.97
1387354_at signal transducer and activator of transcription 1 Stat1 ARE -1.65 -1.26 -2.99
1379444_at Transcribed locus --- 1.53 -1.17 -2.99
1377669_at RAB27A, member RAS oncogene family Rab27a ARE -1.27 -1.06 -3.02
1384852_at RAB27A, member RAS oncogene family Rab27a -1.29 -1.05 -3.03
1372757_at signal transducer and activator of transcription 1 Stat1 -1.72 -1.27 -3.05
1398640_at Transcribed locus --- -1.03 -1.67 -3.07
1379606_at RAB30, member RAS oncogene family Rab30 ARE 1.22 -1.30 -3.11
1377821_at Transcribed locus --- 1.12 -1.78 -3.13
1395427_at Transcribed locus --- -1.47 -1.51 -3.13
1376878_at similar to RIKEN cDNA 2310022B05 (predicted) RGD1559896 1.06 -2.20 -3.19
1387625_at insulin-like growth factor binding protein 6 Igfbp6 -1.25 -1.40 -3.23
1396090_at similar to RIKEN cDNA A630007N06 gene (predicted) RGD1304572 -1.28 -1.88 -3.25
1384132_at immunoglobulin superfamily, member 4A Igsf4a -1.21 -1.87 -3.31
1368146_at dual specificity phosphatase 1 Dusp1 ARE 1.74 -1.06 -3.31
1382044_at hypothetical protein LOC498796 LOC498796 ARE -1.42 -1.91 -3.34
1380133_at odd-skipped related 2 (Drosophila) Osr2 ARE -1.44 -1.42 -3.35
1367974_at annexin A3 Anxa3 ARE -1.09 -2.27 -3.35
1368147_at dual specificity phosphatase 1 Dusp1 1.95 -1.00 -3.42
1368835_at signal transducer and activator of transcription 1 Stat1 -2.02 -1.29 -3.42
1373521_at similar to RIKEN cDNA D430044G18 RGD1309038 ARE -1.52 -1.82 -3.45
1376337_at SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a,
member 2
Smarca2
ARE
-1.53 -1.69 -3.45
1372133_at related RAS viral (r-ras) oncogene homolog 2 Rras2 -1.11 -2.13 -3.45
1383064_at Transcribed locus --- -1.43 -1.57 -3.53
1385759_at serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), member 10 Serpinb10 -2.89 1.17 -3.62
1372111_at --- --- ARE -1.39 -1.82 -3.64
1385074_at SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a,
member 2
Smarca2 -1.65 -1.74 -3.66
1382060_at Transcribed locus --- -1.46 -1.98 -3.74
1368322_at superoxide dismutase 3, extracellular Sod3 -1.76 -1.40 -3.79
1383795_at Transcribed locus --- -1.46 -1.62 -3.80
1374131_at Transcribed locus --- -1.32 -1.88 -3.87
1393281_at CDC42 effector protein (Rho GTPase binding) 5 (predicted) Cdc42ep5 -1.51 -1.87 -3.87
1389146_at hypothetical protein LOC498796 LOC498796 -1.40 -2.12 -3.91
1370061_at RAB3B, member RAS oncogene family Rab3b -1.48 -1.13 -3.93
1388471_at t-complex 11 (mouse) like 2 Tcp11l2 ARE -1.92 -1.90 -3.94
1392301_at SH3 domain and tetratricopeptide repeats 1 (predicted) Sh3tc1 -1.70 -2.42 -4.07
1372457_at mitochondrial tumor suppressor 1 Mtus1 1.20 -3.22 -4.12
1383842_at Transcribed locus --- -1.86 -2.42 -4.22
1383063_a_at Transcribed locus --- -1.54 -1.59 -4.28
1392246_at Transcribed locus --- -1.45 -2.29 -4.29
1395313_s_at Annexin A3 Anxa3 1.11 -3.37 -4.34
1397837_at Transcribed locus --- -2.00 -1.65 -4.34
1369182_at coagulation factor III F3 ARE -1.60 -2.74 -4.42
1378413_at Transcribed locus --- -2.27 -2.42 -4.42
1386907_at Carboxypeptidase D Cpd -1.29 -1.71 -4.45
1374159_at Transcribed locus --- -1.40 -2.77 -4.45
1378753_at occludin Ocln 2.16 -3.53 -4.50
1376919_at Similar to expressed sequence AW212394 (predicted) RGD1562317 -1.44 -2.26 -4.59
1373315_at Aryl hydrocarbon receptor nuclear translocator 2 Arnt2 -1.72 -2.40 -4.62
1369973_at Programmed cell death 4 Pdcd4 ARE -1.31 -3.42 -4.62
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1377968_at Transcribed locus --- -2.10 -2.26 -4.68
1380017_at Transcribed locus --- -1.25 -3.29 -4.68
1379252_at Transcribed locus --- -1.41 -2.24 -4.75
1373881_at Rho, GDP dissociation inhibitor (GDI) beta Arhgdib -1.76 -2.34 -4.77
1371922_at Transcribed locus --- -1.81 -2.66 -4.78
1385876_at similar to Gpc6 protein (predicted) RGD1563063 -2.20 -2.45 -4.80
1369972_at serine (or cysteine) peptidase inhibitor, clade B, member 5 Serpinb5 ARE -1.53 -3.25 -4.84
1396736_at Similar to Gpc6 protein (predicted) RGD1563063 -2.31 -2.22 -4.84
1384163_at Transcribed locus --- ARE -1.92 -2.60 -4.87
1387581_at peptidylglycine alpha-amidating monooxygenase COOH-terminal interactor Pamci ARE 1.09 -3.92 -4.90
1367940_at chemokine orphan receptor 1 Cmkor1 ARE -1.02 -2.86 -4.94
1394833_at Transcribed locus --- -1.25 -3.25 -4.98
1370131_at caveolin Cav -1.68 -2.13 -5.01
1385687_at hypothetical protein LOC682044 LOC682044 -2.51 1.04 -5.02
1389867_at Transcribed locus --- -1.91 -2.52 -5.07
1390403_at similar to CG8312-PA RGD1304790 ARE -2.35 -1.90 -5.10
1382185_at similar to C1q and tumor necrosis factor related protein 2 (predicted) RGD1561041 -1.07 -4.11 -5.13
1376657_at immunoglobulin superfamily, member 4A Igsf4a ARE -1.45 -2.34 -5.15
1374458_at Transcribed locus, strongly similar to XP_001060531.1 --- ARE -1.87 -3.17 -5.20
1393719_at Transcribed locus --- -1.85 -2.13 -5.23
1368052_at tetraspanin 8 Tspan8 -1.27 -2.48 -5.33
1387004_at neuroblastoma, suppression of tumorigenicity 1 Nbl1 -2.52 -2.89 -5.34
1369519_at endothelin 1 Edn1 2.10 -4.90 -5.51
1367975_at annexin A3 Anxa3 1.10 -3.98 -5.52
1372466_at Transcribed locus --- -1.78 -3.25 -5.60
1388195_at CUG triplet repeat, RNA binding protein 2 Cugbp2 ARE -2.01 -2.58 -5.64
1372610_at procollagen-proline, 2-oxoglutarate 4-dioxygenase, alpha II polypeptide (predicted) P4ha2 -1.31 -4.14 -5.74
1388792_at growth arrest and DNA-damage-inducible 45 gamma Gadd45g 1.53 -3.29 -5.82
1398727_at CDNA clone IMAGE:7374368 --- -2.48 -2.80 -5.96
1379108_at Proteasome (prosome, macropain) 26S subunit, non-ATPase, 7 (predicted) Psmd7 ARE -1.76 -2.79 -6.02
1375144_at Transcribed locus --- -1.81 -2.65 -6.04
1372820_at Transcribed locus --- ARE -2.36 -2.70 -6.20
1369959_at zinc finger protein 36, C3H type-like 1 Zfp36l1 ARE -2.35 -2.13 -6.25
1388312_at Transcribed locus --- -1.89 -2.71 -6.34
1376520_at Transcribed locus --- -2.27 -3.42 -6.38
1392971_at Transcribed locus --- -2.58 -3.62 -6.42
1383212_at CDNA clone IMAGE:7462850 --- -1.61 -2.43 -6.51
1368870_at inhibitor of DNA binding 2 Id2 ARE -3.40 -2.15 -6.66
1391154_at Transcribed locus --- -1.18 -2.71 -7.01
1386827_at similar to procollagen, type IV, alpha 6 LOC363458 -3.41 -3.69 -7.14
1372403_at similar to Nuclear membrane binding protein NUCLING (predicted) RGD1560011 -1.40 -2.07 -7.17
1398354_at catenin (cadherin associated protein), alpha-like 1 (predicted) Ctnnal1 ARE -2.57 -2.31 -7.18
1383012_at rhophilin, Rho GTPase binding protein 2 (predicted) Rhpn2 ARE -2.86 -1.43 -7.20
1376285_at GULP, engulfment adaptor PTB domain containing 1 Gulp1 ARE -1.27 -6.12 -7.47
1390159_at Transcribed locus --- 1.49 -5.67 -7.47
1374176_at similar to DNA segment, Chr 4, Brigham & Womens Genetics 0951 expressed RGD1308059 ARE 1.16 -5.85 -7.49
1374038_at Transcribed locus --- -1.51 -6.12 -7.55
1375270_at Transcribed locus --- -1.19 -6.39 -7.65
1383565_at Transcribed locus --- ARE -1.17 -2.97 -7.66
1379526_at Myelin basic protein Mbp -2.82 -2.12 -7.73
1374746_at Ab1-152 LOC500877 ARE -3.85 -4.32 -7.82
1383479_at Myelin basic protein Mbp ARE -2.80 -2.04 -7.94
1389253_at vanin 1 Vnn1 ARE -2.09 -5.77 -7.94
1381557_at guanine nucleotide binding protein, alpha 14 Gna14 ARE -2.31 -4.59 -7.98
1372728_at Sortilin 1 Sort1 -1.90 -6.93 -8.06
1371988_at mannosidase 1, alpha (predicted) Man1a ARE -2.96 -3.93 -8.09
1398406_at Transcribed locus --- -1.68 -3.99 -8.13
1384834_at cordon-bleu (predicted) Cobl ARE -1.46 -2.68 -8.15
1384709_at --- --- ARE 1.50 -4.31 -8.20
1373108_at protein phosphatase 1, regulatory (inhibitor) subunit 3C Ppp1r3c -2.35 -4.87 -8.48
1387669_a_at epoxide hydrolase 1, microsomal Ephx1 -2.51 -4.75 -8.85
1389496_at A kinase (PRKA) anchor protein 7 Akap7 ARE -1.63 -2.40 -8.87
1389779_at SH2 domain containing 4A Sh2d4a -1.04 -3.25 -8.91
1385098_at Transcribed locus --- 1.19 -7.26 -9.05
1372708_at --- --- -1.22 -6.27 -9.06
1385008_at Transcribed locus --- -3.57 -2.85 -9.27
1389600_at --- --- ARE -2.67 -1.91 -9.31
1374649_at RAS guanyl releasing protein 2 (calcium and DAG-regulated) (predicted) Rasgrp2 -2.55 -5.39 -9.33
1379493_at Transcribed locus --- -1.37 -4.19 -9.48
1390566_a_at creatine kinase, mitochondrial 1, ubiquitous Ckmt1 2.69 -6.76 -9.53
1393000_at Zinc finger, DHHC domain containing 6 Zdhhc6 -1.82 -4.32 -9.79
1367823_at tissue inhibitor of metalloproteinase 2 Timp2 -2.44 -3.71 -9.90
1393825_at guanine nucleotide binding protein, alpha 14 Gna14 -2.37 -4.90 -9.94
1393015_at similar to hypothetical protein FLJ14146 RGD1310587 -1.55 -5.79 -10.07
1397335_at sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3D Sema3d ARE 1.35 -7.95 -10.14
1392079_at A kinase (PRKA) anchor protein 7 Akap7 -1.68 -2.69 -10.23
1377795_at Transcribed locus --- -3.57 -2.95 -10.31
1387493_at A kinase (PRKA) anchor protein 5 Akap5 -1.26 -8.58 -10.39
1384816_at coxsackie virus and adenovirus receptor Cxadr ARE -1.65 -7.32 -10.53
1376165_at solute carrier family 24 (sodium/potassium/calcium exchanger), member 3 Slc24a3 ARE 1.21 -10.72 -10.82
1380477_at Transcribed locus --- -1.25 -7.01 -11.28
1387644_at betacellulin Btc ARE -1.58 -7.33 -11.47
1375026_at Hypothetical protein LOC688757 LOC688757 -3.99 -6.37 -11.69
1398227_at Transcribed locus --- -1.33 -7.88 -11.73
1388936_at cadherin 11 Cdh11 ARE -1.83 -5.47 -11.86
1385243_at V-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) Maf ARE -1.60 -6.86 -12.32
1389107_at Similar to KIAA1749 protein (predicted) RGD1304623 -1.10 -5.98 -12.92
1373312_at Transcribed locus --- -3.56 -8.97 -13.31
1376105_at procollagen, type XIV, alpha 1 (predicted) Col14a1 ARE -1.67 -8.14 -13.31
1368114_at fibroblast growth factor 13 Fgf13 ARE -1.29 -7.46 -13.92
1383460_at --- --- -1.35 -9.32 -14.51
1378327_at doublesex and mab-3 related transcription factor 2 (predicted) Dmrt2 -1.41 -7.08 -14.61
1388753_at sulfatase 2 Sulf2 -2.90 -6.37 -14.97
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1374942_at carboxypeptidase X 2 (M14 family) (predicted) Cpxm2 -3.45 -7.34 -15.05
1372107_at four and a half LIM domains 1 Fhl1 ARE 1.23 -8.73 -15.11
1367673_at selenium binding protein 2 Selenbp1 -3.19 -6.07 -15.49
1384707_at Transcribed locus --- -3.99 -7.95 -15.80
1373740_at --- --- ARE -1.17 -8.67 -17.10
1387232_at bone morphogenetic protein 4 Bmp4 ARE -1.90 -10.34 -18.82
1368223_at a disintegrin-like and metallopeptidse (reprolysin type) with thrombospondin type 1 motif, 1 Adamts1 ARE -2.32 -12.63 -19.39
1384276_at similar to procollagen, type IV, alpha 6 LOC363458 ARE -5.62 -5.37 -19.94
1374089_at Transcribed locus --- -1.11 -17.79 -20.43
1368683_at oxidized low density lipoprotein (lectin-like) receptor 1 Oldlr1 ARE -1.84 -4.26 -21.26
1390049_at four and a half LIM domains 1 Fhl1 1.36 -14.97 -22.37
1368991_at sphingomyelin phosphodiesterase 3, neutral Smpd3 -1.13 -8.61 -22.46
1384487_at doublesex and mab-3 related transcription factor 2 (predicted) Dmrt2 -1.57 -8.62 -22.82
1378699_at Sorting nexin 22 (predicted) Snx22 -4.89 -16.29 -23.06
1373148_at carboxypeptidase X 2 (M14 family) (predicted) Cpxm2 -4.14 -8.90 -23.47
1383047_at growth arrest specific 6 Gas6 ARE -2.08 -10.17 -27.00
1376619_at similar to protein tyrosine phosphatase, receptor type, D (predicted) RGD1561090 -2.13 -16.24 -30.65
1374591_at similar to protein tyrosine phosphatase, receptor type, D (predicted) RGD1561090 ARE -2.05 -15.10 -32.59
1375638_at serum deprivation response protein Sdpr -2.79 -7.30 -55.92
1382452_at serum deprivation response protein Sdpr -2.94 -9.40 -56.26
1376648_at v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) Mycn ARE -1.58 -18.99 -67.66
Affymetrix probe IDs that were synergistically regulated after 72 hours of treatment with 5mM IPTG and 3ng/ml TGF-
! together, compared to either treatment alone and untreated cells. Fold change represents expression in Ras expressing
and/or TGF-! treated samples compared to untreated. Gene expression increases and decreases are defined as greater
than 2-fold. Presence of an ARE (AU-rich element) was determined by analysis using the ARE database, ARED3.0
(Bakheet et al., 2006).
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Table 6: Genes differentially expressed in RIE:iRas and human CRC
Human Ensembl Gene ID Gene Symbol Gene Name
ENSG00000078328 A2BP1 Ataxin-2-binding protein 1
ENSG00000118507 AKAP7 A-kinase anchor protein 7 isoform gamma
ENSG00000154122 ANKH Progressive ankylosis protein homolog
ENSG00000188042 ARL4C ADP-ribosylation factor-like protein 4C
ENSG00000198363 ASPH Aspartyl/asparaginyl beta-hydroxylase
ENSG00000168487 BMP1 Bone morphogenetic protein 1
ENSG00000125378 BMP4 Bone morphogenetic protein 4
ENSG00000131873 CHSY1 Chondroitin sulfate synthase 1
ENSG00000187955 COL14A1 Collagen alpha-1(XIV)
ENSG00000080573 COL5A3 Collagen alpha-3(V)
ENSG00000108515 ENO3 Beta-enolase
ENSG00000065361 ERBB3 Receptor tyrosine-protein kinase erbB-3
ENSG00000124882 EREG Epiregulin precursor
ENSG00000183508 FAM46C Protein FAM46C
ENSG00000113578 FGF1 Heparin-binding growth factor 1
ENSG00000134363 FST Follistatin
ENSG00000159921 GNE Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-
acetylmannosamine kinase
ENSG00000122641 INHBA Inhibin beta A
ENSG00000161638 ITGA5 Integrin alpha-5
ENSG00000136826 KLF4 Krueppel-like factor 4
ENSG00000131711 MAP1B Microtubule-associated protein 1B
ENSG00000197971 MBP Myelin basic protein
ENSG00000129422 MTUS1 Mitochondrial tumor suppressor 1 isoform 3
ENSG00000165795 NDRG2 Protein NDRG2
ENSG00000164125 NP_001026870.1 AD021 protein (C4orf18)
ENSG00000151690 NP_060164.2 CDNA FLJ20160
ENSG00000153823 NP_060403.3 CDNA FLJ43369
ENSG00000173391 OLR1 Oxidized low-density lipoprotein receptor 1
ENSG00000127838 PNKD Myofibrillogenesis regulator 1 isoform 1
ENSG00000153707 PTPRD Receptor-type tyrosine-protein phosphatase delta
ENSG00000069974 RAB27A Ras-related protein Rab-27A
ENSG00000100784 RPS6KA5 Ribosomal protein S6 kinase alpha-5
ENSG00000143416 SELENBP1 Selenium-binding protein 1
ENSG00000106366 SERPINE1 Plasminogen activator inhibitor 1 (PAI-1)
ENSG00000104611 SH2D4A SH2 domain-containing protein 4A
ENSG00000080503 SMARCA2 SWI/SNF-related matrix- associated actin-dependent
regulator of chromatin subfamily A member 2
ENSG00000176170 SPHK1 Sphingosine kinase 1
ENSG00000137767 SQRDL Sulfide:quinone oxidoreductase
ENSG00000102359 SRPX2 Sushi-repeat-containing protein, X-linked 2
ENSG00000003436 TFPI Tissue factor pathway inhibitor
ENSG00000105329 TGFB1 Transforming growth factor beta-1
ENSG00000035862 TIMP2 Tissue inhibitor of metalloproteinases 2
ENSG00000137831 UACA Uveal autoantigen with coiled-coil domains and ankyrin
repeats
ENSG00000112715 VEGFA Vascular endothelial growth factor A
List of the genes differentially regulated in stage 4 adenocarcinomas compared to adenomas and the human
orthologs of the  genes synergistically regulated by oncogenic Ras and TGF-! in RIE:iRas cells.
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Table 7: ARE-containing genes differentially expressed in adenomas vs. stage 4
adenocarcinomas
Ensembl GID Gene Symbol Gene Description
ENSG00000179869 ABCA13 ATP-binding cassette sub-family A member 13. [Source:Uniprot/SWISSPROT;Acc:Q86UQ4]
ENSG00000023839 ABCC2
Canalicular multispecific organic anion transporter 1 (ATP-binding cassette sub-family C member 2) (Multidrug resistance-
associated protein 2) (Canalicular multidrug resistance protein). [Source:Uniprot/SWISSPROT;Acc:Q92887]
ENSG00000125257 ABCC4
Multidrug resistance-associated protein 4 (ATP-binding cassette sub- family C member 4) (MRP/cMOAT-related ABC
transporter) (Multi-specific organic anion transporter-B) (MOAT-B). [Source:Uniprot/SWISSPROT;Acc:O15439]
ENSG00000069431 ABCC9 ATP-binding cassette transporter sub-family C member 9 (Sulfonylurea receptor 2). [Source:Uniprot/SWISSPROT;Acc:O60706]
ENSG00000196177 ACADSB
Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial precursor (EC 1.3.99.-) (SBCAD) (2-methyl branched
chain acyl-CoA dehydrogenase) (2-MEBCAD) (2-methylbutyryl-coenzyme A dehydrogenase) (2-methylbutyryl-CoA
dehydrogenase). [Source:Uniprot/SWISSPROT;Acc:P45954]
ENSG00000123983 ACSL3
Long-chain-fatty-acid--CoA ligase 3 (EC 6.2.1.3) (Long-chain acyl-CoA synthetase 3) (LACS 3).
[Source:Uniprot/SWISSPROT;Acc:O95573]
ENSG00000068366 ACSL4
Long-chain-fatty-acid--CoA ligase 4 (EC 6.2.1.3) (Long-chain acyl-CoA synthetase 4) (LACS 4).
[Source:Uniprot/SWISSPROT;Acc:O60488]
ENSG00000184009 ACTG1 Actin, cytoplasmic 2 (Gamma-actin). [Source:Uniprot/SWISSPROT;Acc:P63261]
ENSG00000138107 ACTR1A
Alpha-centractin (Centractin) (Centrosome-associated actin homolog) (Actin-RPV) (ARP1).
[Source:Uniprot/SWISSPROT;Acc:P61163]
ENSG00000115170 ACVR1
Activin receptor type-1 precursor (EC 2.7.11.30) (Activin receptor type I) (ACTR-I) (Serine/threonine-protein kinase receptor R1)
(SKR1) (Activin receptor-like kinase 2) (ALK-2) (TGF-B superfamily receptor type I) (TSR-I).
[Source:Uniprot/SWISSPROT;Acc:Q04771]
ENSG00000123612 ACVR1C
Activin receptor type 1C precursor (EC 2.7.11.30) (ACTR-IC) (Activin receptor-like kinase 7) (ALK-7).
[Source:Uniprot/SWISSPROT;Acc:Q8NER5]
ENSG00000135074 ADAM19
ADAM 19 precursor (EC 3.4.24.-) (A disintegrin and metalloproteinase domain 19) (Meltrin beta) (Metalloprotease and
disintegrin dentritic antigen marker) (MADDAM). [Source:Uniprot/SWISSPROT;Acc:Q9H013]
ENSG00000008277 ADAM22
ADAM 22 precursor (A disintegrin and metalloproteinase domain 22) (Metalloproteinase-like, disintegrin-like, and cysteine-rich
protein 2) (Metalloproteinase-disintegrin ADAM22-3). [Source:Uniprot/SWISSPROT;Acc:Q9P0K1]
ENSG00000140873 ADAMTS18
ADAMTS-18 precursor (EC 3.4.24.-) (A disintegrin and metalloproteinase with thrombospondin motifs 18) (ADAM-TS 18)
(ADAM-TS18). [Source:Uniprot/SWISSPROT;Acc:Q8TE60]
ENSG00000154736 ADAMTS5
ADAMTS-5 precursor (EC 3.4.24.-) (A disintegrin and metalloproteinase with thrombospondin motifs 5) (ADAM-TS 5) (ADAM-
TS5) (Aggrecanase-2) (ADMP-2) (ADAM-TS 11). [Source:Uniprot/SWISSPROT;Acc:Q9UNA0]
ENSG00000136378 ADAMTS7 ADAM metallopeptidase with thrombospondin type 1 motif, 7 preproprotein [Source:RefSeq_peptide;Acc:NP_055087]
ENSG00000133597 ADCK2 aarF domain containing kinase 2 [Source:RefSeq_peptide;Acc:NP_443085]
ENSG00000170425 ADORA2B Adenosine A2b receptor. [Source:Uniprot/SWISSPROT;Acc:P29275]
ENSG00000155966 AFF2
AF4/FMR2 family member 2 (Fragile X mental retardation 2 protein) (Protein FMR-2) (FMR2P) (Protein Ox19) (Fragile X E
mental retardation syndrome protein). [Source:Uniprot/SWISSPROT;Acc:P51816]
ENSG00000072364 AFF4
AF4/FMR2 family member 4 (ALL1-fused gene from chromosome 5q31) (Major CDK9 elongation factor-associated protein).
[Source:Uniprot/SWISSPROT;Acc:Q9UHB7]
ENSG00000119844 AFTPH Aftiphilin. [Source:Uniprot/SWISSPROT;Acc:Q6ULP2]
ENSG00000162688 AGL
Glycogen debranching enzyme (Glycogen debrancher) [Includes: 4-alpha- glucanotransferase (EC 2.4.1.25) (Oligo-1,4-1,4-
glucantransferase); Amylo-alpha-1,6-glucosidase (EC 3.2.1.33) (Amylo-1,6-glucosidase) (Dextrin 6-alpha-D-glucosidase)].
[Source:Uniprot/SWISSPROT;Acc:P35573]
ENSG00000018510 AGPS
Alkyldihydroxyacetonephosphate synthase, peroxisomal precursor (EC 2.5.1.26) (Alkyl-DHAP synthase) (Alkylglycerone-
phosphate synthase) (Aging-associated protein 5). [Source:Uniprot/SWISSPROT;Acc:O00116]
ENSG00000144891 AGTR1 Type-1 angiotensin II receptor (AT1) (AT1AR) (AT1BR). [Source:Uniprot/SWISSPROT;Acc:P30556]
ENSG00000118507 AKAP7
A-kinase anchor protein 7 isoform gamma (Protein kinase A-anchoring protein 7 isoform gamma) (A-kinase anchor protein 18).
[Source:Uniprot/SWISSPROT;Acc:Q9P0M2]
ENSG00000117020 AKT3
RAC-gamma serine/threonine-protein kinase (EC 2.7.11.1) (RAC-PK-gamma) (Protein kinase Akt-3) (Protein kinase B, gamma)
(PKB gamma) (STK-2). [Source:Uniprot/SWISSPROT;Acc:Q9Y243]
ENSG00000184254 ALDH1A3
Aldehyde dehydrogenase 1A3 (EC 1.2.1.5) (Aldehyde dehydrogenase 6) (Retinaldehyde dehydrogenase 3) (RALDH-3).
[Source:Uniprot/SWISSPROT;Acc:P47895]
ENSG00000154122 ANKH Progressive ankylosis protein homolog (ANK). [Source:Uniprot/SWISSPROT;Acc:Q9HCJ1]
ENSG00000001629 ANKIB1 Ankyrin repeat and IBR domain-containing protein 1 (Fragment). [Source:Uniprot/SWISSPROT;Acc:Q9P2G1]
ENSG00000107890 ANKRD26 Ankyrin repeat domain-containing protein 26. [Source:Uniprot/SWISSPROT;Acc:Q9UPS8]
ENSG00000135299 ANKRD6 Ankyrin repeat domain-containing protein 6. [Source:Uniprot/SWISSPROT;Acc:Q9Y2G4]
ENSG00000182287 AP1S2
AP-1 complex subunit sigma-2 (Adapter-related protein complex 1 sigma- 1B subunit) (Sigma-adaptin 1B) (Adaptor protein
complex AP-1 sigma-1B subunit) (Golgi adaptor HA1/AP1 adaptin sigma-1B subunit) (Clathrin assembly protein complex 1
sigma-1B small chai [Source:Uniprot/SWISSPROT;Acc:P56377]
ENSG00000152056 AP1S3
AP-1 complex subunit sigma-3 (Adapter-related protein complex 1 sigma- 1C subunit) (Sigma-adaptin 1C) (Adaptor protein
complex AP-1 sigma-1C subunit) (Golgi adaptor HA1/AP1 adaptin sigma-1C subunit) (Clathrin assembly protein complex 1
sigma-1C small chai [Source:Uniprot/SWISSPROT;Acc:Q96PC3]
ENSG00000102030 ARD1A
N-terminal acetyltransferase complex ARD1 subunit homolog A (EC 2.3.1.88) (EC 2.3.1.-).
[Source:Uniprot/SWISSPROT;Acc:P41227]
ENSG00000104728 ARHGEF10 Rho guanine nucleotide exchange factor 10. [Source:Uniprot/SWISSPROT;Acc:O15013]
ENSG00000116584 ARHGEF2
Rho/Rac guanine nucleotide exchange factor 2 (GEF-H1 protein) (Proliferating cell nucleolar antigen p40).
[Source:Uniprot/SWISSPROT;Acc:Q92974]
ENSG00000102606 ARHGEF7
Rho guanine nucleotide exchange factor 7 (PAK-interacting exchange factor beta) (Beta-Pix) (COOL-1) (p85).
[Source:Uniprot/SWISSPROT;Acc:Q14155]
ENSG00000049618 ARID1B
AT-rich interactive domain-containing protein 1B (ARID domain- containing protein 1B) (Osa homolog 2) (hOsa2) (p250R)
(BRG1-binding protein hELD/OSA1) (BRG1-associated factor 250b) (BAF250B). [Source:Uniprot/SWISSPROT;Acc:Q8NFD5]
ENSG00000032219 ARID4A
AT-rich interactive domain-containing protein 4A (ARID domain- containing protein 4A) (Retinoblastoma-binding protein 1)
(RBBP-1). [Source:Uniprot/SWISSPROT;Acc:P29374]
ENSG00000185305 ARL15 ADP-ribosylation factor-like 15 (ARL15), mRNA [Source:RefSeq_dna;Acc:NM_019087]
ENSG00000188042 ARL4C
ADP-ribosylation factor-like protein 4C (ADP-ribosylation factor-like protein 7) (ADP-ribosylation factor-like protein LAK).
[Source:Uniprot/SWISSPROT;Acc:P56559]
ENSG00000134108 ARL8B
ADP-ribosylation factor-like protein 8B (ADP-ribosylation factor-like protein 10C) (Novel small G protein indispensable for equal
chromosome segregation 1). [Source:Uniprot/SWISSPROT;Acc:Q9NVJ2]
ENSG00000143437 ARNT
Aryl hydrocarbon receptor nuclear translocator (ARNT protein) (Dioxin receptor, nuclear translocator) (Hypoxia-inducible factor 1
beta) (HIF-1 beta). [Source:Uniprot/SWISSPROT;Acc:P27540]
ENSG00000162704 ARPC5
Actin-related protein 2/3 complex subunit 5 (ARP2/3 complex 16 kDa subunit) (p16-ARC).
[Source:Uniprot/SWISSPROT;Acc:O15511]
ENSG00000111339 ART4
Ecto-ADP-ribosyltransferase 4 precursor (EC 2.4.2.31) (NAD(P)(+)-- arginine ADP-ribosyltransferase 4) (Mono(ADP-
ribosyl)transferase 4) (Dombrock blood group carrier molecule) (CD297 antigen). [Source:Uniprot/SWISSPROT;Acc:Q93070]
ENSG00000117407 ARTN Artemin precursor (Enovin) (Neublastin). [Source:Uniprot/SWISSPROT;Acc:Q5T4W7]
ENSG00000004848 ARX Homeobox protein ARX (Aristaless-related homeobox). [Source:Uniprot/SWISSPROT;Acc:Q96QS3]
ENSG00000168387 ASB14 Ankyrin repeat and SOCS box protein 14 (ASB-14). [Source:Uniprot/SWISSPROT;Acc:Q8WXK2]
ENSG00000198363 ASPH
Aspartyl/asparaginyl beta-hydroxylase (EC 1.14.11.16) (Aspartate beta- hydroxylase) (ASP beta-hydroxylase) (Peptide-aspartate
beta- dioxygenase). [Source:Uniprot/SWISSPROT;Acc:Q12797]
ENSG00000148219 ASTN2 astrotactin 2 isoform c [Source:RefSeq_peptide;Acc:NP_937830]
ENSG00000157087 ATP2B2 Plasma membrane calcium-transporting ATPase 2 (EC 3.6.3.8) (PMCA2) (Plasma membrane calcium pump isoform 2) (Plasma
membrane calcium ATPase isoform 2). [Source:Uniprot/SWISSPROT;Acc:Q01814]
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membrane calcium ATPase isoform 2). [Source:Uniprot/SWISSPROT;Acc:Q01814]
ENSG00000118217 ATF6
Cyclic AMP-dependent transcription factor ATF-6 alpha (Activating transcription factor 6 alpha) (ATF6-alpha).
[Source:Uniprot/SWISSPROT;Acc:P18850]
ENSG00000145782 ATG12 Autophagy-related protein 12 (APG12-like). [Source:Uniprot/SWISSPROT;Acc:O94817]
ENSG00000085978 ATG16L1 Autophagy-related protein 16-1 (APG16-like 1). [Source:Uniprot/SWISSPROT;Acc:Q676U5]
ENSG00000111676 ATN1 Atrophin-1 (Dentatorubral-pallidoluysian atrophy protein). [Source:Uniprot/SWISSPROT;Acc:P54259]
ENSG00000206190 ATP10A
Probable phospholipid-transporting ATPase VA (EC 3.6.3.1) (ATPVA) (Aminophospholipid translocase VA).
[Source:Uniprot/SWISSPROT;Acc:O60312]
ENSG00000118322 ATP10B Probable phospholipid-transporting ATPase VB (EC 3.6.3.1). [Source:Uniprot/SWISSPROT;Acc:O94823]
ENSG00000068650 ATP11A
Probable phospholipid-transporting ATPase IH (EC 3.6.3.1) (ATPase class I type 11A) (ATPase IS).
[Source:Uniprot/SWISSPROT;Acc:P98196]
ENSG00000058063 ATP11B
Probable phospholipid-transporting ATPase IF (EC 3.6.3.1) (ATPase class I type 11B) (ATPase IR).
[Source:Uniprot/SWISSPROT;Acc:Q9Y2G3]
ENSG00000101974 ATP11C
Probable phospholipid-transporting ATPase IG (EC 3.6.3.1) (ATPase class I type 11C) (ATPase IG) (ATPase IQ) (ATPase class
VI type 11C). [Source:Uniprot/SWISSPROT;Acc:Q8NB49]
ENSG00000174437 ATP2A2
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (EC 3.6.3.8) (Calcium pump 2) (SERCA2) (SR Ca(2+)-ATPase 2)
(Calcium-transporting ATPase sarcoplasmic reticulum type, slow twitch skeletal muscle isoform) (Endoplasmic reticulum class
1/2 Ca(2+) ATPase). [Source:Uniprot/SWISSPROT;Acc:P16615]
ENSG00000125375 ATP5S
ATP synthase subunit s, mitochondrial precursor (ATP synthase coupling factor B) (Mitochondrial ATP synthase regulatory
component factor B). [Source:Uniprot/SWISSPROT;Acc:Q99766]
ENSG00000165240 ATP7A
Copper-transporting ATPase 1 (EC 3.6.3.4) (Copper pump 1) (Menkes disease-associated protein).
[Source:Uniprot/SWISSPROT;Acc:Q04656]
ENSG00000123472 ATPAF1 ATP synthase mitochondrial F1 complex assembly factor 1 isoform 1 precursor [Source:RefSeq_peptide;Acc:NP_073582]
ENSG00000124788 ATXN1 Ataxin-1 (Spinocerebellar ataxia type 1 protein). [Source:Uniprot/SWISSPROT;Acc:P54253]
ENSG00000148090 AUH
Methylglutaconyl-CoA hydratase, mitochondrial precursor (EC 4.2.1.18) (AU-specific RNA-binding enoyl-CoA hydratase) (AU-
binding protein/enoyl-CoA hydratase). [Source:Uniprot/SWISSPROT;Acc:Q13825]
ENSG00000155096 AZIN1 Antizyme inhibitor 1 (AZI) (Ornithine decarboxylase antizyme inhibitor). [Source:Uniprot/SWISSPROT;Acc:O14977]
ENSG00000169255 B3GALNT1
UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 1 (EC 2.4.1.79) (Beta-3-GalNAc-T1) (Beta-1,3-galactosyltransferase 3)
(Beta-1,3- GalTase 3) (Beta3Gal-T3) (b3Gal-T3) (Galactosylgalactosylglucosylceramide beta-D-acetyl-
galactosaminyltransferase) (UDP [Source:Uniprot/SWISSPROT;Acc:O75752]
ENSG00000006453 BAIAP2L1
Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1 (BAI1-associated protein 2-like protein 1).
[Source:Uniprot/SWISSPROT;Acc:Q9UHR4]
ENSG00000122507 PTHB1_HUMAN
Protein PTHB1 (Parathyroid hormone-responsive B1 gene protein) (Bardet-Biedl syndrome 9 protein).
[Source:Uniprot/SWISSPROT;Acc:Q3SYG4]
ENSG00000124243 BCAS4 Breast carcinoma amplified sequence 4. [Source:Uniprot/SWISSPROT;Acc:Q8TDM0]
ENSG00000060982 BCAT1
Branched-chain-amino-acid aminotransferase, cytosolic (EC 2.6.1.42) (BCAT(c)) (ECA39 protein).
[Source:Uniprot/SWISSPROT;Acc:P54687]
ENSG00000171791 BCL2 Apoptosis regulator Bcl-2. [Source:Uniprot/SWISSPROT;Acc:P10415]
ENSG00000153094 BCL2L11 Bcl-2-like protein 11 (Bcl2-interacting mediator of cell death). [Source:Uniprot/SWISSPROT;Acc:O43521]
ENSG00000121380 BCL2L14 Apoptosis facilitator Bcl-2-like 14 protein (Apoptosis regulator Bcl- G). [Source:Uniprot/SWISSPROT;Acc:Q9BZR8]
ENSG00000085185 BCORL1 BCL6 co-repressor-like 1 [Source:RefSeq_peptide;Acc:NP_068765]
ENSG00000186716 BCR Breakpoint cluster region protein (EC 2.7.11.1) (NY-REN-26 antigen). [Source:Uniprot/SWISSPROT;Acc:P11274]
ENSG00000101966 BIRC4
Baculoviral IAP repeat-containing protein 4 (Inhibitor of apoptosis protein 3) (X-linked inhibitor of apoptosis protein) (X-linked
IAP) (IAP-like protein) (HILP). [Source:Uniprot/SWISSPROT;Acc:P98170]
ENSG00000204217 BMPR2
Bone morphogenetic protein receptor type-2 precursor (EC 2.7.11.30) (Bone morphogenetic protein receptor type II) (BMP type II
receptor) (BMPR-II). [Source:Uniprot/SWISSPROT;Acc:Q13873]
ENSG00000162813 BPNT1
3'(2'),5'-bisphosphate nucleotidase 1 (EC 3.1.3.7) (Bisphosphate 3'- nucleotidase 1) (PAP-inositol-1,4-phosphatase) (PIP).
[Source:Uniprot/SWISSPROT;Acc:O95861]
ENSG00000185658 BRWD1 Bromodomain and WD repeat domain-containing protein 1 (WD repeat protein 9). [Source:Uniprot/SWISSPROT;Acc:Q9NSI6]
ENSG00000112763 BTN2A1 Butyrophilin subfamily 2 member A1 precursor. [Source:Uniprot/SWISSPROT;Acc:Q7KYR7]
ENSG00000165424 C10orf56 C10orf56 protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q5U5T9]
ENSG00000158636 C11orf30 Protein EMSY. [Source:Uniprot/SWISSPROT;Acc:Q7Z589]
ENSG00000174718 C12orf35 C12orf35 protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q4KN17]
ENSG00000134548 C12orf39
Protein C12orf39 precursor [Contains: Putative amidated peptide NWTPQAMLYLKGAQ].
[Source:Uniprot/SWISSPROT;Acc:Q9BT56]
ENSG00000151287 C13orf27 OTTHUMP00000018668. [Source:Uniprot/SPTREMBL;Acc:Q5JUR7]
ENSG00000050130 C14orf100 Medulloblastoma antigen MU-MB-50.4. [Source:Uniprot/SWISSPROT;Acc:Q9P055]
ENSG00000100629 C14orf145 CN145_HUMAN Isoform 2 of Q6ZU80 - Homo sapiens (Human) [Source:Uniprot/Varsplic;Acc:Q6ZU80-2]
ENSG00000196943 C14orf21
Leukotriene B4 receptor 2 (LTB4-R2) (Seven transmembrane receptor BLTR2) (Leukotriene B4 receptor BLT2) (LTB4 receptor
JULF2). [Source:Uniprot/SWISSPROT;Acc:Q9NPC1]
ENSG00000151327 C14orf24 Uncharacterized protein C14orf24. [Source:Uniprot/SWISSPROT;Acc:Q8N128]
ENSG00000178761 C15orf17 Uncharacterized protein C15orf17. [Source:Uniprot/SWISSPROT;Acc:Q5XKK7]
ENSG00000141622 RNF165 RING finger protein 165. [Source:Uniprot/SWISSPROT;Acc:Q6ZSG1]
ENSG00000152242 C18orf25 Uncharacterized protein C18orf25. [Source:Uniprot/SWISSPROT;Acc:Q96B23]
ENSG00000131943 C19orf12 C19orf12 protein. [Source:Uniprot/SPTREMBL;Acc:Q9BSL7]
ENSG00000173436 CA151_HUMAN UPF0327 protein C1orf151. [Source:Uniprot/SWISSPROT;Acc:Q5TGZ0]
ENSG00000159208 C1orf51 Uncharacterized protein C1orf51. [Source:Uniprot/SWISSPROT;Acc:Q8N365]
ENSG00000160679 C1orf77 Uncharacterized protein C1orf77. [Source:Uniprot/SWISSPROT;Acc:Q9Y3Y2]
ENSG00000154429 C1orf96 C1orf96 protein. [Source:Uniprot/SPTREMBL;Acc:Q6P9G2]
ENSG00000139178 C1RL complement component 1, r subcomponent-like precursor [Source:RefSeq_peptide;Acc:NP_057630]
ENSG00000089177 SNX23_HUMAN Kinesin-like motor protein C20orf23 (Sorting nexin-23). [Source:Uniprot/SWISSPROT;Acc:Q96L93]
ENSG00000089101 CT026_HUMAN Uncharacterized protein C20orf26. [Source:Uniprot/SWISSPROT;Acc:Q8NHU2]
ENSG00000172296 C20orf38 Uncharacterized protein C20orf38. [Source:Uniprot/SWISSPROT;Acc:Q9NUV7]
ENSG00000125514 C20orf51 Putative uncharacterized protein C20orf51. [Source:Uniprot/SWISSPROT;Acc:Q9H493]
ENSG00000101247 NP_077025.2 CDNA: FLJ22324 fis, clone HRC05551 (C20orf7 protein). [Source:Uniprot/SPTREMBL;Acc:Q9H6F4]
ENSG00000101230 Q9H599_HUMAN OTTHUMP00000030295 (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q9H599]
ENSG00000169621 C2orf13 Uncharacterized protein C2orf13. [Source:Uniprot/SWISSPROT;Acc:Q8IW19]
ENSG00000115827 C2orf37 CDNA FLJ13096 fis, clone NT2RP3002166. [Source:Uniprot/SPTREMBL;Acc:Q9H908]
ENSG00000183624 C3orf37 UPF0361 protein DC12. [Source:Uniprot/SWISSPROT;Acc:Q96FZ2]
ENSG00000180611 C3orf59 Uncharacterized protein C3orf59. [Source:Uniprot/SWISSPROT;Acc:Q8IYB1]
ENSG00000120519 C4orf13 C4orf13 protein. [Source:Uniprot/SPTREMBL;Acc:Q8IZ62]
ENSG00000197405 C5AR1 C5a anaphylatoxin chemotactic receptor (C5a-R) (C5aR) (CD88 antigen). [Source:Uniprot/SWISSPROT;Acc:P21730]
ENSG00000181904 C5orf24 CDNA FLJ37562 fis, clone BRCOC2000487. [Source:Uniprot/SPTREMBL;Acc:Q8N1T9]
ENSG00000170085 C5orf25 Uncharacterized protein C5orf25. [Source:Uniprot/SWISSPROT;Acc:Q8NDZ2]
ENSG00000196821 C6orf106 CF106_HUMAN Isoform 2 of Q9H6K1 - Homo sapiens (Human) [Source:Uniprot/Varsplic;Acc:Q9H6K1-2]
ENSG00000135338 C6orf152
ENSG00000135334 C6orf166 CDNA FLJ10342 fis, clone NT2RM2000837. (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q9NW35]
ENSG00000156928 C7orf30
ENSG00000153790 C7orf31
ENSG00000188732 C7orf46 C7orf46 protein. [Source:Uniprot/SPTREMBL;Acc:Q4G0Q7]
ENSG00000147679 C8orf53 CDNA FLJ30717 fis, clone FCBBF2001672. [Source:Uniprot/SPTREMBL;Acc:Q96NJ8]
ENSG00000137135 C9orf100 OTTHUMP00000021341 (C9orf100 protein). [Source:Uniprot/SPTREMBL;Acc:Q5T4R2]
ENSG00000120159 C9orf82 Uncharacterized protein C9orf82. [Source:Uniprot/SWISSPROT;Acc:Q9H8G2]
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ENSG00000164989 C9orf93 Uncharacterized protein C9orf93. [Source:Uniprot/SWISSPROT;Acc:Q6TFL3]
ENSG00000178031 C9orf94 Protein C9orf94 precursor. [Source:Uniprot/SWISSPROT;Acc:Q496M8]
ENSG00000178538 CA8 Carbonic anhydrase-related protein (CARP) (CA-VIII). [Source:Uniprot/SWISSPROT;Acc:P35219]
ENSG00000182389 CACNB4
Voltage-dependent L-type calcium channel subunit beta-4 (CAB4) (Calcium channel voltage-dependent subunit beta 4).
[Source:Uniprot/SWISSPROT;Acc:O00305]
ENSG00000136436 CALCOCO2 calcium binding and coiled-coil domain 2 [Source:RefSeq_peptide;Acc:NP_005822]
ENSG00000160014 CALM1 Calmodulin (CaM). [Source:Uniprot/SWISSPROT;Acc:P62158]
ENSG00000183049 CAMK1D
Calcium/calmodulin-dependent protein kinase type 1D (EC 2.7.11.17) (CaM kinase ID) (CaM kinase I delta) (CaMKI-delta)
(CaM-KI delta) (CaMKI delta) (Camk1D) (CamKI-like protein kinase) (CKLiK). [Source:Uniprot/SWISSPROT;Acc:Q8IU85]
ENSG00000118200 CAMSAP1L1 calmodulin regulated spectrin-associated protein 1-like 1 [Source:RefSeq_peptide;Acc:NP_982284]
ENSG00000105971 CAV2 Caveolin-2. [Source:Uniprot/SWISSPROT;Acc:P51636]
ENSG00000078699 CBFA2T2
Protein CBFA2T2 (MTG8-like protein) (MTG8-related protein 1) (Myeloid translocation-related protein 1) (ETO homologous on
chromosome 20) (p85). [Source:Uniprot/SWISSPROT;Acc:O43439]
ENSG00000122565 CBX3
Chromobox protein homolog 3 (Heterochromatin protein 1 homolog gamma) (HP1 gamma) (Modifier 2 protein) (HECH).
[Source:Uniprot/SWISSPROT;Acc:Q13185]
ENSG00000100307 CBX7 Chromobox protein homolog 7. [Source:Uniprot/SWISSPROT;Acc:O95931]
ENSG00000183287 CCBE1 collagen and calcium binding EGF domains 1 [Source:RefSeq_peptide;Acc:NP_597716]
ENSG00000152492 CCDC50 Coiled-coil domain-containing protein 50 (Protein Ymer). [Source:Uniprot/SWISSPROT;Acc:Q8IVM0]
ENSG00000176155 CCDC57 coiled-coil domain containing 57 [Source:RefSeq_peptide;Acc:NP_932348]
ENSG00000133773 CCDC59 coiled-coil domain containing 59 [Source:RefSeq_peptide;Acc:NP_054886]
ENSG00000147082 CCNB3 G2/mitotic-specific cyclin-B3. [Source:Uniprot/SWISSPROT;Acc:Q8WWL7]
ENSG00000163468 CCT3 T-complex protein 1 subunit gamma (TCP-1-gamma) (CCT-gamma) (hTRiC5). [Source:Uniprot/SWISSPROT;Acc:P49368]
ENSG00000177575 CD163
Scavenger receptor cysteine-rich type 1 protein M130 precursor (CD163 antigen) (Hemoglobin scavenger receptor) [Contains:
Soluble CD163 (sCD163)]. [Source:Uniprot/SWISSPROT;Acc:Q86VB7]
ENSG00000135535 CD164
Putative mucin core protein 24 precursor (Multi-glycosylated core protein 24) (MGC-24) (MUC-24) (CD164 antigen).
[Source:Uniprot/SWISSPROT;Acc:Q04900]
ENSG00000163606 CD200R1
Cell surface glycoprotein OX2 receptor precursor (CD200 cell surface glycoprotein receptor).
[Source:Uniprot/SWISSPROT;Acc:Q8TD46]
ENSG00000153283 CD96
T-cell surface protein tactile precursor (T cell-activated increased late expression protein) (CD96 antigen).
[Source:Uniprot/SWISSPROT;Acc:P40200]
ENSG00000079335 CDC14A
Dual specificity protein phosphatase CDC14A (EC 3.1.3.48) (EC 3.1.3.16) (CDC14 cell division cycle 14 homolog A).
[Source:Uniprot/SWISSPROT;Acc:Q9UNH5]
ENSG00000163171 CDC42EP3
Cdc42 effector protein 3 (Binder of Rho GTPases 2) (MSE55-related Cdc42-binding protein).
[Source:Uniprot/SWISSPROT;Acc:Q9UKI2]
ENSG00000094804 CDC6
Cell division control protein 6 homolog (CDC6-related protein) (p62(cdc6)) (HsCDC6) (HsCDC18).
[Source:Uniprot/SWISSPROT;Acc:Q99741]
ENSG00000123374 CDK2 Cell division protein kinase 2 (EC 2.7.11.22) (p33 protein kinase). [Source:Uniprot/SWISSPROT;Acc:P24941]
ENSG00000176749 CDK5R1
Cyclin-dependent kinase 5 activator 1 precursor (CDK5 activator 1) (Cyclin-dependent kinase 5 regulatory subunit 1) (Tau protein
kinase II 23 kDa subunit) (TPKII regulatory subunit) (p23) (p25) (p35) [Contains: Cyclin-dependent kinase 5 activator 1, p35;
[Source:Uniprot/SWISSPROT;Acc:Q15078]
ENSG00000129355 CDKN2D Cyclin-dependent kinase 4 inhibitor D (p19-INK4d). [Source:Uniprot/SWISSPROT;Acc:P55273]
ENSG00000115163 CENPA Uncharacterized protein C2orf18 precursor. [Source:Uniprot/SWISSPROT;Acc:Q8N357]
ENSG00000114331 CENTB2 Centaurin-beta 2 (Cnt-b2). [Source:Uniprot/SWISSPROT;Acc:Q15057]
ENSG00000047365 CENTD1
Centaurin-delta 1 (Cnt-d1) (Arf-GAP, Rho-GAP, ankyrin repeat and pleckstrin homology domain-containing protein 2) (PARX
protein). [Source:Uniprot/SWISSPROT;Acc:Q8WZ64]
ENSG00000001626 CFTR
Cystic fibrosis transmembrane conductance regulator (CFTR) (cAMP- dependent chloride channel) (ATP-binding cassette
transporter sub- family C member 7). [Source:Uniprot/SWISSPROT;Acc:P13569]
ENSG00000170791 CHCHD7 Coiled-coil-helix-coiled-coil-helix domain-containing protein 7. [Source:Uniprot/SWISSPROT;Acc:Q9BUK0]
ENSG00000128656 CHN1
N-chimaerin (NC) (N-chimerin) (Alpha chimerin) (A-chimaerin) (Rho- GTPase-activating protein 2).
[Source:Uniprot/SWISSPROT;Acc:P15882]
ENSG00000131873 CHSY1
Chondroitin sulfate synthase 1 (EC 2.4.1.175) (Glucuronosyl-N- acetylgalactosaminyl-proteoglycan 4-beta-N-
acetylgalactosaminyltransferase 1) (Chondroitin sulfate synthase 1) (N-acetylgalactosaminyl-proteoglycan 3-beta-
glucuronosyltransferase 1) (EC 2.4.1 [Source:Uniprot/SWISSPROT;Acc:Q86X52]
ENSG00000099622 CIRBP
Cold-inducible RNA-binding protein (Glycine-rich RNA-binding protein CIRP) (A18 hnRNP).
[Source:Uniprot/SWISSPROT;Acc:Q14011]
ENSG00000114737 CISH
Cytokine-inducible SH2-containing protein (CIS) (CIS-1) (Suppressor of cytokine signaling) (SOCS) (Protein G18).
[Source:Uniprot/SWISSPROT;Acc:Q9NSE2]
ENSG00000163539 CLASP2 CLIP-associating protein 2 (Cytoplasmic linker-associated protein 2). [Source:Uniprot/SWISSPROT;Acc:O75122]
ENSG00000172243 CLEC7A dendritic cell-associated C-type lectin 1 isoform a [Source:RefSeq_peptide;Acc:NP_922938]
ENSG00000169504 CLIC4
Chloride intracellular channel protein 4 (Intracellular chloride ion channel protein p64H1).
[Source:Uniprot/SWISSPROT;Acc:Q9Y696]
ENSG00000183723 CMTM4
CKLF-like MARVEL transmembrane domain-containing protein 4 (Chemokine- like factor superfamily member 4).
[Source:Uniprot/SWISSPROT;Acc:Q8IZR5]
ENSG00000198515 CNGA1
cGMP-gated cation channel alpha 1 (CNG channel alpha 1) (CNG-1) (CNG1) (Cyclic nucleotide-gated channel alpha 1) (Cyclic
nucleotide-gated channel, photoreceptor) (Cyclic nucleotide-gated cation channel 1) (Rod photoreceptor cGMP-gated channel
subunit alph [Source:Uniprot/SWISSPROT;Acc:P29973]
ENSG00000149970 CNKSR2
Connector enhancer of kinase suppressor of ras 2 (Connector enhancer of KSR2) (CNK2).
[Source:Uniprot/SWISSPROT;Acc:Q8WXI2]
ENSG00000125107 CNOT1 CCR4-NOT transcription complex, subunit 1 isoform a [Source:RefSeq_peptide;Acc:NP_057368]
ENSG00000106714 CNTNAP3 Contactin-associated protein-like 3 precursor (Cell recognition molecule Caspr3). [Source:Uniprot/SWISSPROT;Acc:Q9BZ76]
ENSG00000082438 COBLL1 COBL-like 1 [Source:RefSeq_peptide;Acc:NP_055715]
ENSG00000168434 COG7 Conserved oligomeric Golgi complex component 7. [Source:Uniprot/SWISSPROT;Acc:P83436]
ENSG00000123500 COL10A1 Collagen alpha-1(X) chain precursor. [Source:Uniprot/SWISSPROT;Acc:Q03692]
ENSG00000111799 COL12A1 Collagen alpha-1(XII) chain precursor. [Source:Uniprot/SWISSPROT;Acc:Q99715]
ENSG00000187955 COL14A1 Collagen alpha-1(XIV) chain precursor (Undulin). [Source:Uniprot/SWISSPROT;Acc:Q05707]
ENSG00000204262 COL5A2 Collagen alpha-2(V) chain precursor. [Source:Uniprot/SWISSPROT;Acc:P05997]
ENSG00000198612 COPS8
COP9 signalosome complex subunit 8 (Signalosome subunit 8) (SGN8) (JAB1-containing signalosome subunit 8) (COP9
homolog) (hCOP9). [Source:Uniprot/SWISSPROT;Acc:Q99627]
ENSG00000167186 COQ7
Ubiquinone biosynthesis protein COQ7 homolog (Coenzyme Q biosynthesis protein 7 homolog) (Timing protein clk-1 homolog).
[Source:Uniprot/SWISSPROT;Acc:Q99807]
ENSG00000203710 CR1 Complement receptor type 1 precursor (C3b/C4b receptor) (CD35 antigen). [Source:Uniprot/SWISSPROT;Acc:P17927]
ENSG00000118260 CREB1 cAMP response element-binding protein (CREB). [Source:Uniprot/SWISSPROT;Acc:P16220]
ENSG00000111269 CREBL2 cAMP responsive element binding protein-like 2 [Source:RefSeq_peptide;Acc:NP_001301]
ENSG00000150938 CRIM1
Cysteine-rich motor neuron 1 protein precursor (CRIM-1) (Cysteine-rich repeat-containing protein S52).
[Source:Uniprot/SWISSPROT;Acc:Q9NZV1]
ENSG00000112282 CRSP3
CRSP complex subunit 3 (Cofactor required for Sp1 transcriptional activation subunit 3) (Transcriptional coactivator CRSP130)
(Vitamin D3 receptor-interacting protein complex 130 kDa component) (DRIP130) (Activator-recruited cofactor 130 kDa
component) (A [Source:Uniprot/SWISSPROT;Acc:Q9ULK4]
ENSG00000198223 CSF2RA
Granulocyte-macrophage colony-stimulating factor receptor alpha chain precursor (GM-CSF-R-alpha) (GMR) (CD116 antigen)
(CDw116). [Source:Uniprot/SWISSPROT;Acc:P15509]
ENSG00000113712 CSNK1A1 Casein kinase I isoform alpha (EC 2.7.11.1) (CKI-alpha) (CK1). [Source:Uniprot/SWISSPROT;Acc:P48729]
ENSG00000100181 CSNK1E Casein kinase I isoform epsilon (EC 2.7.11.1) (CKI-epsilon) (CKIe). [Source:Uniprot/SWISSPROT;Acc:P49674]
ENSG00000101439 CST3 Cystatin C precursor (Neuroendocrine basic polypeptide) (Gamma-trace) (Post-gamma-globulin).
[Source:Uniprot/SWISSPROT;Acc:P01034]
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[Source:Uniprot/SWISSPROT;Acc:P01034]
ENSG00000151792 CTSO Cathepsin O precursor (EC 3.4.22.42). [Source:Uniprot/SWISSPROT;Acc:P43234]
ENSG00000036257 CUL3 Cullin-3 (CUL-3). [Source:Uniprot/SWISSPROT;Acc:Q13618]
ENSG00000006210 CX3CL1
Fractalkine precursor (CX3CL1) (Neurotactin) (CX3C membrane-anchored chemokine) (Small inducible cytokine D1).
[Source:Uniprot/SWISSPROT;Acc:P78423]
ENSG00000163735 CXCL5
Small inducible cytokine B5 precursor (CXCL5) (Epithelial-derived neutrophil-activating protein 78) (Neutrophil-activating
peptide ENA- 78) (ENA-78(1-78)) [Contains: ENA-78(8-78); ENA-78(9-78)]. [Source:Uniprot/SWISSPROT;Acc:P42830]
ENSG00000123575 CX039_HUMAN Uncharacterized protein CXorf39. [Source:Uniprot/SWISSPROT;Acc:Q6PEV8]
ENSG00000055163 CYFIP2 cytoplasmic FMR1 interacting protein 2 [Source:RefSeq_peptide;Acc:NP_055191]
ENSG00000136848 DAB2IP
Disabled homolog 2-interacting protein (DAB2-interacting protein) (DAB2 interaction protein) (ASK-interacting protein 1).
[Source:Uniprot/SWISSPROT;Acc:Q5VWQ8]
ENSG00000070190 DAPP1
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3- phosphoinositide (hDAPP1) (B cell adapter molecule of 32 kDa)
(B lymphocyte adapter protein Bam32). [Source:Uniprot/SWISSPROT;Acc:Q9UN19]
ENSG00000043093 DCUN1D1
DCN1-like protein 1 (Defective in cullin neddylation protein 1-like protein 1) (DCUN1 domain-containing protein 1) (Squamous
cell carcinoma-related oncogene). [Source:Uniprot/SWISSPROT;Acc:Q96GG9]
ENSG00000150401 DCUN1D2
DCN1-like protein 2 (Defective in cullin neddylation protein 1-like protein 2) (DCUN1 domain-containing protein 2).
[Source:Uniprot/SWISSPROT;Acc:Q6PH85]
ENSG00000153317 DDEF1
130 kDa phosphatidylinositol 4,5-biphosphate-dependent ARF1 GTPase- activating protein (PIP2-dependent ARF1 GAP) (ADP-
ribosylation factor- directed GTPase-activating protein 1) (ARF GTPase-activating protein 1) (Development and differentiation-
enhancing f [Source:Uniprot/SWISSPROT;Acc:Q9ULH1]
ENSG00000124487 DDX3X
ATP-dependent RNA helicase DDX3X (EC 3.6.1.-) (DEAD box protein 3, X- chromosomal) (Helicase-like protein 2) (HLP2)
(DEAD box, X isoform). [Source:Uniprot/SWISSPROT;Acc:O00571]
ENSG00000162701 DENND1B DENN/MADD domain containing 1B [Source:RefSeq_peptide;Acc:NP_659414]
ENSG00000162777 DENND2D DENN domain-containing protein 2D. [Source:Uniprot/SWISSPROT;Acc:Q9H6A0]
ENSG00000211448 DIO2
Type II iodothyronine deiodinase (EC 1.97.1.10) (Type-II 5' deiodinase) (DIOII) (Type 2 DI) (5DII).
[Source:Uniprot/SWISSPROT;Acc:Q92813]
ENSG00000150764 DIXDC1 DIX domain containing 1 isoform b [Source:RefSeq_peptide;Acc:NP_219493]
ENSG00000116652 DLEU2L Leukemia-associated protein 2 (Deleted in lymphocytic leukemia 2). [Source:Uniprot/SWISSPROT;Acc:O43262]
ENSG00000075711 DLG1 Disks large homolog 1 (Synapse-associated protein 97) (SAP-97) (hDlg). [Source:Uniprot/SWISSPROT;Acc:Q12959]
ENSG00000100206 DMC1 Meiotic recombination protein DMC1/LIM15 homolog. [Source:Uniprot/SWISSPROT;Acc:Q14565]
ENSG00000105993 DNAJB6
DnaJ homolog subfamily B member 6 (Heat shock protein J2) (HSJ-2) (MSJ-1) (HHDJ1) (MRJ).
[Source:Uniprot/SWISSPROT;Acc:O75190]
ENSG00000100246 DNAL4 Dynein light chain 4, axonemal. [Source:Uniprot/SWISSPROT;Acc:O96015]
ENSG00000154813 DPH3
CSL-type zinc finger-containing protein 2 (DelGEF-interacting protein 1) (DelGIP1).
[Source:Uniprot/SWISSPROT;Acc:Q96FX2]
ENSG00000113657 DPYSL3
Dihydropyrimidinase-related protein 3 (DRP-3) (Unc-33-like phosphoprotein) (ULIP protein) (Collapsin response mediator protein
4) (CRMP-4). [Source:Uniprot/SWISSPROT;Acc:Q14195]
ENSG00000101412 E2F1
Transcription factor E2F1 (E2F-1) (Retinoblastoma-binding protein 3) (RBBP-3) (PRB-binding protein E2F-1) (PBR3)
(Retinoblastoma-associated protein 1) (RBAP-1). [Source:Uniprot/SWISSPROT;Acc:Q01094]
ENSG00000145194 ECE2 Endothelin-converting enzyme 2 (EC 3.4.24.71) (ECE-2). [Source:Uniprot/SWISSPROT;Acc:O60344]
ENSG00000116406 EDEM3 ER degradation-enhancing alpha-mannosidase-like 3. [Source:Uniprot/SWISSPROT;Acc:Q9BZQ6]
ENSG00000164176 EDIL3
EGF-like repeat and discoidin I-like domain-containing protein 3 precursor (EGF-like repeats and discoidin I-like domains protein
3) (Developmentally-regulated endothelial cell locus 1 protein) (Integrin-binding protein DEL1).
[Source:Uniprot/SWISSPROT;Acc:O43854]
ENSG00000151617 EDNRA Endothelin-1 receptor precursor (Endothelin A receptor) (ET-A) (hET- AR) (ETA-R). [Source:Uniprot/SWISSPROT;Acc:P25101]
ENSG00000055332 EIF2AK2
Interferon-induced, double-stranded RNA-activated protein kinase (EC 2.7.11.1) (Interferon-inducible RNA-dependent protein
kinase) (Protein kinase RNA-activated) (PKR) (p68 kinase) (P1/eIF-2A protein kinase).
[Source:Uniprot/SWISSPROT;Acc:P19525]
ENSG00000123908 EIF2C2
Eukaryotic translation initiation factor 2C 2 (eIF2C 2) (eIF-2C 2) (Argonaute-2) (Slicer protein) (PAZ Piwi domain protein)
(PPD). [Source:Uniprot/SWISSPROT;Acc:Q9UKV8]
ENSG00000066044 ELAVL1 ELAV-like protein 1 (Hu-antigen R). [Source:Uniprot/SWISSPROT;Acc:Q15717]
ENSG00000105656 ELL
RNA polymerase II elongation factor ELL (Eleven-nineteen lysine-rich leukemia protein).
[Source:Uniprot/SWISSPROT;Acc:P55199]
ENSG00000062598 ELMO2 Engulfment and cell motility protein 2 (CED-12 homolog A) (hCED-12A). [Source:Uniprot/SWISSPROT;Acc:Q96JJ3]
ENSG00000135638 EMX1
Homeobox protein EMX1 (Empty spiracles homolog 1) (Empty spiracles- like protein 1).
[Source:Uniprot/SWISSPROT;Acc:Q04741]
ENSG00000001561 ENPP4 ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative function) [Source:RefSeq_peptide;Acc:NP_055751]
ENSG00000112796 ENPP5
Ectonucleotide pyrophosphatase/phosphodiesterase 5 precursor (EC 3.1.-.-) (E-NPP5) (NPP-5).
[Source:Uniprot/SWISSPROT;Acc:Q9UJA9]
ENSG00000129595 EPB41L4A Band 4.1-like protein 4A (Protein NBL4). [Source:Uniprot/SWISSPROT;Acc:Q9HCS5]
ENSG00000095203 EPB41L4B Band 4.1-like protein 4B (Protein EHM2) (FERM-containing protein CG1). [Source:Uniprot/SWISSPROT;Acc:Q9H329]
ENSG00000135999 EPC2 Enhancer of polycomb homolog 2. [Source:Uniprot/SWISSPROT;Acc:Q52LR7]
ENSG00000124882 EREG Epiregulin precursor. [Source:Uniprot/SWISSPROT;Acc:O14944]
ENSG00000197930 ERO1L
ERO1-like protein alpha precursor (EC 1.8.4.-) (ERO1-Lalpha) (Oxidoreductin-1-Lalpha) (Endoplasmic oxidoreductin-1-like
protein) (ERO1-L). [Source:Uniprot/SWISSPROT;Acc:Q96HE7]
ENSG00000134954 ETS1 C-ets-1 protein (p54). [Source:Uniprot/SWISSPROT;Acc:P14921]
ENSG00000006468 ETV1 ETS translocation variant 1 (ER81 protein). [Source:Uniprot/SWISSPROT;Acc:P50549]
ENSG00000149573 EVA1 Epithelial V-like antigen 1 precursor. [Source:Uniprot/SWISSPROT;Acc:O60487]
ENSG00000085276 EVI1 Ecotropic virus integration site 1 protein homolog (EVI-1). [Source:Uniprot/SWISSPROT;Acc:Q03112]
ENSG00000067208 EVI5
Ecotropic viral integration site 5 protein homolog (EVI-5) (Neuroblastoma stage 4S gene).
[Source:Uniprot/SWISSPROT;Acc:O60447]
ENSG00000185104 FAF1 FAS-associated factor 1 (Protein FAF1) (hFAF1). [Source:Uniprot/SWISSPROT;Acc:Q9UNN5]
ENSG00000162636 FAM102B Protein FAM102B. [Source:Uniprot/SWISSPROT;Acc:Q5T8I3]
ENSG00000189057 FAM111B family with sequence similarity 111, member B (FAM111B), mRNA [Source:RefSeq_dna;Acc:NM_198947]
ENSG00000197712 FAM114A1 family with sequence similarity 114, member A1 (FAM114A1), mRNA [Source:RefSeq_dna;Acc:NM_138389]
ENSG00000171928 FAM18B Protein FAM18B. [Source:Uniprot/SWISSPROT;Acc:Q9NYZ1]
ENSG00000138172 FAM26B Protein FAM26B. [Source:Uniprot/SWISSPROT;Acc:Q9HA72]
ENSG00000203667 FAM36A Protein FAM36A. [Source:Uniprot/SWISSPROT;Acc:Q5RI15]
ENSG00000139146 FAM60A Protein FAM60A (Tera protein homolog). [Source:Uniprot/SWISSPROT;Acc:Q9NP50]
ENSG00000009780 FAM76A Protein FAM76A. [Source:Uniprot/SWISSPROT;Acc:Q8TAV0]
ENSG00000026103 FAS
Tumor necrosis factor receptor superfamily member 6 precursor (FASLG receptor) (Apoptosis-mediating surface antigen FAS)
(Apo-1 antigen) (CD95 antigen). [Source:Uniprot/SWISSPROT;Acc:P25445]
ENSG00000083857 FAT Cadherin-related tumor suppressor homolog precursor (Protein fat homolog). [Source:Uniprot/SWISSPROT;Acc:Q14517]
ENSG00000166147 FBN1 Fibrillin-1 precursor. [Source:Uniprot/SWISSPROT;Acc:P35555]
ENSG00000147364 FBXO25 F-box only protein 25. [Source:Uniprot/SWISSPROT;Acc:Q8TCJ0]
ENSG00000164117 FBXO8 F-box only protein 8 (F-box/SEC7 protein FBS). [Source:Uniprot/SWISSPROT;Acc:Q9NRD0]
ENSG00000137714 FDX1
Adrenodoxin, mitochondrial precursor (Adrenal ferredoxin) (Ferredoxin- 1) (Hepatoredoxin).
[Source:Uniprot/SWISSPROT;Acc:P10109]
ENSG00000156427 FGF18 Fibroblast growth factor 18 precursor (FGF-18) (zFGF5). [Source:Uniprot/SWISSPROT;Acc:O76093]
ENSG00000105550 FGF21 Fibroblast growth factor 21 precursor (FGF-21). [Source:Uniprot/SWISSPROT;Acc:Q9NSA1]
ENSG00000118972 FGF23
Fibroblast growth factor 23 precursor (FGF-23) (Tumor-derived hypophosphatemia-inducing factor).
[Source:Uniprot/SWISSPROT;Acc:Q9GZV9]
ENSG00000111790 FGFR1OP2 FGFR1 oncogene partner 2 [Source:RefSeq_peptide;Acc:NP_056448]
121
ENSG00000106080 FKBP14
FK506-binding protein 14 precursor (EC 5.2.1.8) (Peptidyl-prolyl cis- trans isomerase) (PPIase) (Rotamase) (22 kDa FK506-
binding protein) (FKBP-22). [Source:Uniprot/SWISSPROT;Acc:Q9NWM8]
ENSG00000181027 FKRP Fukutin-related protein (EC 2.-.-.-). [Source:Uniprot/SWISSPROT;Acc:Q9H9S5]
ENSG00000160688 FLAD1 flavin adenine dinucleotide synthetase isoform 1 [Source:RefSeq_peptide;Acc:NP_079483]
ENSG00000125848 FLRT3
Leucine-rich repeat transmembrane protein FLRT3 precursor (Fibronectin-like domain-containing leucine-rich transmembrane
protein 3). [Source:Uniprot/SWISSPROT;Acc:Q9NZU0]
ENSG00000162769 FLVC1_HUMAN
Feline leukemia virus subgroup C receptor-related protein 1 (Feline leukemia virus subgroup C receptor) (hFLVCR).
[Source:Uniprot/SWISSPROT;Acc:Q9Y5Y0]
ENSG00000094963 FMO2
Dimethylaniline monooxygenase [N-oxide-forming] 2 (EC 1.14.13.8) (Pulmonary flavin-containing monooxygenase 2) (FMO 2)
(Dimethylaniline oxidase 2) (FMO 1B1). [Source:Uniprot/SWISSPROT;Acc:Q99518]
ENSG00000170802 FOXN2 Forkhead box protein N2 (Human T-cell leukemia virus enhancer factor). [Source:Uniprot/SWISSPROT;Acc:P32314]
ENSG00000139445 FOXN4 Forkhead box protein N4. [Source:Uniprot/SWISSPROT;Acc:Q96NZ1]
ENSG00000114861 FOXP1 Forkhead box protein P1. [Source:Uniprot/SWISSPROT;Acc:Q9H334]
ENSG00000171049 FPRL1
FMLP-related receptor I (FMLP-R-I) (Lipoxin A4 receptor) (LXA4 receptor) (Formyl peptide receptor-like 1) (RFP) (HM63).
[Source:Uniprot/SWISSPROT;Acc:P25090]
ENSG00000163430 FSTL1 Follistatin-related protein 1 precursor (Follistatin-like 1). [Source:Uniprot/SWISSPROT;Acc:Q12841]
ENSG00000089280 FUS
RNA-binding protein FUS (Oncogene FUS) (Oncogene TLS) (Translocated in liposarcoma protein) (POMp75) (75 kDa DNA-
pairing protein). [Source:Uniprot/SWISSPROT;Acc:P35637]
ENSG00000174951 FUT1
Galactoside 2-alpha-L-fucosyltransferase 1 (EC 2.4.1.69) (GDP-L- fucose:beta-D-galactoside 2-alpha-L-fucosyltransferase 1)
(Alpha(1,2)FT 1) (Fucosyltransferase 1) (Blood group H alpha 2- fucosyltransferase). [Source:Uniprot/SWISSPROT;Acc:P19526]
ENSG00000138757 G3BP2
Ras-GTPase-activating protein-binding protein 2 (GAP SH3-domain- binding protein 2) (G3BP-2).
[Source:Uniprot/SWISSPROT;Acc:Q9UN86]
ENSG00000022355 GABRA1
Gamma-aminobutyric-acid receptor subunit alpha-1 precursor (GABA(A) receptor subunit alpha-1).
[Source:Uniprot/SWISSPROT;Acc:P14867]
ENSG00000128683 GAD1
Glutamate decarboxylase 1 (EC 4.1.1.15) (Glutamate decarboxylase 67 kDa isoform) (GAD-67) (67 kDa glutamic acid
decarboxylase). [Source:Uniprot/SWISSPROT;Acc:Q99259]
ENSG00000109586 GALNT7
N-acetylgalactosaminyltransferase 7 (EC 2.4.1.-) (Protein-UDP acetylgalactosaminyltransferase 7) (UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase 7) (Polypeptide GalNAc transferase 7) (GalNAc-T7) (pp-GaNTase 7).
[Source:Uniprot/SWISSPROT;Acc:Q86SF2]
ENSG00000165219 GAPVD1 GTPase activating protein and VPS9 domains 1 [Source:RefSeq_peptide;Acc:NP_056450]
ENSG00000180447 GAS1 Growth-arrest-specific protein 1 precursor (GAS-1). [Source:Uniprot/SWISSPROT;Acc:P54826]
ENSG00000117228 GBP1
Interferon-induced guanylate-binding protein 1 (GTP-binding protein 1) (Guanine nucleotide-binding protein 1) (GBP-1) (HuGBP-
1). [Source:Uniprot/SWISSPROT;Acc:P32455]
ENSG00000174500 GCET2
Germinal center B-cell expressed transcript 2 protein (Germinal center-associated lymphoma protein) (hGAL).
[Source:Uniprot/SWISSPROT;Acc:Q8N6F7]
ENSG00000127554 GFER Augmenter of liver regeneration (hERV1 protein). [Source:Uniprot/SWISSPROT;Acc:P55789]
ENSG00000131459 GFPT2
Glucosamine--fructose-6-phosphate aminotransferase [isomerizing] 2 (EC 2.6.1.16) (Hexosephosphate aminotransferase 2) (D-
fructose-6- phosphate amidotransferase 2) (GFAT 2) (GFAT2). [Source:Uniprot/SWISSPROT;Acc:O94808]
ENSG00000139278 GLIPR1 Glioma pathogenesis-related protein 1 precursor (GliPR 1) (RTVP-1 protein). [Source:Uniprot/SWISSPROT;Acc:P48060]
ENSG00000115419 GLS
Glutaminase kidney isoform, mitochondrial precursor (EC 3.5.1.2) (GLS) (L-glutamine amidohydrolase) (K-glutaminase).
[Source:Uniprot/SWISSPROT;Acc:O94925]
ENSG00000087338 GMCL1 Germ cell-less protein-like 1. [Source:Uniprot/SWISSPROT;Acc:Q96IK5]
ENSG00000087258 GNAO1 Guanine nucleotide-binding protein G(o) subunit alpha 2. [Source:Uniprot/SWISSPROT;Acc:P29777]
ENSG00000156052 GNAQ
Guanine nucleotide-binding protein G(q) subunit alpha (Guanine nucleotide-binding protein alpha-q).
[Source:Uniprot/SWISSPROT;Acc:P50148]
ENSG00000159921 GNE
Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (UDP-GlcNAc-2-epimerase/ManAc kinase)
[Includes: UDP-N- acetylglucosamine 2-epimerase (EC 5.1.3.14) (Uridine diphosphate-N- acetylglucosamine-2-epimerase) (UDP-
GlcNAc-2-epimerase) [Source:Uniprot/SWISSPROT;Acc:Q9Y223]
ENSG00000168243 GNG4 Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-4 subunit precursor. [Source:Uniprot/SWISSPROT;Acc:P50150]
ENSG00000109163 GNRHR Gonadotropin-releasing hormone receptor (GnRH receptor) (GnRH-R). [Source:Uniprot/SWISSPROT;Acc:P30968]
ENSG00000143457 GOLPH3L GPP34-related protein [Source:RefSeq_peptide;Acc:NP_060648]
ENSG00000111711 GOLT1B
Vesicle transport protein GOT1B (Golgi transport 1 homolog B) (hGOT1a) (Putative NF-kappa-B-activating protein 470).
[Source:Uniprot/SWISSPROT;Acc:Q9Y3E0]
ENSG00000108587 GOSR1
Golgi SNAP receptor complex member 1 (28 kDa Golgi SNARE protein) (28 kDa cis-Golgi SNARE p28) (GOS-28).
[Source:Uniprot/SWISSPROT;Acc:O95249]
ENSG00000092978 GPATC2 G patch domain-containing protein 2. [Source:Uniprot/SWISSPROT;Acc:Q9NW75]
ENSG00000135387 GPIAP1
GPI-anchored membrane protein 1 (GPI-anchored protein p137) (p137GPI) (Membrane component chromosome 11 surface
marker 1). [Source:Uniprot/SWISSPROT;Acc:Q14444]
ENSG00000183484 GPR132 Probable G-protein coupled receptor 132 (G2 accumulation protein). [Source:Uniprot/SWISSPROT;Acc:Q9UNW8]
ENSG00000106070 GRB10
Growth factor receptor-bound protein 10 (GRB10 adaptor protein) (Insulin receptor-binding protein GRB-IR).
[Source:Uniprot/SWISSPROT;Acc:Q13322]
ENSG00000177885 GRB2
Growth factor receptor-bound protein 2 (Adapter protein GRB2) (SH2/SH3 adapter GRB2) (Protein Ash).
[Source:Uniprot/SWISSPROT;Acc:P62993]
ENSG00000164284 GRPEL2 GrpE protein homolog 2, mitochondrial precursor (Mt-GrpE#2). [Source:Uniprot/SWISSPROT;Acc:Q8TAA5]
ENSG00000180613 GSH2_HUMAN Homeobox protein GSH-2. [Source:Uniprot/SWISSPROT;Acc:Q9BZM3]
ENSG00000105793 GTPBP10 claudin 12 isoform 1 [Source:RefSeq_peptide;Acc:NP_001036182]
ENSG00000172432 GTPBP2 GTP-binding protein 2. [Source:Uniprot/SWISSPROT;Acc:Q9BX10]
ENSG00000070019 GUCY2C
Heat-stable enterotoxin receptor precursor (GC-C) (Intestinal guanylate cyclase) (EC 4.6.1.2) (STA receptor) (hSTAR).
[Source:Uniprot/SWISSPROT;Acc:P25092]
ENSG00000105968 H2AFV Histone H2AV (H2A.F/Z). [Source:Uniprot/SWISSPROT;Acc:Q71UI9]
ENSG00000103044 HAS3
Hyaluronan synthase 3 (EC 2.4.1.212) (Hyaluronate synthase 3) (Hyaluronic acid synthase 3) (HA synthase 3).
[Source:Uniprot/SWISSPROT;Acc:O00219]
ENSG00000138411 HECW2 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 [Source:RefSeq_peptide;Acc:NP_065811]
ENSG00000019991 HGF
Hepatocyte growth factor precursor (Scatter factor) (SF) (Hepatopoeitin A) [Contains: Hepatocyte growth factor alpha chain;
Hepatocyte growth factor beta chain]. [Source:Uniprot/SWISSPROT;Acc:P14210]
ENSG00000111911 HINT3 histidine triad nucleotide binding protein 3 [Source:RefSeq_peptide;Acc:NP_612638]
ENSG00000160883 HK3 Hexokinase-3 (EC 2.7.1.1) (Hexokinase type III) (HK III). [Source:Uniprot/SWISSPROT;Acc:P52790]
ENSG00000152795 HNRPDL heterogeneous nuclear ribonucleoprotein D-like [Source:RefSeq_peptide;Acc:NP_112740]
ENSG00000096746 HNRPH3 Heterogeneous nuclear ribonucleoprotein H3 (hnRNP H3) (hnRNP 2H9). [Source:Uniprot/SWISSPROT;Acc:P31942]
ENSG00000153187 HNRPU
Heterogeneous nuclear ribonucleoprotein U (hnRNP U) (Scaffold attachment factor A) (SAF-A) (p120) (pp120).
[Source:Uniprot/SWISSPROT;Acc:Q00839]
ENSG00000152413 HOMER1 Homer protein homolog 1. [Source:Uniprot/SWISSPROT;Acc:Q86YM7]
ENSG00000173917 HOXB2 Homeobox protein Hox-B2 (Hox-2H) (Hox-2.8) (K8). [Source:Uniprot/SWISSPROT;Acc:P14652]
ENSG00000110756 HPS5
Hermansky-Pudlak syndrome 5 protein (Alpha-integrin-binding protein 63) (Ruby-eye protein 2 homolog) (Ru2).
[Source:Uniprot/SWISSPROT;Acc:Q9UPZ3]
ENSG00000136720 HS6ST1 Heparan-sulfate 6-O-sulfotransferase 1 (EC 2.8.2.-) (HS6ST-1). [Source:Uniprot/SWISSPROT;Acc:O60243]
ENSG00000166598 HSP90B1
Endoplasmin precursor (Heat shock protein 90 kDa beta member 1) (94 kDa glucose-regulated protein) (GRP94) (gp96 homolog)
(Tumor rejection antigen 1). [Source:Uniprot/SWISSPROT;Acc:P14625]
ENSG00000120694 HSPH1 Heat-shock protein 105 kDa (Heat shock 110 kDa protein) (Antigen NY- CO-25). [Source:Uniprot/SWISSPROT;Acc:Q92598]
ENSG00000102468 HTR2A 5-hydroxytryptamine 2A receptor (5-HT-2A) (Serotonin receptor 2A) (5- HT-2). [Source:Uniprot/SWISSPROT;Acc:P28223]
ENSG00000142149 HUNK
Hormonally up-regulated neu tumor-associated kinase (EC 2.7.11.1) (Serine/threonine-protein kinase MAK-V) (B19).
[Source:Uniprot/SWISSPROT;Acc:P57058]
ENSG00000136273 HUS1_HUMAN Checkpoint protein HUS1 (hHUS1). [Source:Uniprot/SWISSPROT;Acc:O60921]
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ENSG00000119912 IDE Insulin-degrading enzyme (EC 3.4.24.56) (Insulysin) (Insulinase) (Insulin protease). [Source:Uniprot/SWISSPROT;Acc:P14735]
ENSG00000137080 IFNA21 Interferon alpha-21 precursor (Interferon alpha-F) (LeIF F). [Source:Uniprot/SWISSPROT;Acc:P01568]
ENSG00000142166 IFNAR1 Interferon-alpha/beta receptor alpha chain precursor (IFN-alpha-REC). [Source:Uniprot/SWISSPROT;Acc:P17181]
ENSG00000006652 IFRD1
Interferon-related developmental regulator 1 (Nerve growth factor- inducible protein PC4).
[Source:Uniprot/SWISSPROT;Acc:O00458]
ENSG00000159217 IGF2BP1 insulin-like growth factor 2 mRNA binding protein 1 [Source:RefSeq_peptide;Acc:NP_006537]
ENSG00000163453 IGFBP7
Insulin-like growth factor-binding protein 7 precursor (IGFBP-7) (IBP- 7) (IGF-binding protein 7) (MAC25 protein) (Prostacyclin-
stimulating factor) (PGI2-stimulating factor) (IGFBP-rP1). [Source:Uniprot/SWISSPROT;Acc:Q16270]
ENSG00000132740 IGHMBP2
DNA-binding protein SMUBP-2 (EC 3.6.1.-) (ATP-dependent helicase IGHMBP2) (Immunoglobulin mu-binding protein 2)
(SMUBP-2) (Glial factor 1) (GF-1). [Source:Uniprot/SWISSPROT;Acc:P38935]
ENSG00000136696 IL1F8
Interleukin-1 family member 8 (IL-1F8) (Interleukin-1 eta) (IL-1 eta) (FIL1 eta) (Interleukin-1 homolog 2) (IL-1H2).
[Source:Uniprot/SWISSPROT;Acc:Q9NZH7]
ENSG00000115594 IL1R1
Interleukin-1 receptor type I precursor (IL-1R-1) (IL-1RT1) (IL-1R- alpha) (p80) (CD121a antigen).
[Source:Uniprot/SWISSPROT;Acc:P14778]
ENSG00000109471 IL2 Interleukin-2 precursor (IL-2) (T-cell growth factor) (TCGF) (Aldesleukin). [Source:Uniprot/SWISSPROT;Acc:P60568]
ENSG00000162891 IL20 Interleukin-20 precursor (IL-20) (Four alpha helix cytokine Zcyto10). [Source:Uniprot/SWISSPROT;Acc:Q9NYY1]
ENSG00000113520 IL4
Interleukin-4 precursor (IL-4) (B-cell stimulatory factor 1) (BSF-1) (Lymphocyte stimulatory factor 1) (Binetrakin) (Pitrakinra).
[Source:Uniprot/SWISSPROT;Acc:P05112]
ENSG00000169429 IL8
Interleukin-8 precursor (IL-8) (CXCL8) (Monocyte-derived neutrophil chemotactic factor) (MDNCF) (T-cell chemotactic factor)
(Neutrophil- activating protein 1) (NAP-1) (Protein 3-10C) (Granulocyte chemotactic protein 1) (GCP-1) (Monocyte-derived
neutrophil [Source:Uniprot/SWISSPROT;Acc:P10145]
ENSG00000104331 IMPAD1 myo-inositol monophosphatase A3 [Source:RefSeq_peptide;Acc:NP_060283]
ENSG00000122641 INHBA
Inhibin beta A chain precursor (Activin beta-A chain) (Erythroid differentiation protein) (EDF).
[Source:Uniprot/SWISSPROT;Acc:P08476]
ENSG00000198825 INPP5F inositol polyphosphate-5-phosphatase F [Source:RefSeq_peptide;Acc:NP_055752]
ENSG00000186480 INSIG1 Insulin-induced gene 1 protein (INSIG-1). [Source:Uniprot/SWISSPROT;Acc:O15503]
ENSG00000127080 IPPK
Inositol-pentakisphosphate 2-kinase (EC 2.7.1.-) (Inositol-1,3,4,5,6- pentakisphosphate 2-kinase) (Ins(1,3,4,5,6)P5 2-kinase)
(InsP5 2- kinase) (IPK1 homolog). [Source:Uniprot/SWISSPROT;Acc:Q9H8X2]
ENSG00000140575 IQGAP1 Ras GTPase-activating-like protein IQGAP1 (p195). [Source:Uniprot/SWISSPROT;Acc:P46940]
ENSG00000128604 IRF5 Interferon regulatory factor 5 (IRF-5). [Source:Uniprot/SWISSPROT;Acc:Q13568]
ENSG00000160255 ITGB2
Integrin beta-2 precursor (Cell surface adhesion glycoproteins LFA- 1/CR3/p150,95 subunit beta) (Complement receptor C3
subunit beta) (CD18 antigen). [Source:Uniprot/SWISSPROT;Acc:P05107]
ENSG00000056345 ITGB3
Integrin beta-3 precursor (Platelet membrane glycoprotein IIIa) (GPIIIa) (CD61 antigen).
[Source:Uniprot/SWISSPROT;Acc:P05106]
ENSG00000101384 JAG1 Jagged-1 precursor (Jagged1) (hJ1) (CD339 antigen). [Source:Uniprot/SWISSPROT;Acc:P78504]
ENSG00000073614 JARID1A
Jumonji/ARID domain-containing protein 1A (Retinoblastoma-binding protein 2) (RBBP-2).
[Source:Uniprot/SWISSPROT;Acc:P29375]
ENSG00000011201 KAL1
Anosmin-1 precursor (Kallmann syndrome protein) (Adhesion molecule- like X-linked).
[Source:Uniprot/SWISSPROT;Acc:P23352]
ENSG00000176595 KBTBD11
Kelch repeat and BTB domain-containing protein 11 (Kelch domain- containing protein 7B).
[Source:Uniprot/SWISSPROT;Acc:O94819]
ENSG00000170852 KBTBD2
Kelch repeat and BTB domain-containing protein 2 (BTB and kelch domain-containing protein 1).
[Source:Uniprot/SWISSPROT;Acc:Q8IY47]
ENSG00000171385 KCND3
Potassium voltage-gated channel subfamily D member 3 (Voltage-gated potassium channel subunit Kv4.3).
[Source:Uniprot/SWISSPROT;Acc:Q9UK17]
ENSG00000153885 KCTD15 BTB/POZ domain-containing protein KCTD15. [Source:Uniprot/SWISSPROT;Acc:Q96SI1]
ENSG00000128052 KDR
Vascular endothelial growth factor receptor 2 precursor (EC 2.7.10.1) (VEGFR-2) (Kinase insert domain receptor) (Protein-
tyrosine kinase receptor Flk-1) (CD309 antigen). [Source:Uniprot/SWISSPROT;Acc:P35968]
ENSG00000112624 KIAA0240 KIAA0240 (KIAA0240), mRNA [Source:RefSeq_dna;Acc:NM_015349]
ENSG00000196663 KIAA0329 Protein KIAA0329/KIAA0297. [Source:Uniprot/SWISSPROT;Acc:O15040]
ENSG00000107771 KIAA1128 granule cell antiserum positive 14 [Source:RefSeq_peptide;Acc:NP_061872]
ENSG00000087301 KIAA1344 Thioredoxin-domain containing protein KIAA1344 precursor. [Source:Uniprot/SWISSPROT;Acc:Q9P2K2]
ENSG00000119698 KIAA1622 HEAT-like repeat-containing protein isoform 1 [Source:RefSeq_peptide;Acc:NP_478144]
ENSG00000148841 KIAA1754 KIAA1754 (KIAA1754), mRNA [Source:RefSeq_dna;Acc:NM_033397]
ENSG00000137177 KIF13A Kinesin-like protein KIF13A (Kinesin-like protein RBKIN). [Source:Uniprot/SWISSPROT;Acc:Q9H1H9]
ENSG00000197892 KIF13B Kinesin-like protein KIF13B (Kinesin-like protein GAKIN). [Source:Uniprot/SWISSPROT;Acc:Q9NQT8]
ENSG00000131437 KIF3A Kinesin-like protein KIF3A (Microtubule plus end-directed kinesin motor 3A). [Source:Uniprot/SWISSPROT;Acc:Q9Y496]
ENSG00000125498 KIR3DL2
Killer cell immunoglobulin-like receptor 3DL2 precursor (MHC class I NK cell receptor) (Natural killer-associated transcript 4)
(NKAT-4) (p70 natural killer cell receptor clone CL-5) (CD158k antigen). [Source:Uniprot/SWISSPROT;Acc:P43630]
ENSG00000183853 KIRREL
Kin of IRRE-like protein 1 precursor (Kin of irregular chiasm-like protein 1) (Nephrin-like protein 1).
[Source:Uniprot/SWISSPROT;Acc:Q96J84]
ENSG00000049130 KITLG
Kit ligand precursor (C-kit ligand) (Stem cell factor) (SCF) (Mast cell growth factor) (MGF).
[Source:Uniprot/SWISSPROT;Acc:P21583]
ENSG00000172059 KLF11
Krueppel-like factor 11 (Transforming growth factor-beta-inducible early growth response protein 2) (TGFB-inducible early
growth response protein 2) (TIEG-2). [Source:Uniprot/SWISSPROT;Acc:O14901]
ENSG00000163884 KLF15 Krueppel-like factor 15 (Kidney-enriched krueppel-like factor). [Source:Uniprot/SWISSPROT;Acc:Q9UIH9]
ENSG00000197776 KLHDC1 Kelch domain-containing protein 1. [Source:Uniprot/SWISSPROT;Acc:Q8N7A1]
ENSG00000187961 KLHL17 Kelch-like protein 17 (Actinfilin). [Source:Uniprot/SWISSPROT;Acc:Q6TDP4]
ENSG00000198642 KLHL9 Kelch-like protein 9. [Source:Uniprot/SWISSPROT;Acc:Q9P2J3]
ENSG00000025800 KPNA6 Importin alpha-7 subunit (Karyopherin alpha-6). [Source:Uniprot/SWISSPROT;Acc:O60684]
ENSG00000133703 KRAS GTPase KRas (K-Ras 2) (Ki-Ras) (c-K-ras) (c-Ki-ras). [Source:Uniprot/SWISSPROT;Acc:P01116]
ENSG00000186831 KRT17 Keratin, type I cytoskeletal 17 (Cytokeratin-17) (CK-17) (Keratin-17) (K17) (39.1). [Source:Uniprot/SWISSPROT;Acc:Q04695]
ENSG00000162511 LAPTM5
Lysosomal-associated transmembrane protein 5 (Lysosomal-associated multitransmembrane protein 5) (Retinoic acid-inducible E3
protein). [Source:Uniprot/SWISSPROT;Acc:Q13571]
ENSG00000161813 LARP4 La-related protein 4 (La ribonucleoprotein domain family member 4). [Source:Uniprot/SWISSPROT;Acc:Q71RC2]
ENSG00000090661 LASS4 LAG1 longevity assurance homolog 4. [Source:Uniprot/SWISSPROT;Acc:Q9HA82]
ENSG00000178177 LCORL transcription factor MLR1 [Source:RefSeq_peptide;Acc:NP_710153]
ENSG00000116678 LEPR Leptin receptor precursor (LEP-R) (OB receptor) (OB-R) (HuB219) (CD295 antigen). [Source:Uniprot/SWISSPROT;Acc:P48357]
ENSG00000168924 LETM1
Leucine zipper-EF-hand-containing transmembrane protein 1, mitochondrial precursor.
[Source:Uniprot/SWISSPROT;Acc:O95202]
ENSG00000100097 LGALS1
Galectin-1 (Lectin galactoside-binding soluble 1) (Beta-galactoside- binding lectin L-14-I) (Lactose-binding lectin 1) (S-Lac lectin
1) (Galaptin) (14 kDa lectin) (HPL) (HBL) (Putative MAPK-activating protein MP12).
[Source:Uniprot/SWISSPROT;Acc:P09382]
ENSG00000116977 LGALS8
Galectin-8 (Gal-8) (Prostate carcinoma tumor antigen 1) (PCTA-1) (Po66 carbohydrate-binding protein) (Po66-CBP).
[Source:Uniprot/SWISSPROT;Acc:O00214]
ENSG00000106852 LHX6 LIM/homeobox protein Lhx6.1 (Lhx6). [Source:Uniprot/SWISSPROT;Acc:Q9UPM6]
ENSG00000050405 LIMA1 LIM domain and actin-binding protein 1 (Epithelial protein lost in neoplasm). [Source:Uniprot/SWISSPROT;Acc:Q9UHB6]
ENSG00000140471 LINS1 lines homolog 1 [Source:RefSeq_peptide;Acc:NP_001035706]
ENSG00000143013 LMO4
LIM domain transcription factor LMO4 (LIM domain only protein 4) (LMO- 4) (Breast tumor autoantigen).
[Source:Uniprot/SWISSPROT;Acc:P61968]
ENSG00000072201 LNX1
Ubiquitin ligase LNX (EC 6.3.2.-) (Numb-binding protein 1) (Ligand of Numb-protein X 1).
[Source:Uniprot/SWISSPROT;Acc:Q8TBB1]
ENSG00000123684 LPGAT1 Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 (EC 2.3.1.-). [Source:Uniprot/SWISSPROT;Acc:Q92604]
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ENSG00000144749 LRIG1 Leucine-rich repeats and immunoglobulin-like domains protein 1 precursor (LIG-1). [Source:Uniprot/SWISSPROT;Acc:Q96JA1]
ENSG00000182504 LRRIQ2 leucine-rich repeats and IQ motif containing 2 [Source:RefSeq_peptide;Acc:NP_078824]
ENSG00000155858 LSM11 U7 snRNA-associated Sm-like protein LSm11. [Source:Uniprot/SWISSPROT;Acc:P83369]
ENSG00000119681 LTBP2 Latent-transforming growth factor beta-binding protein 2 precursor (LTBP-2). [Source:Uniprot/SWISSPROT;Acc:Q14767]
ENSG00000139329 LUM Lumican precursor (Keratan sulfate proteoglycan lumican) (KSPG lumican). [Source:Uniprot/SWISSPROT;Acc:P51884]
ENSG00000169641 LUZP1 Leucine zipper protein 1. [Source:Uniprot/SWISSPROT;Acc:Q86V48]
ENSG00000187123 LYPD6 LY6/PLAUR domain-containing protein 6 precursor. [Source:Uniprot/SWISSPROT;Acc:Q86Y78]
ENSG00000061337 LZTS1
Leucine zipper putative tumor suppressor 1 (F37/esophageal cancer- related gene-coding leucine-zipper motif) (Fez1).
[Source:Uniprot/SWISSPROT;Acc:Q9Y250]
ENSG00000127603 MACF1 Microtubule-actin cross-linking factor 1, isoform 4. [Source:Uniprot/SWISSPROT;Acc:Q96PK2]
ENSG00000197063 MAFG
Transcription factor MafG (V-maf musculoaponeurotic fibrosarcoma oncogene homolog G) (hMAF).
[Source:Uniprot/SWISSPROT;Acc:O15525]
ENSG00000081026 MAGI3 membrane-associated guanylate kinase-related 3 isoform 2 [Source:RefSeq_peptide;Acc:NP_690864]
ENSG00000017621 NP_079135.1 PDZ domain containing, X chromosome [Source:RefSeq_peptide;Acc:NP_079135]
ENSG00000172469 MANEA mannosidase, endo-alpha [Source:RefSeq_peptide;Acc:NP_078917]
ENSG00000139625 MAP3K12
Mitogen-activated protein kinase kinase kinase 12 (EC 2.7.11.25) (Mixed lineage kinase) (Leucine-zipper protein kinase) (ZPK)
(Dual leucine zipper bearing kinase) (DLK) (MAPK-upstream kinase) [Source:Uniprot/SWISSPROT;Acc:Q12852]
ENSG00000135341 MAP3K7
Mitogen-activated protein kinase kinase kinase 7 (EC 2.7.11.25) (Transforming growth factor-beta-activated kinase 1) (TGF-beta-
activated kinase 1). [Source:Uniprot/SWISSPROT;Acc:O43318]
ENSG00000135525 MAP7
Ensconsin (Microtubule-associated protein 7) (Epithelial microtubule- associated protein of 115 kDa) (E-MAP-115).
[Source:Uniprot/SWISSPROT;Acc:Q14244]
ENSG00000137802 MAPKBP1 mitogen-activated protein kinase binding protein 1-like [Source:RefSeq_peptide;Acc:NP_055809]
ENSG00000101367 MAPRE1
Microtubule-associated protein RP/EB family member 1 (APC-binding protein EB1) (End-binding protein 1) (EB1).
[Source:Uniprot/SWISSPROT;Acc:Q15691]
ENSG00000145416 MAR1 membrane-associated RING-CH protein I [Source:RefSeq_peptide;Acc:NP_060393]
ENSG00000204406 MBD5 Methyl-CpG-binding domain protein 5 (Methyl-CpG-binding protein MBD5). [Source:Uniprot/SWISSPROT;Acc:Q9P267]
ENSG00000151332 MBIP
MAP3K12-binding inhibitory protein 1 (MAPK upstream kinase-binding inhibitory protein) (MUK-binding inhibitory protein).
[Source:Uniprot/SWISSPROT;Acc:Q9NS73]
ENSG00000152601 MBNL1 Muscleblind-like protein (Triplet-expansion RNA-binding protein). [Source:Uniprot/SWISSPROT;Acc:Q9NR56]
ENSG00000139793 MBNL2 muscleblind-like 2 isoform 1 [Source:RefSeq_peptide;Acc:NP_659002]
ENSG00000197971 MBP
Myelin basic protein (MBP) (Myelin A1 protein) (Myelin membrane encephalitogenic protein).
[Source:Uniprot/SWISSPROT;Acc:P02686]
ENSG00000140943 MBTPS1
Membrane-bound transcription factor site 1 protease precursor (EC 3.4.21.-) (S1P endopeptidase) (Site-1 protease)
(Subtilisin/kexin- isozyme 1) (SKI-1). [Source:Uniprot/SWISSPROT;Acc:Q14703]
ENSG00000065328 MCM10 minichromosome maintenance protein 10 isoform 2 [Source:RefSeq_peptide;Acc:NP_060988]
ENSG00000166823 MESP1 mesoderm posterior 1 [Source:RefSeq_peptide;Acc:NP_061140]
ENSG00000140545 MFGE8
Lactadherin precursor (Milk fat globule-EGF factor 8) (MFG-E8) (HMFG) (Breast epithelial antigen BA46) (MFGM) [Contains:
Lactadherin short form; Medin]. [Source:Uniprot/SWISSPROT;Acc:Q08431]
ENSG00000141503 MINK1
Misshapen-like kinase 1 (EC 2.7.11.1) (Mitogen-activated protein kinase kinase kinase kinase 6) (MAPK/ERK kinase kinase
kinase 6) (MEK kinase kinase 6) (MEKKK 6) (Misshapen/NIK-related kinase) (GCK family kinase MiNK).
[Source:Uniprot/SWISSPROT;Acc:Q8N4C8]
ENSG00000186260 MKL2
MKL/myocardin-like protein 2 (Myocardin-related transcription factor B) (MRTF-B) (Megakaryoblastic leukemia 2).
[Source:Uniprot/SWISSPROT;Acc:Q9ULH7]
ENSG00000128585 MKLN1 Muskelin. [Source:Uniprot/SWISSPROT;Acc:Q9UL63]
ENSG00000150051 MKX mohawk homeobox [Source:RefSeq_peptide;Acc:NP_775847]
ENSG00000005483 MLL5 myeloid/lymphoid or mixed-lineage leukemia 5 [Source:RefSeq_peptide;Acc:NP_061152]
ENSG00000143443 MLLT11 Protein AF1q. [Source:Uniprot/SWISSPROT;Acc:Q13015]
ENSG00000171843 MLLT3
Protein AF-9 (ALL1 fused gene from chromosome 9 protein) (Myeloid/lymphoid or mixed-lineage leukemia translocated to
chromosome 3 protein) (YEATS domain-containing protein 3). [Source:Uniprot/SWISSPROT;Acc:P42568]
ENSG00000108960 MMD
Monocyte to macrophage differentiation protein (Progestin and adipoQ receptor family member XI).
[Source:Uniprot/SWISSPROT;Acc:Q15546]
ENSG00000196549 MME
Neprilysin (EC 3.4.24.11) (Neutral endopeptidase) (NEP) (Enkephalinase) (Neutral endopeptidase 24.11) (Atriopeptidase)
(Common acute lymphocytic leukemia antigen) (CALLA) (CD10 antigen). [Source:Uniprot/SWISSPROT;Acc:P08473]
ENSG00000056586 MNAB Membrane-associated nucleic acid-binding protein (RING finger protein 164). [Source:Uniprot/SWISSPROT;Acc:Q9HBD1]
ENSG00000114978 MOBK1B
Mps one binder kinase activator-like 1B (Mob1 homolog 1B) (Mob1 alpha) (Mob1A) (Protein Mob4B).
[Source:Uniprot/SWISSPROT;Acc:Q9H8S9]
ENSG00000133422 MORC2
MORC family CW-type zinc finger protein 2 (Zinc finger CW-type coiled- coil domain protein 1).
[Source:Uniprot/SWISSPROT;Acc:Q9Y6X9]
ENSG00000101928 MOSPD1 Motile sperm domain-containing protein 1. [Source:Uniprot/SWISSPROT;Acc:Q9UJG1]
ENSG00000150054 MPP7 palmitoylated membrane protein 7 [Source:RefSeq_peptide;Acc:NP_775767]
ENSG00000114686 MRPL3 Mitochondrial 39S ribosomal protein L3 (L3mt) (MRP-L3). [Source:Uniprot/SWISSPROT;Acc:P09001]
ENSG00000147065 MSN Moesin (Membrane-organizing extension spike protein). [Source:Uniprot/SWISSPROT;Acc:P26038]
ENSG00000165929 MTAC2D1
Membrane targeting tandem C2 domain-containing protein 1 (Tandem C2 protein in nucleus) (Tac2-N).
[Source:Uniprot/SWISSPROT;Acc:Q8N9U0]
ENSG00000065911 MTHFD2
Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial precursor [Includes: NAD-dependent
methylenetetrahydrofolate dehydrogenase (EC 1.5.1.15); Methenyltetrahydrofolate cyclohydrolase (EC 3.5.4.9)].
[Source:Uniprot/SWISSPROT;Acc:P13995]
ENSG00000171100 MTM1 Myotubularin (EC 3.1.3.48). [Source:Uniprot/SWISSPROT;Acc:Q13496]
ENSG00000087053 MTMR2 Myotubularin-related protein 2 (EC 3.1.3.-). [Source:Uniprot/SWISSPROT;Acc:Q13614]
ENSG00000170873 MTSS1
Metastasis suppressor protein 1 (Missing in metastasis protein) (Metastasis suppressor YGL-1).
[Source:Uniprot/SWISSPROT;Acc:O43312]
ENSG00000129422 MTUS1 mitochondrial tumor suppressor 1 isoform 3 [Source:RefSeq_peptide;Acc:NP_001001927]
ENSG00000120279 MYCT1 myc target 1 [Source:RefSeq_peptide;Acc:NP_079383]
ENSG00000104177 MYEF2 Myelin expression factor 2 (MyEF-2) (MST156). [Source:Uniprot/SWISSPROT;Acc:Q9P2K5]
ENSG00000133026 MYH10
Myosin-10 (Myosin heavy chain, nonmuscle IIb) (Nonmuscle myosin heavy chain IIb) (NMMHC II-b) (NMMHC-IIB) (Cellular
myosin heavy chain, type B) (Nonmuscle myosin heavy chain-B) (NMMHC-B). [Source:Uniprot/SWISSPROT;Acc:P35580]
ENSG00000095777 MYO3A Myosin IIIA (EC 2.7.11.1). [Source:Uniprot/SWISSPROT;Acc:Q8NEV4]
ENSG00000166886 NAB2
NGFI-A-binding protein 2 (EGR-1-binding protein 2) (Melanoma- associated delayed early response protein) (Protein MADER).
[Source:Uniprot/SWISSPROT;Acc:Q15742]
ENSG00000114503 NCBP2
Nuclear cap-binding protein subunit 2 (20 kDa nuclear cap-binding protein) (NCBP 20 kDa subunit) (CBP20) (NCBP-interacting
protein 1) (NIP1) (Cell proliferation-inducing gene 55 protein). [Source:Uniprot/SWISSPROT;Acc:P52298]
ENSG00000128609 NDUFA5
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 (EC 1.6.5.3) (EC 1.6.99.3) (NADH-ubiquinone oxidoreductase
13 kDa-B subunit) (Complex I-13kD-B) (CI-13kD-B) (Complex I subunit B13). [Source:Uniprot/SWISSPROT;Acc:Q16718]
ENSG00000078114 NEBL Nebulette (Actin-binding Z-disk protein). [Source:Uniprot/SWISSPROT;Acc:O76041]
ENSG00000049759 NEDD4L E3 ubiquitin-protein ligase NEDD4-like protein (EC 6.3.2.-) (Nedd4-2) (NEDD4.2). [Source:Uniprot/SWISSPROT;Acc:Q96PU5]
ENSG00000119408 NEK6
Serine/threonine-protein kinase Nek6 (EC 2.7.11.1) (NimA-related protein kinase 6) (Protein kinase SID6-1512).
[Source:Uniprot/SWISSPROT;Acc:Q9HC98]
ENSG00000165973 NELL1
Protein kinase C-binding protein NELL1 precursor (NEL-like protein 1) (Nel-related protein 1).
[Source:Uniprot/SWISSPROT;Acc:Q92832]
ENSG00000102908 NFAT5
Nuclear factor of activated T-cells 5 (T-cell transcription factor NFAT5) (NF-AT5) (Tonicity-responsive enhancer-binding protein)
(TonE- binding protein) (TonEBP). [Source:Uniprot/SWISSPROT;Acc:O94916]
ENSG00000147862 NFIB
Nuclear factor 1 B-type (Nuclear factor 1/B) (NF1-B) (NFI-B) (NF-I/B) (CCAAT-box-binding transcription factor) (CTF)
(TGGCA-binding protein). [Source:Uniprot/SWISSPROT;Acc:O00712]
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ENSG00000100503 NIN
Ninein (hNinein) (Glycogen synthase kinase 3 beta-interacting protein) (GSK3B-interacting protein).
[Source:Uniprot/SWISSPROT;Acc:Q8N4C6]
ENSG00000136783 NIPSNAP3A Protein NipSnap3A (NipSnap4) (Target for Salmonella secreted protein C) (TassC). [Source:Uniprot/SWISSPROT;Acc:Q9UFN0]
ENSG00000181368 NM_032947.3 MSTP150 (MST150), mRNA [Source:RefSeq_dna;Acc:NM_032947]
ENSG00000115761 NOL10 Nucleolar protein 10. [Source:Uniprot/SWISSPROT;Acc:Q9BSC4]
ENSG00000146909 NOM1 nucleolar protein with MIF4G domain 1 [Source:RefSeq_peptide;Acc:NP_612409]
ENSG00000164867 NOS3
Nitric-oxide synthase, endothelial (EC 1.14.13.39) (EC-NOS) (NOS type III) (NOSIII) (Endothelial NOS) (eNOS) (Constitutive
NOS) (cNOS). [Source:Uniprot/SWISSPROT;Acc:P29474]
ENSG00000074181 NOTCH3
Neurogenic locus notch homolog protein 3 precursor (Notch 3) [Contains: Notch 3 extracellular truncation; Notch 3 intracellular
domain]. [Source:Uniprot/SWISSPROT;Acc:Q9UM47]
ENSG00000102763 NP_055873.1 OTTHUMP00000018324 (KIAA0564 protein). [Source:Uniprot/SPTREMBL;Acc:Q5VW08]
ENSG00000160131 NP_001017980.1
ENSG00000154153 NP_001030022.1 CDNA: FLJ22155 fis, clone HRC00205 (Hypothetical protein FLJ20152). [Source:Uniprot/SPTREMBL;Acc:Q9H6L5]
ENSG00000163945 NP_065945.1
ENSG00000139597 NP_438169.1 CG018 protein. [Source:Uniprot/SPTREMBL;Acc:Q8WTU5]
ENSG00000181982 NP_775734.1 CDNA FLJ43363 fis, clone NT2RP7017474. [Source:Uniprot/SPTREMBL;Acc:Q6ZUS6]
ENSG00000149308 NPAT nuclear protein, ataxia-telangiectasia locus [Source:RefSeq_peptide;Acc:NP_002510]
ENSG00000124222 NPEPL1 Syntaxin-16 (Syn16). [Source:Uniprot/SWISSPROT;Acc:O14662]
ENSG00000126368 NR1D1 Orphan nuclear receptor NR1D1 (V-erbA-related protein EAR-1) (Rev- erbA-alpha). [Source:Uniprot/SWISSPROT;Acc:P20393]
ENSG00000119508 NR4A3
Orphan nuclear receptor NR4A3 (Nuclear hormone receptor NOR-1) (Neuron-derived orphan receptor 1) (Mitogen-induced
nuclear orphan receptor). [Source:Uniprot/SWISSPROT;Acc:Q92570]
ENSG00000178425 NT5DC1 5'-nucleotidase domain-containing protein 1. [Source:Uniprot/SWISSPROT;Acc:Q5TFE4]
ENSG00000074590 NUAK1 NUAK family SNF1-like kinase 1 (EC 2.7.11.1) (AMPK-related protein kinase 5). [Source:Uniprot/SWISSPROT;Acc:O60285]
ENSG00000120526 NUDCD1 NudC domain containing 1 [Source:RefSeq_peptide;Acc:NP_116258]
ENSG00000112874 NUDT12
Peroxisomal NADH pyrophosphatase NUDT12 (EC 3.6.1.22) (Nucleoside diphosphate-linked moiety X motif 12) (Nudix motif
12). [Source:Uniprot/SWISSPROT;Acc:Q9BQG2]
ENSG00000101888 NXT2 NTF2-related export protein 2 (p15-2 protein). [Source:Uniprot/SWISSPROT;Acc:Q9NPJ8]
ENSG00000173559 OBFC2A oligonucleotide/oligosaccharide-binding fold containing 2A [Source:RefSeq_peptide;Acc:NP_001026886]
ENSG00000149256 ODZ4 Teneurin-4 (Ten-4) (Tenascin-M4) (Ten-m4) (Protein Odd Oz/ten-m homolog 4). [Source:Uniprot/SWISSPROT;Acc:Q6N022]
ENSG00000087263 OGFOD1 2-oxoglutarate and iron-dependent oxygenase domain containing 1 [Source:RefSeq_peptide;Acc:NP_060703]
ENSG00000184881 OR51B2 Olfactory receptor 51B2 (Odorant receptor HOR5'beta3). [Source:Uniprot/SWISSPROT;Acc:Q9Y5P1]
ENSG00000091039 OSBPL8 Oxysterol-binding protein-related protein 8 (OSBP-related protein 8) (ORP-8). [Source:Uniprot/SWISSPROT;Acc:Q9BZF1]
ENSG00000164823 OSGIN2 Oxidative stress induced growth inhibitor 2 (hT41). [Source:Uniprot/SWISSPROT;Acc:Q9Y236]
ENSG00000145623 OSMR oncostatin M receptor [Source:RefSeq_peptide;Acc:NP_003990]
ENSG00000081087 OSTM1 Osteopetrosis-associated transmembrane protein 1 precursor. [Source:Uniprot/SWISSPROT;Acc:Q86WC4]
ENSG00000007168 PAFAH1B1
Platelet-activating factor acetylhydrolase IB subunit alpha (PAF acetylhydrolase 45 kDa subunit) (PAF-AH 45 kDa subunit) (PAF-
AH alpha) (PAFAH alpha) (Lissencephaly-1 protein) (LIS-1). [Source:Uniprot/SWISSPROT;Acc:P43034]
ENSG00000120727 PAIP2
Polyadenylate-binding protein-interacting protein 2 (Poly(A)-binding protein-interacting protein 2) (PABP-interacting protein 2)
(PAIP-2). [Source:Uniprot/SWISSPROT;Acc:Q9BPZ3]
ENSG00000149269 PAK1
Serine/threonine-protein kinase PAK 1 (EC 2.7.11.1) (p21-activated kinase 1) (PAK-1) (P65-PAK) (Alpha-PAK).
[Source:Uniprot/SWISSPROT;Acc:Q13153]
ENSG00000156453 PCDH1 Protocadherin-1 precursor (Protocadherin-42) (PC42) (Cadherin-like protein 1). [Source:Uniprot/SWISSPROT;Acc:Q08174]
ENSG00000081842 PCDHAC1 Protocadherin alpha C2 precursor (PCDH-alpha-C2). [Source:Uniprot/SWISSPROT;Acc:Q9Y5I4]
ENSG00000078674 PCM1 pericentriolar material 1 [Source:RefSeq_peptide;Acc:NP_006188]
ENSG00000115252 PDE1A
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A (EC 3.1.4.17) (Cam-PDE 1A) (61 kDa Cam-PDE)
(hCam-1). [Source:Uniprot/SWISSPROT;Acc:P54750]
ENSG00000178104 PDE4DIP phosphodiesterase 4D interacting protein isoform 2 [Source:RefSeq_peptide;Acc:NP_001002812]
ENSG00000073417 PDE8A
High-affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A (EC 3.1.4.17).
[Source:Uniprot/SWISSPROT;Acc:O60658]
ENSG00000100311 PDGFB
Platelet-derived growth factor B chain precursor (PDGF B-chain) (Platelet-derived growth factor beta polypeptide) (PDGF-2) (c-
sis) (Becaplermin). [Source:Uniprot/SWISSPROT;Acc:P01127]
ENSG00000163110 PDLIM5
PDZ and LIM domain protein 5 (Enigma homolog) (Enigma-like PDZ and LIM domains protein).
[Source:Uniprot/SWISSPROT;Acc:Q96HC4]
ENSG00000198872 PEG10 paternally expressed 10 isoform RF1/2 [Source:RefSeq_peptide;Acc:NP_055883]
ENSG00000139946 PELI2 Protein pellino homolog 2 (Pellino-2). [Source:Uniprot/SWISSPROT;Acc:Q9HAT8]
ENSG00000152684 PELO Integrin alpha-1 (Laminin and collagen receptor) (VLA-1) (CD49a antigen). [Source:Uniprot/SWISSPROT;Acc:P56199]
ENSG00000049246 PER3 Period circadian protein 3 (hPER3). [Source:Uniprot/SWISSPROT;Acc:P56645]
ENSG00000131779 PEX11B
Peroxisomal membrane protein 11B (Peroxin-11B) (Peroxisomal biogenesis factor 11B) (PEX11beta) (Pex11pbeta).
[Source:Uniprot/SWISSPROT;Acc:O96011]
ENSG00000101132 PFDN4 Prefoldin subunit 4 (Protein C-1). [Source:Uniprot/SWISSPROT;Acc:Q9NQP4]
ENSG00000102144 PGK1 Phosphoglycerate kinase 1 (EC 2.7.2.3) (Primer recognition protein 2) (PRP 2). [Source:Uniprot/SWISSPROT;Acc:P00558]
ENSG00000165434 PGM2L1 Phosphoglucomutase-2-like 1 (EC 5.4.2.2) (PMMLP). [Source:Uniprot/SWISSPROT;Acc:Q6PCE3]
ENSG00000013375 PGM3
Phosphoacetylglucosamine mutase (EC 5.4.2.3) (PAGM) (Acetylglucosamine phosphomutase) (N-acetylglucosamine-phosphate
mutase) (Phosphoglucomutase 3). [Source:Uniprot/SWISSPROT;Acc:O95394]
ENSG00000109118 PHF12 PHD finger protein 12 (PHD factor 1) (Pf1). [Source:Uniprot/SWISSPROT;Acc:Q96QT6]
ENSG00000135365 PHF21A PHD finger protein 21A (BRAF35-HDAC complex protein BHC80) (BHC80a). [Source:Uniprot/SWISSPROT;Acc:Q96BD5]
ENSG00000118482 PHF3 PHD finger protein 3. [Source:Uniprot/SWISSPROT;Acc:Q92576]
ENSG00000010318 PHF7 PHD finger protein 7 (Testis development protein NYD-SP6). [Source:Uniprot/SWISSPROT;Acc:Q9BWX1]
ENSG00000006576 PHTF2 putative homeodomain transcription factor 2 [Source:RefSeq_peptide;Acc:NP_065165]
ENSG00000073921 PICALM
Phosphatidylinositol-binding clathrin assembly protein (Clathrin assembly lymphoid myeloid leukemia protein).
[Source:Uniprot/SWISSPROT;Acc:Q13492]
ENSG00000100151 PICK1
PRKCA-binding protein (Protein kinase C-alpha-binding protein) (Protein interacting with C kinase 1).
[Source:Uniprot/SWISSPROT;Acc:Q9NRD5]
ENSG00000051382 PIK3CB
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta isoform (EC 2.7.1.153) (PI3-kinase p110 subunit beta)
(PtdIns-3-kinase p110) (PI3K) (PI3Kbeta). [Source:Uniprot/SWISSPROT;Acc:P42338]
ENSG00000065243 PKN2
Serine/threonine-protein kinase N2 (EC 2.7.11.13) (Protein kinase C- like 2) (Protein-kinase C-related kinase 2).
[Source:Uniprot/SWISSPROT;Acc:Q16513]
ENSG00000181690 PLAG1 pleiomorphic adenoma gene 1 [Source:RefSeq_peptide;Acc:NP_002646]
ENSG00000122861 PLAU
Urokinase-type plasminogen activator precursor (EC 3.4.21.73) (uPA) (U-plasminogen activator) [Contains: Urokinase-type
plasminogen activator long chain A; Urokinase-type plasminogen activator short chain A; Urokinase-type plasminogen activator
chain B]. [Source:Uniprot/SWISSPROT;Acc:P00749]
ENSG00000115896 PLCL1 phospholipase C-like 1 [Source:RefSeq_peptide;Acc:NP_006217]
ENSG00000106086 PLEKHA8
pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 8
[Source:RefSeq_peptide;Acc:NP_116028]
ENSG00000141682 PMAIP1
Phorbol-12-myristate-13-acetate-induced protein 1 (PMA-induced protein 1) (Immediate-early-response protein APR).
[Source:Uniprot/SWISSPROT;Acc:Q13794]
ENSG00000177666 PNPLA2 patatin-like phospholipase domain containing 2 [Source:RefSeq_peptide;Acc:NP_065109]
ENSG00000085998 POMGNT1
Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 (EC 2.4.1.-) (POMGnT1) (UDP-GlcNAc:alpha-D-
mannoside beta-1,2-N- acetylglucosaminyltransferase I.2) (GnT I.2). [Source:Uniprot/SWISSPROT;Acc:Q8WZA1]
ENSG00000133110 POSTN Periostin precursor (PN) (Osteoblast-specific factor 2) (OSF-2). [Source:Uniprot/SWISSPROT;Acc:Q15063]
ENSG00000151615 POU4F2
POU domain, class 4, transcription factor 2 (Brain-specific homeobox/POU domain protein 3B) (Brn-3B).
[Source:Uniprot/SWISSPROT;Acc:Q12837]
ENSG00000186951 PPARA Peroxisome proliferator-activated receptor alpha (PPAR-alpha). [Source:Uniprot/SWISSPROT;Acc:Q07869]
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ENSG00000138032 PPM1B Protein phosphatase 2C isoform beta (EC 3.1.3.16) (PP2C-beta). [Source:Uniprot/SWISSPROT;Acc:O75688]
ENSG00000058272 PPP1R12A
Protein phosphatase 1 regulatory subunit 12A (Myosin phosphatase- targeting subunit 1) (Myosin phosphatase target subunit 1)
(Protein phosphatase myosin-binding subunit). [Source:Uniprot/SWISSPROT;Acc:O14974]
ENSG00000138814 PPP3CA
Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform (EC 3.1.3.16) (Calmodulin-dependent calcineurin A
subunit alpha isoform) (CAM-PRP catalytic subunit). [Source:Uniprot/SWISSPROT;Acc:Q08209]
ENSG00000119414 PPP6C Serine/threonine-protein phosphatase 6 (EC 3.1.3.16) (PP6). [Source:Uniprot/SWISSPROT;Acc:O00743]
ENSG00000130711 PRDM12 PR domain zinc finger protein 12 (PR domain-containing protein 12). [Source:Uniprot/SWISSPROT;Acc:Q9H4Q4]
ENSG00000142875 PRKACB cAMP-dependent protein kinase, beta-catalytic subunit (EC 2.7.11.11) (PKA C-beta). [Source:Uniprot/SWISSPROT;Acc:P22694]
ENSG00000108946 PRKAR1A
cAMP-dependent protein kinase type I-alpha regulatory subunit (Tissue- specific extinguisher 1) (TSE1).
[Source:Uniprot/SWISSPROT;Acc:P10644]
ENSG00000114302 PRKAR2A cAMP-dependent protein kinase type II-alpha regulatory subunit. [Source:Uniprot/SWISSPROT;Acc:P13861]
ENSG00000185532 PRKG1
cGMP-dependent protein kinase 1, beta isozyme (EC 2.7.11.12) (cGK 1 beta) (cGKI-beta).
[Source:Uniprot/SWISSPROT;Acc:P14619]
ENSG00000183943 PRKX Serine/threonine-protein kinase PRKX (EC 2.7.11.1) (Protein kinase PKX1). [Source:Uniprot/SWISSPROT;Acc:P51817]
ENSG00000113494 PRLR Prolactin receptor precursor (PRL-R). [Source:Uniprot/SWISSPROT;Acc:P16471]
ENSG00000141127 PRPSAP2
Phosphoribosyl pyrophosphate synthetase-associated protein 2 (PRPP synthetase-associated protein 2) (41 kDa
phosphoribosypyrophosphate synthetase-associated protein) (PAP41). [Source:Uniprot/SWISSPROT;Acc:O60256]
ENSG00000116132 PRRX1
Paired mesoderm homeobox protein 1 (PRX-1) (Paired-related homeobox protein 1) (Homeobox protein PHOX1).
[Source:Uniprot/SWISSPROT;Acc:P54821]
ENSG00000126067 PSMB2
Proteasome subunit beta type 2 (EC 3.4.25.1) (Proteasome component C7- I) (Macropain subunit C7-I) (Multicatalytic
endopeptidase complex subunit C7-I). [Source:Uniprot/SWISSPROT;Acc:P49721]
ENSG00000136930 PSMB7
Proteasome subunit beta type 7 precursor (EC 3.4.25.1) (Proteasome subunit Z) (Macropain chain Z) (Multicatalytic endopeptidase
complex chain Z). [Source:Uniprot/SWISSPROT;Acc:Q99436]
ENSG00000131470 PSMC3IP TBP-1 interacting protein isoform 1 [Source:RefSeq_peptide;Acc:NP_037422]
ENSG00000188647 PTAR1 PTAR1 protein (Fragment). [Source:Uniprot/SPTREMBL;Acc:Q7Z6K3]
ENSG00000011304 PTBP1
Polypyrimidine tract-binding protein 1 (PTB) (Heterogeneous nuclear ribonucleoprotein I) (hnRNP I) (57 kDa RNA-binding
protein PPTB-1). [Source:Uniprot/SWISSPROT;Acc:P26599]
ENSG00000168229 PTGDR Prostaglandin D2 receptor (Prostanoid DP receptor) (PGD receptor). [Source:Uniprot/SWISSPROT;Acc:Q13258]
ENSG00000050628 PTGER3
Prostaglandin E2 receptor, EP3 subtype (Prostanoid EP3 receptor) (PGE receptor, EP3 subtype) (PGE2-R).
[Source:Uniprot/SWISSPROT;Acc:P43115]
ENSG00000171522 PTGER4
Prostaglandin E2 receptor, EP4 subtype (Prostanoid EP4 receptor) (PGE receptor, EP4 subtype).
[Source:Uniprot/SWISSPROT;Acc:P35408]
ENSG00000153707 PTPRD
Receptor-type tyrosine-protein phosphatase delta precursor (EC 3.1.3.48) (Protein-tyrosine phosphatase delta) (R-PTP-delta).
[Source:Uniprot/SWISSPROT;Acc:P23468]
ENSG00000173482 PTPRM
Receptor-type tyrosine-protein phosphatase mu precursor (EC 3.1.3.48) (Protein-tyrosine phosphatase mu) (R-PTP-mu).
[Source:Uniprot/SWISSPROT;Acc:P28827]
ENSG00000172733 PURG Purine-rich element-binding protein gamma. [Source:Uniprot/SWISSPROT;Acc:Q9UJV8]
ENSG00000177707 PVRL3
Poliovirus receptor-related protein 3 precursor (Nectin-3) (CD113 antigen) (CDw113).
[Source:Uniprot/SWISSPROT;Acc:Q9NQS3]
ENSG00000160220 PWP2H Periodic tryptophan protein 2 homolog. [Source:Uniprot/SWISSPROT;Acc:Q15269]
ENSG00000130508 PXDN peroxidasin homolog [Source:RefSeq_peptide;Acc:NP_036425]
ENSG00000206539 Q6ZTN9_HUMAN CDNA FLJ44459 fis, clone UTERU2024656. [Source:Uniprot/SPTREMBL;Acc:Q6ZTN9]
ENSG00000180044 Q8N5S4_HUMAN
ENSG00000170682 Q96NU5_HUMAN CDNA FLJ30064 fis, clone ADRGL2000323. [Source:Uniprot/SPTREMBL;Acc:Q96NU5]
ENSG00000198780 Q9H989_HUMAN
CDNA FLJ12919 fis, clone NT2RP2004587, weakly similar to NEUROFILAMENT TRIPLET M PROTEIN.
[Source:Uniprot/SPTREMBL;Acc:Q9H989]
ENSG00000112531 QKI Quaking protein (Hqk). [Source:Uniprot/SWISSPROT;Acc:Q96PU8]
ENSG00000156675 RAB11FIP1 Rab11 family-interacting protein 1 (Rab11-FIP1) (Rab-coupling protein). [Source:Uniprot/SWISSPROT;Acc:Q6WKZ4]
ENSG00000138069 RAB1A Ras-related protein Rab-1A (YPT1-related protein). [Source:Uniprot/SWISSPROT;Acc:P62820]
ENSG00000080371 RAB21 Ras-related protein Rab-21. [Source:Uniprot/SWISSPROT;Acc:Q9UL25]
ENSG00000069974 RAB27A Ras-related protein Rab-27A (Rab-27) (GTP-binding protein Ram). [Source:Uniprot/SWISSPROT;Acc:P51159]
ENSG00000184014 RAB6IP1 Rab6-interacting protein 1 (Rab6IP1). [Source:Uniprot/SWISSPROT;Acc:Q6IQ26]
ENSG00000017797 RALBP1
RalA-binding protein 1 (RalBP1) (Ral-interacting protein 1) (76 kDa Ral-interacting protein) (Dinitrophenyl S-glutathione
ATPase) (DNP-SG ATPase). [Source:Uniprot/SWISSPROT;Acc:Q15311]
ENSG00000123728 RAP2C Ras-related protein Rap-2c precursor. [Source:Uniprot/SWISSPROT;Acc:Q9Y3L5]
ENSG00000091428 RAPGEF4
Rap guanine nucleotide exchange factor 4 (cAMP-regulated guanine nucleotide exchange factor II) (cAMP-GEFII) (Exchange
factor directly activated by cAMP 2) (Epac 2). [Source:Uniprot/SWISSPROT;Acc:Q8WZA2]
ENSG00000077092 RARB Retinoic acid receptor beta (RAR-beta) (RAR-epsilon) (HBV-activated protein). [Source:Uniprot/SWISSPROT;Acc:P10826]
ENSG00000123094 RASSF8
Ras association domain-containing protein 8 (Carcinoma-associated protein HOJ-1).
[Source:Uniprot/SWISSPROT;Acc:Q8NHQ8]
ENSG00000162437 RAVER2 Ribonucleoprotein PTB-binding 2 (Protein raver-2). [Source:Uniprot/SWISSPROT;Acc:Q9HCJ3]
ENSG00000146587 RBAK RB-associated KRAB repressor [Source:RefSeq_peptide;Acc:NP_066986]
ENSG00000103479 RBL2
Retinoblastoma-like protein 2 (130 kDa retinoblastoma-associated protein) (PRB2) (P130) (RBR-2).
[Source:Uniprot/SWISSPROT;Acc:Q08999]
ENSG00000119707 RBM25
Probable RNA-binding protein 25 (RNA-binding motif protein 25) (RNA- binding region-containing protein 7) (Protein S164).
[Source:Uniprot/SWISSPROT;Acc:P49756]
ENSG00000056586 MNAB Membrane-associated nucleic acid-binding protein (RING finger protein 164). [Source:Uniprot/SWISSPROT;Acc:Q9HBD1]
ENSG00000143344 RGL1 Ral guanine nucleotide dissociation stimulator-like 1 (RalGDS-like 1). [Source:Uniprot/SWISSPROT;Acc:Q9NZL6]
ENSG00000143333 RGS16
Regulator of G-protein signaling 16 (RGS16) (Retinally abundant regulator of G-protein signaling) (RGS-R) (A28-RGS14P).
[Source:Uniprot/SWISSPROT;Acc:O15492]
ENSG00000143248 RGS5 Regulator of G-protein signaling 5 (RGS5). [Source:Uniprot/SWISSPROT;Acc:O15539]
ENSG00000143878 RHOB Rho-related GTP-binding protein RhoB precursor (H6). [Source:Uniprot/SWISSPROT;Acc:P62745]
ENSG00000126858 RHOT1
Mitochondrial Rho GTPase 1 (EC 3.6.5.-) (MIRO-1) (hMiro-1) (Ras homolog gene family member T1) (Rac-GTP-binding
protein-like protein). [Source:Uniprot/SWISSPROT;Acc:Q8IXI2]
ENSG00000111785 RIC8B Synembryn-B (Brain synembrin) (hSyn) (Protein Ric-8B). [Source:Uniprot/SWISSPROT;Acc:Q9NVN3]
ENSG00000101098 RIMS4
Regulating synaptic membrane exocytosis protein 4 (Rab3-interacting molecule 4) (RIM 4) (RIM4 gamma).
[Source:Uniprot/SWISSPROT;Acc:Q9H426]
ENSG00000058729 RIOK2 Serine/threonine-protein kinase RIO2 (EC 2.7.11.1) (RIO kinase 2). [Source:Uniprot/SWISSPROT;Acc:Q9BVS4]
ENSG00000104312 RIPK2
Receptor-interacting serine/threonine-protein kinase 2 (EC 2.7.11.1) (RIP-like-interacting CLARP kinase) (Receptor-interacting
protein 2) (RIP-2) (CARD-containing interleukin-1 beta-converting enzyme- associated kinase) (CARD-containing IL-1 beta ICE-
kina [Source:Uniprot/SWISSPROT;Acc:O43353]
ENSG00000171865 RNASEH1 Ribonuclease H1 (EC 3.1.26.4) (RNase H1) (Ribonuclease H type II). [Source:Uniprot/SWISSPROT;Acc:O60930]
ENSG00000163162 RNF149 ring finger protein 149 [Source:RefSeq_peptide;Acc:NP_775918]
ENSG00000164197 RNF180 ring finger protein 180 [Source:RefSeq_peptide;Acc:NP_848627]
ENSG00000108375 RNF43
Transcription elongation factor SPT4 (hSPT4) (DRB sensitivity-inducing factor small subunit) (DSIF small subunit) (DSIF p14).
[Source:Uniprot/SWISSPROT;Acc:P63272]
ENSG00000111880 RNGTT
mRNA capping enzyme (HCE) (HCAP1) [Includes: Polynucleotide 5'- triphosphatase (EC 3.1.3.33) (mRNA 5'-triphosphatase)
(TPase); mRNA guanylyltransferase (EC 2.7.7.50) (GTP--RNA guanylyltransferase) (GTase)].
[Source:Uniprot/SWISSPROT;Acc:O60942]
ENSG00000197756 RPL37A 60S ribosomal protein L37a. [Source:Uniprot/SWISSPROT;Acc:P61513]
ENSG00000159216 RUNX1
Runt-related transcription factor 1 (Core-binding factor, alpha 2 subunit) (CBF-alpha 2) (Acute myeloid leukemia 1 protein)
(Oncogene AML-1) (Polyomavirus enhancer-binding protein 2 alpha B subunit) (PEBP2-alpha B) (PEA2-alpha B) (SL3-3
enhancer factor 1 [Source:Uniprot/SWISSPROT;Acc:Q01196]
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ENSG00000198853 RUSC2 RUN and SH3 domain-containing protein 2. [Source:Uniprot/SWISSPROT;Acc:Q8N2Y8]
ENSG00000163785 RYK Tyrosine-protein kinase RYK precursor (EC 2.7.10.1). [Source:Uniprot/SWISSPROT;Acc:P34925]
ENSG00000187634 SAMD11 sterile alpha motif domain containing 11 [Source:RefSeq_peptide;Acc:NP_689699]
ENSG00000110075 SAPS3 SAPS domain family, member 3 [Source:RefSeq_peptide;Acc:NP_060782]
ENSG00000085365 SCAMP1
Secretory carrier-associated membrane protein 1 (Secretory carrier membrane protein 1).
[Source:Uniprot/SWISSPROT;Acc:O15126]
ENSG00000146285 SCML4 sex comb on midleg-like 4 [Source:RefSeq_peptide;Acc:NP_932347]
ENSG00000196876 SCN8A
Sodium channel protein type 8 subunit alpha (Sodium channel protein type VIII subunit alpha) (Voltage-gated sodium channel
subunit alpha Nav1.6). [Source:Uniprot/SWISSPROT;Acc:Q9UQD0]
ENSG00000144306 SCRN3 secernin 3 [Source:RefSeq_peptide;Acc:NP_078859]
ENSG00000164022 SCYE1
Multisynthetase complex auxiliary component p43 [Contains: Endothelial monocyte-activating polypeptide 2 (EMAP-II) (Small
inducible cytokine subfamily E member 1)]. [Source:Uniprot/SWISSPROT;Acc:Q12904]
ENSG00000000457 SCYL3
Protein-associating with the carboxyl-terminal domain of ezrin (Ezrin- binding protein PACE-1) (SCY1-like protein 3).
[Source:Uniprot/SWISSPROT;Acc:Q8IZE3]
ENSG00000075223 SEMA3C Semaphorin-3C precursor (Semaphorin E) (Sema E). [Source:Uniprot/SWISSPROT;Acc:Q99985]
ENSG00000092421 SEMA6A
Semaphorin-6A precursor (Semaphorin VIA) (Sema VIA) (Semaphorin 6A-1) (SEMA6A-1).
[Source:Uniprot/SWISSPROT;Acc:Q9H2E6]
ENSG00000119231 SENP5 Sentrin-specific protease 5 (EC 3.4.22.-) (Sentrin/SUMO-specific protease SENP5). [Source:Uniprot/SWISSPROT;Acc:Q96HI0]
ENSG00000086475 SEPHS1
Selenide, water dikinase 1 (EC 2.7.9.3) (Selenophosphate synthetase 1) (Selenium donor protein 1).
[Source:Uniprot/SWISSPROT;Acc:P49903]
ENSG00000164402 SEPT8 Septin-8. [Source:Uniprot/SWISSPROT;Acc:Q92599]
ENSG00000132824 SERINC3 Serine incorporator 3 (Tumor differentially expressed protein 1). [Source:Uniprot/SWISSPROT;Acc:Q13530]
ENSG00000106366 SERPINE1
Plasminogen activator inhibitor 1 precursor (PAI-1) (Endothelial plasminogen activator inhibitor) (PAI).
[Source:Uniprot/SWISSPROT;Acc:P05121]
ENSG00000173349 SFT2D3 Vesicle transport protein SFT2C (SFT2 domain-containing protein 3). [Source:Uniprot/SWISSPROT;Acc:Q587I9]
ENSG00000164466 SFXN1 Sideroflexin-1 (Tricarboxylate carrier protein) (TCC). [Source:Uniprot/SWISSPROT;Acc:Q9H9B4]
ENSG00000126821 SGPP1
Sphingosine-1-phosphate phosphatase 1 (EC 3.1.3.-) (Sphingosine-1- phosphatase 1) (SPPase1) (Spp1) (hSPPase1).
[Source:Uniprot/SWISSPROT;Acc:Q9BX95]
ENSG00000198478 SH3BGRL2
SH3 domain-binding glutamic acid-rich-like protein 2 (Fovea-associated SH3 domain-binding protein).
[Source:Uniprot/SWISSPROT;Acc:Q9UJC5]
ENSG00000087266 SH3BP2 SH3 domain-binding protein 2 (3BP-2). [Source:Uniprot/SWISSPROT;Acc:P78314]
ENSG00000131370 SH3BP5
SH3 domain-binding protein 5 (SH3 domain-binding protein that preferentially associates with BTK).
[Source:Uniprot/SWISSPROT;Acc:O60239]
ENSG00000154447 SH3RF1 SH3 domain containing ring finger 1 [Source:RefSeq_peptide;Acc:NP_065921]
ENSG00000168779 SHOX2
Short stature homeobox protein 2 (Paired-related homeobox protein SHOT) (Homeobox protein Og12X).
[Source:Uniprot/SWISSPROT;Acc:O60902]
ENSG00000110013 SIAE
Sialate O-acetylesterase precursor (EC 3.1.1.53) (Sialic acid-specific 9-O-acetylesterase) (H-Lse).
[Source:Uniprot/SWISSPROT;Acc:Q9HAT2]
ENSG00000101307 SIRPB1 Signal-regulatory protein beta-1 precursor (SIRP-beta-1) (CD172b antigen). [Source:Uniprot/SWISSPROT;Acc:O00241]
ENSG00000100625 SIX4 Homeobox protein SIX4 (Sine oculis homeobox homolog 4). [Source:Uniprot/SWISSPROT;Acc:Q9UIU6]
ENSG00000018280 SLC11A1 Natural resistance-associated macrophage protein 1 (NRAMP 1). [Source:Uniprot/SWISSPROT;Acc:P49279]
ENSG00000110911 SLC11A2
Natural resistance-associated macrophage protein 2 (NRAMP 2) (Divalent metal transporter 1) (DMT1).
[Source:Uniprot/SWISSPROT;Acc:P49281]
ENSG00000074803 SLC12A1
Solute carrier family 12 member 1 (Bumetanide-sensitive sodium- (potassium)-chloride cotransporter 2) (Kidney-specific Na-K-Cl
symporter). [Source:Uniprot/SWISSPROT;Acc:Q13621]
ENSG00000112394 SLC16A10 solute carrier family 16, member 10 [Source:RefSeq_peptide;Acc:NP_061063]
ENSG00000165449 SLC16A9 solute carrier family 16 (monocarboxylic acid transporters), member 9 [Source:RefSeq_peptide;Acc:NP_919274]
ENSG00000110436 SLC1A2
Excitatory amino acid transporter 2 (Sodium-dependent glutamate/aspartate transporter 2).
[Source:Uniprot/SWISSPROT;Acc:P43004]
ENSG00000102743 SLC25A15 Mitochondrial ornithine transporter 1 (Solute carrier family 25 member 15). [Source:Uniprot/SWISSPROT;Acc:Q9Y619]
ENSG00000085491 SLC25A24 solute carrier family 25 member 24 isoform 2 [Source:RefSeq_peptide;Acc:NP_998816]
ENSG00000155850 SLC26A2
Sulfate transporter (Diastrophic dysplasia protein) (Solute carrier family 26 member 2).
[Source:Uniprot/SWISSPROT;Acc:P50443]
ENSG00000125520 SLC2A4RG
SLC2A4 regulator (GLUT4 enhancer factor) (GEF) (Huntington disease gene regulatory region-binding protein 1) (HDBP-1).
[Source:Uniprot/SWISSPROT;Acc:Q9NR83]
ENSG00000145740 SLC30A5 zinc transporter ZTL1 isoform 1 [Source:RefSeq_peptide;Acc:NP_075053]
ENSG00000117620 SLC35A3
UDP-N-acetylglucosamine transporter (Golgi UDP-GlcNAc transporter) (Solute carrier family 35 member A3).
[Source:Uniprot/SWISSPROT;Acc:Q9Y2D2]
ENSG00000139209 SLC38A4
Sodium-coupled neutral amino acid transporter 4 (Na(+)-coupled neutral amino acid transporter 4) (Amino acid transporter A3)
(System A amino acid transporter 3) (System N amino acid transporter 3) (Solute carrier family 38 member 4).
[Source:Uniprot/SWISSPROT;Acc:Q969I6]
ENSG00000151012 SLC7A11
Cystine/glutamate transporter (Amino acid transport system xc-) (xCT) (Calcium channel blocker resistance protein CCBR1).
[Source:Uniprot/SWISSPROT;Acc:Q9UPY5]
ENSG00000172716 SLFN11 schlafen family member 11 [Source:RefSeq_peptide;Acc:NP_689483]
ENSG00000184564 SLITRK6 SLIT and NTRK-like protein 6 precursor. [Source:Uniprot/SWISSPROT;Acc:Q9H5Y7]
ENSG00000101166 CT045_HUMAN Uncharacterized protein C20orf45. [Source:Uniprot/SWISSPROT;Acc:Q9Y3B1]
ENSG00000198887 SMC5 SMC5 protein [Source:RefSeq_peptide;Acc:NP_055925]
ENSG00000138041 SMEK2 SMEK homolog 2. [Source:Uniprot/SWISSPROT;Acc:Q5MIZ7]
ENSG00000198742 SMURF1
Smad ubiquitination regulatory factor 1 (EC 6.3.2.-) (Ubiquitin-- protein ligase SMURF1) (Smad-specific E3 ubiquitin ligase 1)
(hSMURF1). [Source:Uniprot/SWISSPROT;Acc:Q9HCE7]
ENSG00000099940 SNAP29
Synaptosomal-associated protein 29 (SNAP-29) (Vesicle-membrane fusion protein SNAP-29) (Soluble 29 kDa NSF attachment
protein). [Source:Uniprot/SWISSPROT;Acc:O95721]
ENSG00000164975 SNAPC3
snRNA-activating protein complex subunit 3 (SNAPc subunit 3) (snRNA- activating protein complex 50 kDa subunit) (SNAPc 50
kDa subunit) (Small nuclear RNA-activating complex polypeptide 3) (Proximal sequence element-binding transcription factor
subunit bet [Source:Uniprot/SWISSPROT;Acc:Q92966]
ENSG00000163877 SNIP1 Smad nuclear-interacting protein 1. [Source:Uniprot/SWISSPROT;Acc:Q8TAD8]
ENSG00000184602 SNN Stannin (AG8_1). [Source:Uniprot/SWISSPROT;Acc:O75324]
ENSG00000172164 SNTB1
Beta-1-syntrophin (59 kDa dystrophin-associated protein A1 basic component 1) (DAPA1B) (Tax interaction protein 43) (TIP-43)
(Syntrophin 2) (BSYN2). [Source:Uniprot/SWISSPROT;Acc:Q13884]
ENSG00000147481 SNTG1 Gamma-1-syntrophin (G1SYN) (Syntrophin 4) (SYN4). [Source:Uniprot/SWISSPROT;Acc:Q9NSN8]
ENSG00000086300 SNX10 Sorting nexin-10. [Source:Uniprot/SWISSPROT;Acc:Q9Y5X0]
ENSG00000120833 SOCS2
Suppressor of cytokine signaling 2 (SOCS-2) (Cytokine-inducible SH2 protein 2) (CIS-2) (STAT-induced STAT inhibitor 2) (SSI-
2). [Source:Uniprot/SWISSPROT;Acc:O14508]
ENSG00000112096 SOD2 Superoxide dismutase [Mn], mitochondrial precursor (EC 1.15.1.1). [Source:Uniprot/SWISSPROT;Acc:P04179]
ENSG00000176887 SOX11 Transcription factor SOX-11. [Source:Uniprot/SWISSPROT;Acc:P35716]
ENSG00000203883 SOX18 Transcription factor SOX-18. [Source:Uniprot/SWISSPROT;Acc:P35713]
ENSG00000182957 SPATA13 spermatogenesis associated 13 [Source:RefSeq_peptide;Acc:NP_694568]
ENSG00000101448 SPINLW1
Eppin precursor (Epididymal protease inhibitor) (Serine protease inhibitor-like with Kunitz and WAP domains 1) (WAP four-
disulfide core domain protein 7) (Protease inhibitor WAP7). [Source:Uniprot/SWISSPROT;Acc:O95925]
ENSG00000172296 C20orf38 Uncharacterized protein C20orf38. [Source:Uniprot/SWISSPROT;Acc:Q9NUV7]
ENSG00000075142 SRI Sorcin (22 kDa protein) (CP-22) (V19). [Source:Uniprot/SWISSPROT;Acc:P30626]
ENSG00000138434 SSFA2 Sperm-specific antigen 2 (Cleavage signal-1 protein) (CS-1). [Source:Uniprot/SWISSPROT;Acc:P28290]
ENSG00000114850 SSR3 Translocon-associated protein subunit gamma (TRAP-gamma) (Signal sequence receptor subunit gamma) (SSR-gamma).
[Source:Uniprot/SWISSPROT;Acc:Q9UNL2]
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[Source:Uniprot/SWISSPROT;Acc:Q9UNL2]
ENSG00000139874 SSTR1 Somatostatin receptor type 1 (SS1R) (SRIF-2). [Source:Uniprot/SWISSPROT;Acc:P30872]
ENSG00000008513 ST3GAL1
CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase (EC 2.4.99.4) (Beta-galactoside alpha-2,3-
sialyltransferase) (Alpha 2,3-ST) (Gal-NAc6S) (Gal-beta-1,3-GalNAc-alpha-2,3-sialyltransferase) (ST3GalIA) (ST3O)
(ST3GalA.1) (SIAT4-A) (ST3Ga [Source:Uniprot/SWISSPROT;Acc:Q11201]
ENSG00000184005 ST6GALNAC3
Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 3 (EC 2.4.99.-) (GalNAc alpha-2,6-sialyltransferase III) (ST6GalNAc
III) (Sialyltransferase 7C) (STY). [Source:Uniprot/SWISSPROT;Acc:Q8NDV1]
ENSG00000117069 ST6GALNAC5
Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 (EC 2.4.99.-) (GalNAc alpha-2,6-sialyltransferase V) (ST6GalNAc
V) (GD1 alpha synthase) (Sialyltransferase 7E). [Source:Uniprot/SWISSPROT;Acc:Q9BVH7]
ENSG00000101972 STAG2 Cohesin subunit SA-2 (Stromal antigen 2) (SCC3 homolog 2). [Source:Uniprot/SWISSPROT;Acc:Q8N3U4]
ENSG00000159167 STC1 Stanniocalcin-1 precursor (STC-1). [Source:Uniprot/SWISSPROT;Acc:P52823]
ENSG00000115661 STK16
Serine/threonine-protein kinase 16 (EC 2.7.11.1) (Protein kinase PKL12) (Myristoylated and palmitoylated serine/threonine-
protein kinase) (MPSK) (TGF-beta-stimulated factor 1) (TSF-1) (hPSK). [Source:Uniprot/SWISSPROT;Acc:O75716]
ENSG00000104375 STK3
Serine/threonine-protein kinase 3 (EC 2.7.11.1) (STE20-like kinase MST2) (MST-2) (Mammalian STE20-like protein kinase 2)
(Serine/threonine-protein kinase Krs-1). [Source:Uniprot/SWISSPROT;Acc:Q13188]
ENSG00000101109 STK4
Serine/threonine-protein kinase 4 (EC 2.7.11.1) (STE20-like kinase MST1) (MST-1) (Mammalian STE20-like protein kinase 1)
(Serine/threonine-protein kinase Krs-2). [Source:Uniprot/SWISSPROT;Acc:Q13043]
ENSG00000196182 STK40
Serine/threonine-protein kinase 40 (EC 2.7.11.1) (SINK-homologous serine/threonine-protein kinase).
[Source:Uniprot/SWISSPROT;Acc:Q8N2I9]
ENSG00000166263 STXBP4 Syntaxin-binding protein 4 (Syntaxin 4-interacting protein) (Synip). [Source:Uniprot/SWISSPROT;Acc:Q6ZWJ1]
ENSG00000168952 STXBP6 Syntaxin-binding protein 6 (Amisyn). [Source:Uniprot/SWISSPROT;Acc:Q8NFX7]
ENSG00000108375 RNF43
Transcription elongation factor SPT4 (hSPT4) (DRB sensitivity-inducing factor small subunit) (DSIF small subunit) (DSIF p14).
[Source:Uniprot/SWISSPROT;Acc:P63272]
ENSG00000143502 SUSD4 Sushi domain-containing protein 4 precursor. [Source:Uniprot/SWISSPROT;Acc:Q5VX71]
ENSG00000198168 SVIP_HUMAN Small VCP/p97-interacting protein. [Source:Uniprot/SWISSPROT;Acc:Q8NHG7]
ENSG00000135316 SYNCRIP
Heterogeneous nuclear ribonucleoprotein Q (hnRNP Q) (hnRNP-Q) (Synaptotagmin-binding, cytoplasmic RNA-interacting
protein) (Glycine- and tyrosine-rich RNA-binding protein) (GRY-RBP) (NS1-associated protein 1).
[Source:Uniprot/SWISSPROT;Acc:O60506]
ENSG00000054654 SYNE2
Nesprin-2 (Nuclear envelope spectrin repeat protein 2) (Syne-2) (Synaptic nuclear envelope protein 2) (Nucleus and actin
connecting element protein) (Protein NUANCE). [Source:Uniprot/SWISSPROT;Acc:Q8WXH0]
ENSG00000119888 TACSTD1
Tumor-associated calcium signal transducer 1 precursor (Major gastrointestinal tumor-associated protein GA733-2) (Epithelial cell
surface antigen) (Epithelial glycoprotein) (EGP) (Adenocarcinoma- associated antigen) (KSA) (KS 1/4 antigen) (Cell surface gl
[Source:Uniprot/SWISSPROT;Acc:P16422]
ENSG00000065882 TBC1D1 TBC1 domain family member 1. [Source:Uniprot/SWISSPROT;Acc:Q86TI0]
ENSG00000065491 TBC1D22B TBC1 domain family member 22B. [Source:Uniprot/SWISSPROT;Acc:Q9NU19]
ENSG00000167202 TBC1D2B TBC1 domain family, member 2B [Source:RefSeq_peptide;Acc:NP_055894]
ENSG00000183735 TBK1
Serine/threonine-protein kinase TBK1 (EC 2.7.11.1) (TANK-binding kinase 1) (T2K) (NF-kappa-B-activating kinase).
[Source:Uniprot/SWISSPROT;Acc:Q9UHD2]
ENSG00000089225 TBX5 T-box transcription factor TBX5 (T-box protein 5). [Source:Uniprot/SWISSPROT;Acc:Q99593]
ENSG00000140262 TCF12
Transcription factor 12 (Transcription factor HTF-4) (E-box-binding protein) (DNA-binding protein HTF4).
[Source:Uniprot/SWISSPROT;Acc:Q99081]
ENSG00000101190 TCFL5
Transcription factor-like 5 protein (Cha transcription factor) (HPV-16 E2-binding protein 1) (E2BP-1).
[Source:Uniprot/SWISSPROT;Acc:Q9UL49]
ENSG00000187621 TCL6 T-cell leukemia/lymphoma 6 protein (Protein TNG1). [Source:Uniprot/SWISSPROT;Acc:P56846]
ENSG00000187621 TCL6 T-cell leukemia/lymphoma 6 protein (Protein TNG1). [Source:Uniprot/SWISSPROT;Acc:P56846]
ENSG00000184786 TCTE3 t-complex-associated-testis-expressed 3 [Source:RefSeq_peptide;Acc:NP_777570]
ENSG00000135269 TES Testin (TESS). [Source:Uniprot/SWISSPROT;Acc:Q9UGI8]
ENSG00000108064 TFAM
Transcription factor A, mitochondrial precursor (mtTFA) (Mitochondrial transcription factor 1) (MtTF1) (Transcription factor 6-
like 2). [Source:Uniprot/SWISSPROT;Acc:Q00059]
ENSG00000003436 TFPI
Tissue factor pathway inhibitor precursor (TFPI) (Lipoprotein- associated coagulation inhibitor) (LACI) (Extrinsic pathway
inhibitor) (EPI). [Source:Uniprot/SWISSPROT;Acc:P10646]
ENSG00000072274 TFRC Transferrin receptor protein 1 (TfR1) (TfR) (Trfr) (CD71 antigen) (T9) (p90). [Source:Uniprot/SWISSPROT;Acc:P02786]
ENSG00000135966 TGFBRAP1 TGF beta receptor associated protein -1 [Source:RefSeq_peptide;Acc:NP_004248]
ENSG00000186340 THBS2 Thrombospondin-2 precursor. [Source:Uniprot/SWISSPROT;Acc:P35442]
ENSG00000151923 TIAL1 Nucleolysin TIAR (TIA-1-related protein). [Source:Uniprot/SWISSPROT;Acc:Q01085]
ENSG00000138297 TIMM23 Mitochondrial import inner membrane translocase subunit Tim23. [Source:Uniprot/SWISSPROT;Acc:O14925]
ENSG00000008952 TLOC1 Translocation protein SEC62 (Translocation protein 1) (TP-1) (hTP-1). [Source:Uniprot/SWISSPROT;Acc:Q99442]
ENSG00000137462 TLR2
Toll-like receptor 2 precursor (Toll/interleukin 1 receptor-like protein 4) (CD282 antigen).
[Source:Uniprot/SWISSPROT;Acc:O60603]
ENSG00000164342 TLR3 Toll-like receptor 3 precursor (CD283 antigen). [Source:Uniprot/SWISSPROT;Acc:O15455]
ENSG00000077147 TM9SF3
Transmembrane 9 superfamily protein member 3 precursor (SM-11044- binding protein) (EP70-P-iso).
[Source:Uniprot/SWISSPROT;Acc:Q9HD45]
ENSG00000117500 TMED5 Transmembrane emp24 domain-containing protein 5 precursor. [Source:Uniprot/SWISSPROT;Acc:Q9Y3A6]
ENSG00000066697 C9orf30 transmembrane protein with EGF-like and two follistatin-like domains 1 [Source:RefSeq_peptide;Acc:NP_003683]
ENSG00000160218 TMEM1
Transmembrane protein 1 (Epilepsy holoprosencephaly candidate 1 protein) (EHOC-1) (GT334 protein).
[Source:Uniprot/SWISSPROT;Acc:P48553]
ENSG00000157111 TMEM171 Transmembrane protein 171. [Source:Uniprot/SWISSPROT;Acc:Q8WVE6]
ENSG00000176273 TMEM20 Transmembrane protein 20. [Source:Uniprot/SWISSPROT;Acc:Q2M3R5]
ENSG00000172375 TMEM24 Transmembrane protein 24 (Protein DLNB23). [Source:Uniprot/SWISSPROT;Acc:O14523]
ENSG00000112697 TMEM30A Cell cycle control protein 50A (Transmembrane protein 30A). [Source:Uniprot/SWISSPROT;Acc:Q9NV96]
ENSG00000123610 TNFAIP6
Tumor necrosis factor-inducible protein TSG-6 precursor (TNF- stimulated gene 6 protein) (Hyaluronate-binding protein).
[Source:Uniprot/SWISSPROT;Acc:P98066]
ENSG00000120889 TNFRSF10B
Tumor necrosis factor receptor superfamily member 10B precursor (Death receptor 5) (TNF-related apoptosis-inducing ligand
receptor 2) (TRAIL receptor 2) (TRAIL-R2) (CD262 antigen). [Source:Uniprot/SWISSPROT;Acc:O14763]
ENSG00000173530 TNFRSF10D
Tumor necrosis factor receptor superfamily member 10D precursor (Decoy receptor 2) (DcR2) (TNF-related apoptosis-inducing
ligand receptor 4) (TRAIL receptor 4) (TRAIL-R4) (TRAIL receptor with a truncated death domain) (CD264 antigen).
[Source:Uniprot/SWISSPROT;Acc:Q9UBN6]
ENSG00000006327 TNFRSF12A
Tumor necrosis factor receptor superfamily member 12A precursor (Fibroblast growth factor-inducible immediate-early response
protein 14) (FGF-inducible 14) (Tweak-receptor) (TweakR) (CD266 antigen). [Source:Uniprot/SWISSPROT;Acc:Q9NP84]
ENSG00000107854 TNKS2
Tankyrase-2 (EC 2.4.2.30) (TANK2) (Tankyrase II) (TNKS-2) (TRF1- interacting ankyrin-related ADP-ribose polymerase 2)
(Tankyrase-like protein) (Tankyrase-related protein). [Source:Uniprot/SWISSPROT;Acc:Q9H2K2]
ENSG00000100354 TNRC6B Trinucleotide repeat-containing 6B protein. [Source:Uniprot/SWISSPROT;Acc:Q9UPQ9]
ENSG00000136205 TNS3 tensin-like SH2 domain containing 1 [Source:RefSeq_peptide;Acc:NP_073585]
ENSG00000141198 TOM1L1
TOM1-like 1 protein (Target of myb-like 1 protein) (Src-activating and signaling molecule protein).
[Source:Uniprot/SWISSPROT;Acc:O75674]
ENSG00000169905 TOR1AIP2 Torsin-1A-interacting protein 2 (Lumenal domain-like LAP1). [Source:Uniprot/SWISSPROT;Acc:Q8NFQ8]
ENSG00000198846 TOX_HUMAN Thymus high mobility group box protein TOX. [Source:Uniprot/SWISSPROT;Acc:O94900]
ENSG00000172315 TP53RK TP53-regulating kinase (EC 2.7.11.1) (p53-related protein kinase) (Nori-2). [Source:Uniprot/SWISSPROT;Acc:Q96S44]
ENSG00000133112 TPT1
Translationally-controlled tumor protein (TCTP) (p23) (Histamine- releasing factor) (HRF) (Fortilin).
[Source:Uniprot/SWISSPROT;Acc:P13693]
ENSG00000144935 TRPC1 Short transient receptor potential channel 1 (TrpC1) (TRP-1 protein). [Source:Uniprot/SWISSPROT;Acc:P48995]
ENSG00000083067 TRPM3
Transient receptor potential cation channel subfamily M member 3 (Long transient receptor potential channel 3) (LTrpC3)
(Melastatin-2) (MLSN2). [Source:Uniprot/SWISSPROT;Acc:Q9HCF6]
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ENSG00000167723 TRPV3
Transient receptor potential cation channel subfamily V member 3 (TrpV3) (Vanilloid receptor-like 3) (VRL-3).
[Source:Uniprot/SWISSPROT;Acc:Q8NET8]
ENSG00000106025 TSPAN12
Tetraspanin-12 (Tspan-12) (Transmembrane 4 superfamily member 12) (Tetraspan NET-2).
[Source:Uniprot/SWISSPROT;Acc:O95859]
ENSG00000126216 TUBGCP3
Gamma-tubulin complex component 3 (GCP-3) (Spindle pole body protein Spc98 homolog) (hSpc98) (hGCP3) (h104p).
[Source:Uniprot/SWISSPROT;Acc:Q96CW5]
ENSG00000122691 TWIST1 Twist-related protein 1 (H-twist). [Source:Uniprot/SWISSPROT;Acc:Q15672]
ENSG00000128791 TWSG1 twisted gastrulation [Source:RefSeq_peptide;Acc:NP_065699]
ENSG00000136810 TXN
Thioredoxin (Trx) (ATL-derived factor) (ADF) (Surface-associated sulphydryl protein) (SASP).
[Source:Uniprot/SWISSPROT;Acc:P10599]
ENSG00000108010 TXNL2
Thioredoxin-like protein 2 (PKC-interacting cousin of thioredoxin) (PKC-theta-interacting protein) (PKCq-interacting protein).
[Source:Uniprot/SWISSPROT;Acc:O76003]
ENSG00000137831 UACA Uveal autoantigen with coiled-coil domains and ankyrin repeats protein. [Source:Uniprot/SWISSPROT;Acc:Q9BZF9]
ENSG00000143569 UBAP2L Ubiquitin-associated protein 2-like (Protein NICE-4). [Source:Uniprot/SWISSPROT;Acc:Q14157]
ENSG00000033178 UBE1L2 ubiquitin-activating enzyme E1-like 2 [Source:RefSeq_peptide;Acc:NP_060697]
ENSG00000109332 UBE2D3
Ubiquitin-conjugating enzyme E2 D3 (EC 6.3.2.19) (Ubiquitin-protein ligase D3) (Ubiquitin carrier protein D3) (Ubiquitin-
conjugating enzyme E2-17 kDa 3) (E2(17)KB 3). [Source:Uniprot/SWISSPROT;Acc:P61077]
ENSG00000184787 UBE2G2
Ubiquitin-conjugating enzyme E2 G2 (EC 6.3.2.19) (Ubiquitin-protein ligase G2) (Ubiquitin carrier protein G2).
[Source:Uniprot/SWISSPROT;Acc:P60604]
ENSG00000169139 UBE2V2
Ubiquitin-conjugating enzyme E2 variant 2 (MMS2) (Enterocyte differentiation-associated factor EDAF-1) (Enterocyte
differentiation- promoting factor) (EDPF-1) (Vitamin D3-inducible protein) (DDVit 1).
[Source:Uniprot/SWISSPROT;Acc:Q15819]
ENSG00000009335 UBE3C Ubiquitin-protein ligase E3C (EC 6.3.2.-). [Source:Uniprot/SWISSPROT;Acc:Q15386]
ENSG00000122042 UBL3
Ubiquitin-like protein 3 precursor (Membrane-anchored ubiquitin-fold protein) (MUB) (HsMUB) (Protein HCG-1).
[Source:Uniprot/SWISSPROT;Acc:O95164]
ENSG00000198258 UBL5 Ubiquitin-like protein 5. [Source:Uniprot/SWISSPROT;Acc:Q9BZL1]
ENSG00000120686 UFM1 Ubiquitin-fold modifier 1 precursor. [Source:Uniprot/SWISSPROT;Acc:P61960]
ENSG00000156467 UQCRB
Ubiquinol-cytochrome c reductase complex 14 kDa protein (EC 1.10.2.2) (Complex III subunit VI) (QP-C).
[Source:Uniprot/SWISSPROT;Acc:P14927]
ENSG00000006611 USH1C
Harmonin (Usher syndrome type-1C protein) (Autoimmune enteropathy- related antigen AIE-75) (Antigen NY-CO-38/NY-CO-
37) (PDZ-73 protein) (NY-REN-3 antigen). [Source:Uniprot/SWISSPROT;Acc:Q9Y6N9]
ENSG00000135655 USP15
Ubiquitin carboxyl-terminal hydrolase 15 (EC 3.1.2.15) (Ubiquitin thioesterase 15) (Ubiquitin-specific-processing protease 15)
(Deubiquitinating enzyme 15) (Unph-2) (Unph4). [Source:Uniprot/SWISSPROT;Acc:Q9Y4E8]
ENSG00000162402 USP24
Ubiquitin carboxyl-terminal hydrolase 24 (EC 3.1.2.15) (Ubiquitin thioesterase 24) (Ubiquitin-specific-processing protease 24)
(Deubiquitinating enzyme 24). [Source:Uniprot/SWISSPROT;Acc:Q9UPU5]
ENSG00000055483 USP36
Ubiquitin carboxyl-terminal hydrolase 36 (EC 3.1.2.15) (Ubiquitin thioesterase 36) (Ubiquitin-specific-processing protease 36)
(Deubiquitinating enzyme 36). [Source:Uniprot/SWISSPROT;Acc:Q9P275]
ENSG00000135913 USP37
Ubiquitin carboxyl-terminal hydrolase 37 (EC 3.1.2.15) (Ubiquitin thioesterase 37) (Ubiquitin-specific-processing protease 37)
(Deubiquitinating enzyme 37). [Source:Uniprot/SWISSPROT;Acc:Q86T82]
ENSG00000071246 VASH1 Vasohibin-1. [Source:Uniprot/SWISSPROT;Acc:Q7L8A9]
ENSG00000112715 VEGFA
Vascular endothelial growth factor A precursor (VEGF-A) (Vascular permeability factor) (VPF).
[Source:Uniprot/SWISSPROT;Acc:P15692]
ENSG00000092820 VIL2 Ezrin (p81) (Cytovillin) (Villin-2). [Source:Uniprot/SWISSPROT;Acc:P15311]
ENSG00000100987 VSX1
Visual system homeobox 1 (Transcription factor VSX1) (Retinal inner nuclear layer homeobox protein) (Homeodomain protein
RINX). [Source:Uniprot/SWISSPROT;Acc:Q9NZR4]
ENSG00000116874 WARS2
Tryptophanyl-tRNA synthetase, mitochondrial precursor (EC 6.1.1.2) (Tryptophan--tRNA ligase) (TrpRS) ((Mt)TrpRS).
[Source:Uniprot/SWISSPROT;Acc:Q9UGM6]
ENSG00000163625 WDFY3
WD repeat and FYVE domain-containing protein 3 (Autophagy-linked FYVE protein) (Alfy).
[Source:Uniprot/SWISSPROT;Acc:Q8IZQ1]
ENSG00000162923 WDR26 WD repeat protein 26. [Source:Uniprot/SWISSPROT;Acc:Q9H7D7]
ENSG00000147548 WHSC1L1
Histone-lysine N-methyltransferase NSD3 (EC 2.1.1.43) (Nuclear SET domain-containing protein 3) (WHSC1-like protein 1)
(Wolf-Hirschhorn syndrome candidate 1-like protein 1) (Whistle) (WHSC1-like 1 isoform 9 with methyltransferase activity to
lysine). [Source:Uniprot/SWISSPROT;Acc:Q9BZ95]
ENSG00000104415 WISP1
WNT1-inducible signaling pathway protein 1 precursor (WISP-1) (Wnt-1- induced secreted protein).
[Source:Uniprot/SWISSPROT;Acc:O95388]
ENSG00000124535 WRNIP1 ATPase WRNIP1 (Werner helicase-interacting protein 1). [Source:Uniprot/SWISSPROT;Acc:Q96S55]
ENSG00000151718 WWC2 WW, C2 and coiled-coil domain containing 2 [Source:RefSeq_peptide;Acc:NP_079225]
ENSG00000047597 XK
Membrane transport protein XK (Kx antigen) (Kell complex 37 kDa component) (XK-related protein 1).
[Source:Uniprot/SWISSPROT;Acc:P51811]
ENSG00000015153 YAF2 YY1-associated factor 2. [Source:Uniprot/SWISSPROT;Acc:Q8IY57]
ENSG00000181704 YIPF6 Protein YIPF6 (YIP1 family member 6). [Source:Uniprot/SWISSPROT;Acc:Q96EC8]
ENSG00000166860 ZBTB39 Zinc finger and BTB domain-containing protein 39. [Source:Uniprot/SWISSPROT;Acc:O15060]
ENSG00000149289 ZC3H12C
ENSG00000123200 ZC3H13 Zinc finger CCCH domain-containing protein 13. [Source:Uniprot/SWISSPROT;Acc:Q5T200]
ENSG00000177764 ZCCHC3 Zinc finger CCHC domain-containing protein 3. [Source:Uniprot/SWISSPROT;Acc:Q9NUD5]
ENSG00000153786 ZDHHC7
Palmitoyltransferase ZDHHC7 (EC 2.3.1.-) (Zinc finger DHHC domain- containing protein 7) (DHHC-7) (Zinc finger protein
370). [Source:Uniprot/SWISSPROT;Acc:Q9NXF8]
ENSG00000180787 ZFP3 Zinc finger protein 3 homolog (Zfp-3). [Source:Uniprot/SWISSPROT;Acc:Q96NJ6]
ENSG00000121741 ZMYM2
Zinc finger protein 198 (Zinc finger MYM-type protein 2) (Fused in myeloproliferative disorders protein) (Rearranged in atypical
myeloproliferative disorder protein). [Source:Uniprot/SWISSPROT;Acc:Q9UBW7]
ENSG00000186448 ZNF197 Zinc finger protein 197 (ZnF20). [Source:Uniprot/SWISSPROT;Acc:O14709]
ENSG00000197657 ZNF323 Zinc finger protein 323. [Source:Uniprot/SWISSPROT;Acc:Q96LW9]
ENSG00000074657 ZNF532 zinc finger protein 532 [Source:RefSeq_peptide;Acc:NP_060651]
ENSG00000198453 ZNF568 zinc finger protein 568 [Source:RefSeq_peptide;Acc:NP_940941]
ENSG00000198740 ZNF652 zinc finger protein 652 [Source:RefSeq_peptide;Acc:NP_055712]
All genes listed in the table are differentially regulated in human CRC stage 4 adenocarcinomas compared to adenomas
and contain an ARE motif in the 3’UTR. Presence of an ARE (AU-rich element) was determined by analysis using the
ARE database, ARED3.0 (Bakheet et al., 2006).
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